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1. Introduction
The splicing factor TRA2B (SFRS10, splicing factor arginine(R)-serine(S)-rich 10) belongs
to the family of SR-splicing factors. It is involved in alternative splicing processes (1.1) and can
modulate splice site selection by direct sequence-specific binding to RNA in a concentration-
dependent fashion (Nayler et al. 1998; Clery et al. 2011). TRA2B is involved in splicing
processes related to neuronal function (Stamm et al. 1999; Kondo et al. 2004; Glatz et al.
2006), development (Chen et al. 2004; Eswarakumar et al. 2005), vascularization (Shukla and
Fisher 2008), obesity (Pihlajamaki et al. 2011) and probably spermatogenesis (Venables et al.
2000; Dreumont et al. 2010; Grellscheid et al. 2011a). It has achieved major attention in our
laboratories as it is directly responsible for the splicing of SMN exon 7 (Hofmann et al. 2000;
Hofmann and Wirth 2002). Functional loss of the SMN1 gene causes spinal muscular atrophy
(SMA), but the severity of the disease is primarily determined by the copy number of the
SMN2 gene that is present in every SMA patient (Wirth et al. 2006). Splicing correction of
SMN2 transcripts to promote exon 7 inclusion is the most promising approach for SMA therapy
(1.6.1), as it has the potential to fully restore levels of functional SMN protein.
TRA2B has been demonstrated to promote inclusion of exon 7 into the SMN2
transcript in a concentration-dependent manner (Hofmann et al. 2000). It was further shown
that histone deacetylase inhibitors capacitate SMN2 transcripts to achieve strongly increased
exon 7 inclusion rates (Riessland et al. 2006; Garbes et al. 2009; Hauke et al. 2009; Riessland et
al. 2010), which was facilitated by transcriptional upregulation of TRA2B (Brichta et al. 2003).
However, higher TRA2B protein levels supposedly alter the splicing patterns of numerous
transcripts. As only a limited number of transcripts are known to be processed by TRA2B, this
study was aiming at the identification of TRA2B splicing targets in vivo using a mouse model.
Previously generated Tra2b knock-out mice are early embryonically lethal (Mende et al. 2010).
In this study a conditional Tra2b-knock-out mouse of the central nervous system was
generated to allow identification and analysis of transcripts targeted by Tra2b in neurons,
which the primary tissue of SMA disease pathology.
Splicing is a complex and highly regulated process and applies to the majority of multi-
exon transcripts. Therefore, the following chapters focus on the control and different kinds of
alternative splicing, as well as the basic principle of the splicing reaction and its regulation.
Furthermore, known Tra2b-related splicing processes but especially its involvement in SMN
exon 7 splicing will be explained in detail.
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1.1. Alternative splicing
Alternative splicing is a mechanism regulating the selection or inclusion of exons into a
mature mRNA. During the splicing process intronic sequences are removed from pre-mRNAs
linking exons to form the mature mRNA. Thus, multiple mRNAs can emerge from a single
pre-mRNA by combinatorial inclusion and exclusion of exons. This increases the informational
content of the genome allowing a relatively small number of genes to encode a much larger
number of mRNAs and proteins (Nilsen and Graveley 2010). About 95 % of all transcripts
encoded by multiple exons undergo alternative splicing (Pan et al. 2008) and numerous
splicing events are evolutionarily highly conserved (Kan et al. 2005). The most intriguing
alternative splicing event is probably the generation of more than 38,000 possible distinct
mRNAs from the Dscam1 gene in Drosophila melanogaster. In Dscam1 exons are selected out
of 4 different exons clusters allowing this huge diversity of transcripts that is necessary for
regular neuronal circuitry formation (Neves et al. 2004; Hattori et al. 2008).
As much as functional variability emerges from conserved alternative splicing events,
erroneous splicing is a major contributor to disease. In the brain there is a higher occurrence of
alternative splicing than in any other tissue (Yeo et al. 2004; Johnson et al. 2009; Zheng and
Black 2013). Thus, 50 percent of known debilitating mutations in RNA-binding proteins cause
neuronal-related disease (Licatalosi and Darnell 2006; Cooper et al. 2009).
Alternative splicing and the ways of combinatorial exon selection are very versatile
(Figure 1) and can enable, alter, or abolish the function of the protein products in many ways
(Faustino and Cooper 2003). Selection of different initial exons can lead to alternative
translational start sites (different N-termini) or results in mRNAs with differently long 5’ UTRs
(Figure 1 (1)). The most common type of alternative event is the cassette exon that is either
included or excluded from a transcript (Figure 1(2)) (Stamm et al. 1999; Stoilov et al. 2004;
Keren et al. 2010). Other splicing patterns for transcript-internal exons include alternative 3’
and 5’ splice sites (Figure 1(3,4)), retention of introns within the mature mRNA (Figure 1(5))
and mutually exclusive exons (Figure 1(6)). On protein level each of these events can cause
inframe deletions or insertions, a shift of the reading frame, or the insertion of a stop codon.
Generation of premature termination codons (PTCs) more than 50 nucleotides upstream of the
terminal intron might target a transcript for nonsense-mediated decay (NMD), which is an
important regulatory mechanism for the regulation of gene expression on a posttranscriptional
level (Lareau et al. 2007; McGlincy and Smith 2008; Nilsen and Graveley 2010). Furthermore,
the selection of alternative terminal exons can result in competition of different
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polyadenylation or cleavage signals resulting in different C-termini or differently long 3’ UTRs
(Figure 1(7,8)).
Alternative exon selection is based on the interplay of different cooperating or
antagonizing splice factors (1.3) and on the recognition of alternative splice sites. Mutations in
splicing-determining sequences can therefore significantly alter splicing of exons and cause
disease (Faustino and Cooper 2003; Cartegni et al. 2006; Liu and Gong 2008). Regulation of
alternative splicing is in part tissue specific and also differentially regulated during
development. This allows generation of protein products with extended or altered
functionality from the same gene depending on the cell type or the developmental stage
(Stamm et al. 1999; Kondo et al. 2004; Glatz et al. 2006). Moreover, alternative splicing has
been shown to mediate cellular responses to different types of stress (Jacob et al. 2013; Wong
et al. 2013).
Besides the sequence with splicing motifs and the trans-factors by which those are
recognized, alternative splicing is also regulated epigenetically via chromatin structure and
histone modifications (reviewed in (Luco et al. 2011)). Commitment of splicing factors and
spliceosmal components (1.2) to exon splicing occurs co-transcriptionally, though completion
of the splicing reaction mostly occurs after transcription (Tardiff et al. 2006). Binding of
spliceosomal components and trans-factors in part depends on RNA topology (i.e. secondary
structure) which can bury or expose sequence recognition motifs (Luco et al. 2011). In turn
secondary structure formation underlies transcriptional speed and is biased by RNA
polymerase performance and pausing (Kornblihtt 2005). Such effects are based on chromatin
structure and especially histone modifications that impact transcription speed. Moreover,
histone modifying proteins have been reported to physically interact with the U1 and U2
spliceosomal components (1.2) (Martinez et al. 2001; Gunderson and Johnson 2009). Further,
nucleosomes themselves do not appear to be randomly positioned along genes but are
enriched at exon-intron junctions, thus marking exons. A stretch of ~147 nucleotides is
wrapped around a single histone octamer and it is speculated that the size of the average exon
being similar to this is not a coincidence (Andersson et al. 2009; Schwartz et al. 2009;
Chodavarapu et al. 2010).
4 Introduction
Figure 1 | Mechanisms of alternative splicing.
Alternative splicing modifies mRNA in different ways, thus significantly impacting the protein-coding information.
Common mechanisms of alternative splicing are: (1) Selection of alternative initial exons (2) Cassette exons (3)
alternative 5’ss (4) alternative 3’ss (5) intron retention (6) mutually exclusive exons (7) selection of alternative
terminal exons and (8) competition of 5’ss with upstream poly-adenylation signals. (From (Faustino and Cooper
2003; Manley and Krainer 2010))
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1.2. The splicing reaction and the spliceosome
Maturation of pre-mRNA to mRNA that can be translated into a peptide requires
several processing steps. Maturation includes 5’-capping with methylated guanosine
triphosphate, 3’-polyadenylation and splicing. During splicing long, non-coding sequence
elements called introns are removed from the transcript, thus linking exons to each other
forming the mature mRNA. This process is facilitated by the spliceosome, which is a multi-
megadalton ribonucleoprotein (RNP) complex. In eukaryotes there are 2 types of spliceosomes
as there are two types of introns that need to be recognized: The U2-dependent spliceosome
(major spliceosome, reviewed by (Will and Luhrmann 2011)) and the less abundant U12-
dependent spliceosome (minor spliceosome, reviewed by (Turunen et al. 2013)). Accordingly,
these splicesomes recognize and process U2-type and U12-type introns, respectively. Both
types of introns are different as to their recognition sequences. Sequence elements
(cis-elements) defining an intron to be recognized by the spliceosome are limited to short
conserved sequence stretches: The 5’ and the 3’ splice site (5’ss and 3’ss), the branch point
(BP) and the polypyrimidine tract (poly Y), which is present in higher eukaryotes downstream
of the branch site (Chen and Manley 2009) (Figure 2). The branch site is usually located 18-40
nucleotides upstream of the 3’ss.
Introns are removed from pre-mRNAs by two transesterification reactions. As shown in
Figure 2A, the 2’ hydroxyl group of the branch point adenosine performs a nucleophilic attack
on the intronic 5’ss. Thereby, the 5’ss is cleaved and ligated to the branch point adenosine
forming a lariat structure. The second transesterification is an attack by the 3’ hydroxyl group
of the exon to the 3’ss of the intron. During this reaction the 3’ and 5’ ends of the exons are
linked forming the mRNA (Will and Luhrmann 2011).
Cis-elements found on the pre-mRNA cannot facilitate the splice reaction by
themselves but require numerous trans-acting factors to assemble and bind the pre-mRNA.
This renders proper positioning of the splice and branch sites within the spliceosomal complex
to allow catalysis. The U2 spliceosome is assembled from the snRNPs (small nuclear ribonucleic
particles) U1, U2, U5 and U4/U6. Each snRNP mainly consists of a snRNA (small nuclear RNA), a
group of 7 common Sm proteins as well as a group of unique (particle-specific) proteins.
Assembly of the spliceosome is a highly ordered mechanism that is based on protein-protein,
protein-RNA and RNA-RNA interactions (Collins and Guthrie 2000). Spliceosome assembly and
catalysis of the splicing reaction occurs stepwise, as snRNA secondary structures, snRNP
conformation and interactions connecting the spliceosome undego fundamental changes
during the splice reaction (Will and Luhrmann 2011) (Figure 2B). The first step of spliceosomal
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assembly is the binding of U1 snRNP to the 5’ splice site (Seraphin and Rosbash 1989). Other
non-snRNP molecules like U2AF/65 and U2AF/35 (U2 auxiliary factor) bind to the branch site
and the polypyrimidine tract. In the next step, U2 snRNA associates with the branch site via
interaction with U2AF forming the pre-spliceosome (Ruskin et al. 1988). In contrast to U1
association, this step is ATP-dependent. U2 snRNP incorporation makes the branch site
adenosine available for the nucleophilic attack of the 5’ splice site, which is the first out of 2
transesterification reactions during the splice process (Query et al. 1994; Furman and Glitz
1995). U4/U6 and U5 snRNP enter the assembling spliceosome (ATP-dependent) as a
pre-assembled snRNP complex forming the catalytic - but still inactive - B complex. Massive
rearrangements lead to the dissociation of U1 and U4 snRNP generating the catalytically active
B complex (Will and Luhrmann 2011). Starting from this complex both splicing reactions are
performed involving gross conformational rearrangements of the spliceosome (Umen and
Guthrie 1995a; Umen and Guthrie 1995b). After completion the spliceosome dissociates and
single snRNP components become available for a new cycle of spliceosome assembly.
The mode of spliceosome assembly largely depends on the intron length. For introns
shorter than approx. 250 nucleotides spliceosome assembly occurs across the intron. For much
longer introns – as it is normality in higher eukaryotes – the initiation of spliceosome assembly
occurs across the exon, which in most cases is rather short. This principle is referred to as exon
definition (Figure 2C). Here, U2AF and U2 snRNP associate to the intron upstream of the
defined exon, while U1 snRNP binds to the 5’ss of the downstream intron (Berget 1995; Fox-
Walsh et al. 2005). Both, the 3’ss upstream of an exon and the 5’ss downstream of an exon
have been shown to be equally crucial for efficient exon recognition by the spliceosome and
thus for efficient exon inclusion into a transcript (Shepard et al. 2011).
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Figure 2 | The splicing reaction and the U2-dependent spliceosome.
(A) Introns contain conserved sequence motifs: the 5’ and 3’ splice sites, the branch point and the polypyrimidine
tract that allow recognition of the intron by the spliceosome. Introns are removed from the pre-mRNA in 2
transesterification reactions. (B) The assembly of the spliceosome occurs stepwise and is based on multiple RNA-
RNA, RNA-protein and protein-protein interactions that undergo massive rearrangements during the splicing
process. Catalytic removal of the intron is facilitated by the active B complex incorporating snRNPs U2, U5 and U6.
(C) In higher eukaryotes spliceosome assembly initiates due to exon recognition as the intermittent introns are
usually very long. The spliceosome assembles spanning an exon by recognizing the 3’ss of the upstream intron and
the 5’ss of the downstream intron. A, adenosine; p, phosphate; YYYYY, polypyrimidin tract; U2AF, U2 snRNP
auxiliary factor; RRM, RNA recognition motif; ESE, exonic splicing enhancer. (Modified from (Mende 2008; Will and
Luhrmann 2011))
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1.3. SR proteins and SR-related proteins
Primary transcripts contain sequence motifs recognized by the spliceosome, which
allows constitutive splicing events. Even though splicing regulatory cis-elements can be found
in virtually every exon and intron, the sequence motifs are relatively degenerated and might
be insufficient to promote effective splicing by the spliceosome. Besides the spliceosome (1.2)
many other accessory splice factors (trans-factors) are involved in the orchestration of most
splicing events (Faustino and Cooper 2003). The trans-factors use exonic or intronic sequence
motifs that are distinct from those used by the spliceosome. Depending on their effect on the
splicing reaction these sequences are referred to as being enhancing (inclusion) or silencing
(skipping) and are therefore termed exonic/intronic splicing enhancers/silencers (ESE/ESS,
ISE/ISS). The number and position of such splicing regulatory elements as well as the
modulating trans-factors that are recruited to these positions convey significant flexibility to
exon definition (Hertel 2008; Shepard et al. 2011).
Typical trans-factors that modify the splicing reaction belong to the families of hnRNPs
(heterogeneous ribonucleoprotein particles) or SR- and SR-related (SRr) (serine-arginine-rich)
splice factors. Members of both families associate to the primary transcript co-transcriptionally
and help regulating the recruitment of spliceosomal components (Blencowe et al. 1999). Both
groups may either exert a positive or a negative effect on exon recognition – they may
cooperate or antagonize each other - depending on their binding positions (Busch and Hertel
2012). Members of the SR and SRr family do not only participate in alternative splice processes
but rather make a general contribution to most constitutive splicing events as well (Graveley
2000). SR proteins are evolutionarily conserved and contain 1 or 2 N-terminal RNA recognition
motifs (RRM) and a serine/arginine-rich (SR) region that is variable in length but comprises at
least 50 amino acids with more than 40 % SR content (Busch and Hertel 2012; Risso et al.
2012). There are 12 SR-proteins described in humans (Figure 3) which mostly retain a similar
domain composition. Only TRA2B has a unique composition with a single RRM flanked by two
RS-rich domains (also in 1.4). The number of SR-proteins varies between organisms and it has
been proposed that the number of SR-proteins increases with the complexity of alternative
splicing (Busch and Hertel 2012). In humans every gene contains on average 8 introns. Only
4 % of genes in yeast contain introns and classical SR-rich proteins are fully absent in yeast.
This demonstrates that SR-proteins are functionally highly related to complex alternative
splicing (Plass et al. 2008; Busch and Hertel 2012).
RRM domains of SR-rich proteins can directly bind to the primary transcript in a
sequence specific manner but have also been reported to mediate interactions to proteins
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(Michlewski et al. 2008; Pelisch et al. 2010). The SR domain is a mediator of protein-protein
interactions and its serine residues undergo extensive phosphorylation which regulates protein
interactions as well as subcellular and subnuclear localization (Xiao and Manley 1998; Risso et
al. 2012; Li et al. 2013). Based on protein-protein interactions with U1 snRNP and U2AF, SR
proteins can initiate spliceosome assembly, thus strengthening potentially weak splice sites
that are not well defined (Ruskin et al. 1988; Fu 1993; Staknis and Reed 1994; Blencowe et al.
1999). Phosphorylation and thus activation of SR proteins enabling protein interactions is
facilitated by SR protein kinases (SRPKs) and by Clk/Sty kinases (Ngo et al. 2005). Given the
versatile functions and possible binding positions of SR proteins, phosphorylation can promote
as well as inhibit exon inclusion. The whole process of exon definition and its balance depends
on the interplay of SR(r) protein abundance and their activity regulated by kinases and
phosphatases, their binding sites on the primary transcript and the presence or recruitment of
cooperating or antagonizing factors (Blencowe et al. 1999; Cowper et al. 2001; Erkelenz et al.
2013). All together orchestrate fine tuning of alternative splicing which makes the prediction of
alternative splicing events a big challenge.
Figure 3 | Domain structure of human canonical SR-proteins.
Typically SR-family members are defined by N-terminal RRMs followed by a downstream RS domain. TRA2B holds
a special role as its domain composition with a single RRM domain flanked by serine-arginine-rich domains differs
from all other SR-proteins. RRM(H), RNA recognition motif (homolog); RS, arginine-serine-rich; Zn, zinc-finger.
(Modified from (Manley and Krainer 2010; Busch and Hertel 2012))
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Next to their important role in alternative splicing, SR-rich proteins have been
implicated in miRNA-mediated translational repression, miRNA processing and post-
translational modification. Moreover, there is evidence of general translational regulation by
SR-rich proteins via the regulation of mRNA stability and mRNA export from the nucleus
(reviewed in (Sanford et al. 2008; Risso et al. 2012)).
1.4. The SR-related splice factor TRA2B (SFRS10)
The splicing factor TRA2B (SFRS10, splicing factor arginine(R)/serine(S)-rich 10) belongs
to the family of arginine-/serine-rich splicing factors and contributes to alternative splicing of
specific exons. Its ortholog transformer-2 was first described in Drosophila melanogaster
where it regulates sex differentiation, that is controlled by alternative splicing (Nagoshi et al.
1988; Baker 1989). While sex in the fly is initially defined by the ratio of X-chromosomes and
autosomes, specific splicing of the doublesex (dsx) gene is a major determinant for maintaining
female sex commitment in the somatic cell lineage. Transformer-2 is strongly expressed in
females and promotes in cooperation with transformer the expression of the female-specific
doublesex isoform by including exon 4 into the dsx transcript. In male flies expression levels of
transformer-2 are low and exon 4 is skipped from the dsx transcript, giving rise to the male
doublesex isoform. Chromosomal females that carry loss of function mutations in
transformer-2, transform physiologically and behaviorally into viable males which are sterile,
however (Belote and Baker 1982; Butler et al. 1986). Mice do not tolerate complete ubiquitous
ablation of their equivalent ortholog Tra2b. Embryos deficient for Tra2b die at early
gestational stages around 7.5 dpc (Mende et al. 2010). This implicates the splicing factor Tra2b
in having a pivotal role during development in mammals.
The human and murine genes of TRA2B (Tra2b) are located on chromosome 3q27.2 in
humans and on chromosome 16qB1 in mice. TRA2B encodes a 288 amino acid (33.7 kDa)
protein that is 100 % identical to the murine version and still preserves 58 % sequence
similarity (45 % identity) compared to Drosophila melanogaster (Segade et al. 1996). The
sequence identity between humans and mice suggests a highly conserved function of TRA2B in
mammals probably with a high number of common target transcripts. In the cell TRA2B
localized to nuclear speckles, which is the typical subnuclear localization expected for splice
factors of the SR-family (Nayler et al. 1998; Chen et al. 2003).
The domain structure of TRA2B is different from other human SR-proteins (Figure 3) as
TRA2B exhibits a unique arrangement of its 2 SR-domains. All other SR-proteins described in
humans possess a single SR-domain that is always located C-terminally of the RRM. The
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canonical isoform TRA2B-1 possesses a single central RRM flanked by two SR-domains at the
N- and C-terminal end (Busch and Hertel 2012) (Figure 4). Splicing of human TRA2B gives rise
to 5 different mRNAs of which 2 produce functionally different protein products. If included,
exon 2 introduces several inframe premature termination codons. Therefore, isoforms
including exon 2 do not yield a protein product. The canonical TRA2B-1 and the TRA2B-3 (also
termed TRA2B-ΔRS1) isoform share the typical initiation codon in exon 1. These isoforms skip
either exon 2 or both exons 2 and 3, respectively. The latter leads to production of the shorter
TRA2B-ΔRS1 isoform that lacks the N-terminal SR-rich domain (Nayler et al. 1998) (Figure 4).
Even though TRA2B is ubiquitously expressed, strongest expression can be found
especially in neuronal tissue and testis but also in the heart and intestine (Chen et al. 2003;
Grellscheid et al. 2011a). Generation of the ΔRS1 isoform is conserved in flies and mammals
and its expression has been reported to be spatiotemporally highly regulated by Clk-kinases
(1.3). Still, no distinct function in splicing has been related to the ΔRS1 isoform (Mattox et al.
1990; Nayler et al. 1998; Daoud et al. 1999; Stoilov et al. 2004). Overexpression of TRA2B-
ΔRS1 has failed to promote inclusion of TRA2B-dependent exons of the Krba1, Pank2, Tra2a
and HIPK3 transcripts, suggesting that the RS1 domain is likely crucial for protein-protein
interactions to allow exon inclusion (Grellscheid et al. 2011a; Grellscheid et al. 2011b).
Depending on the targeted transcript both SR-domain and RRM are necessary to
facilitate exon inclusion. However, TRA2B-ΔRRM constructs (removal of the RRM) have been
demonstrated to exert a negative effect on splicing of target exons, which are effectively
spliced by TRA2B-1. This indicates that cooperative and independent function of SR-domains
and RNA recognition motifs in TRA2B is likely (Dauwalder and Mattox 1998; Grellscheid et al.
2011a). This mechanism bears the potential of tissue-specific alternative exon selection
depending on TRA2B isoform expression in different tissues.
TRA2B facilitates splicing of its own transcript to regulate its expression levels in a
negative feedback-loop. Upon inclusion of the cassette exon 2, premature termination codons
are inserted rendering the transcript non-functional (Stoilov et al. 2004). TRA2B binds to
multiple ESEs within exon 2 to activate its inclusion. In the mouse, exon 2 is the only Tra2b
exon that is alternatively regulated. All other detectable isoforms in the mouse are only
distinguishable by differently long 3’UTRs, based on alternate usage of polyadenylation signals.
These give rise to 4 functional full-length transcripts with 2.1, 2.0, 1.5 and 1.4 kb in size
(Segade et al. 1996). Hyperphosphorylation of TRA2B has firstly been shown to alter
subnuclear and subcellular localization (Li et al. 2013), and secondly, to increase protein-
protein interactions via the SR-domains, which could sequester HTRA2B from RNA (Stoilov et
al. 2004). Both would promote skipping of TRA2B exon 2 and might equally impact other target
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transcripts as well. Other examples of how differential phosphorylation of TRA2B can promote
or inhibit exon inclusion are the exon splicing processes of Mapt (Microtubule associated
protein tau) exon 10 and SMN2 (Survival motor neuron 2) exon 7 (Novoyatleva et al. 2008).
Modulation of TRA2B phosphorylation to enhance SMN2 exon 7 inclusion was even considered
as a therapeutic approach for spinal muscular atrophy (Zhang et al. 2011) (also see chapter
1.6).
TRA2B binds and recognizes exons via short GAA-rich sequence motifs (Tacke et al.
1998; Stoilov et al. 2004; Grellscheid et al. 2011a). Unraveling the complex structure of
RRM-RNA interactions revealed embedding of a 6 nucleotide stretch into the RRM. Inside this,
only the central AGAA motif is specifically recognized by the TRA2B RRM (Clery et al. 2011).
Moreover, a direct but weaker interaction has been demonstrated between the RRM and a
CAA sequence motif, for which a stem-loop secondary structure was a prerequisite, however
(Tsuda et al. 2011).
Figure 4 | Domain structure and splicing of human TRA2B.
The TRA2B gene consists of 10 exons and undergoes alternative splicing forming a total of 5 different mRNAs.
Isoforms including exon 2 do not produce a protein product due to insertion of premature termination codons. Two
functionally different isoforms are produced: the canonical TRA2B-V1 (exon 2 skipped) and TRA2B-ΔRS1 (exons 2
and 3 skipped). The TRA2B protein comprises a central RNA recognition motif (RRM) flanked by 2 serine/arginine-
rich (RS) domains. The domains are encoded by the exons they are linked to. Thus, alternative splicing of exon 3 can
either include or exclude the N-terminal RS1-domain. (Figure inspired by (Stoilov et al. 2004; Mende 2008))
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1.5. TRA2B-mediated alternative splicing and disease
Testis and spermatogenesis
TRA2B is classified to be a non-essential splicing factor as it alone cannot restore
splicing activity to S100 cytoplasmic extracts (Tarn and Steitz 1994; Tacke et al. 1998; Zahler
1999). This and the fact that TRA2B deficiency itself cannot be compensated and is not
tolerated in mammals (Mende et al. 2010) might point towards unique functions and unique
splicing targets of TRA2B. Thus, target exons might dedicatedly rely on TRA2B.
Specific TRA2B-related splicing processes have been implicated in human disease and
in distinct physiological functions in specific tissues. TRA2B is strongly expressed in testis
(Grellscheid et al. 2011a) and its impact on exon inclusion has been shown to be inverted by
direct interaction with the splicing-regulator RBMY on testis-specific transcripts (Venables et
al. 2000; Dreumont et al. 2010). TRA2B has been shown to evoke inhibitory effects on specific
exons of the testis-enriched transcript ACIN1 and CREB, which was turned into a promoting
effect upon RBMY overexpression. Gross alterations of TRA2B function occur upon interaction
with modulating factors in a tissue-specific manner. Moreover, the testis-specific T-exon of the
homeodomain interacting protein kinase 3 (HIPK3-T) has been shown to be tightly regulated
by TRA2B in a highly concentration-dependent manner (Venables et al. 2005). For effective
splicing of HIPK3-T, TRA2B needed to be expressed at elevated levels and required multiple
clustered exonic AGAA binding motifs. Thereby, the effect of switching exon inclusion on or off
in a TRA2B-concentration-dependent fashion has been shown to rely on the intrinsic splice site
strength (Grellscheid et al. 2011b). TRA2B can exert greatest impact and concentration-
dependent modulation on exon splicing on a weak splice site background (Hertel 2008;
Grellscheid et al. 2011b). Its elevated expression and direct involvement in the splicing of
specific transcripts implicate TRA2B having important physiological functions in testis and
probably spermatogenesis.
Tauopathies
TRA2B involvement has also been demonstrated in numerous neuronal-specific
processes. The microtubule associated protein tau (encoded by the MAPT gene) binds to
microtubules and helps to regulate their stability and assembly. Mapt is spliced with a total of
6 different isoforms. Splicing of Mapt exon 10 is determining the number of microtubule-
bidning domains in the protein. Transcripts containing exon 10 will possess 4 binding domains
(isoform 4R), while lack of exon 10 will produce the 3R isoform (3 binding domains) (Goedert
and Jakes 1990). The number of microtubule-binding domains determines the phosphorylation
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of Tau and thus the microtubule binding properties. Disturbance of this regulated system is
associated with tauopathies like Alzheimer’s disease (AD) and Frontotemporal Dementia and
Parkinson linked to chromosome 17 (FTDP-17) (Wang and Liu 2008; Zhou et al. 2008; Denk and
Wade-Martins 2009). Indeed, mutations associated with FTDP-17 aggregate in MAPT exon 10
and can either disturb protein function by amino acid exchange or disrupt splicing regulatory
elements (Liu and Gong 2008; Wang and Liu 2008). Splicing regulation of MAPT exon 10 is
directly regulated by TRA2B. Inclusion of the fourth microtubule binding domain is strictly
regulated in neurons and both 3R and 4R isoforms coexist in a defined ratio. Splicing defects of
exon 10 have equally been demonstrated to cause isoform imbalances causing
neurodegeneration present in tauopathies (Jiang et al. 2003; Kondo et al. 2004; Wang et al.
2005). Supporting this idea, coordinate upregulation of TRA2B1 and MAPT-4R transcripts have
been found in postmortem temporal cortices of AD patients (Glatz 2005; Glatz et al. 2006).
Development and neuronal function
Further transcripts that are known targets of TRA2B include fibroblast growth factor
receptor 2 (Fgfr2) and clathrin light chain b (Cltb). Fgfr2 is implicated in neuronal and non-
neuronal development (Ford-Perriss et al. 2001) while Cltb along with other clathrins encodes
a vesicle coating protein and is involved in the regulation of endocytosis (reviewed in (Brodsky
2012)). Splicing of Cltb exon 5 (also exon EN) has been shown to be indirectly and negatively
regulated by TRA2B in vitro (Stamm et al. 1999). The neuronal Cltb isoform II (exon 5 included)
comprises regulatory features for the C-terminal calmodulin binding domain. This isoform has
been demonstrated to be sensitive to calcium and it has been proposed that skipping of Cltb
exon 5 (isoform III) might keep vesicles in a calcium-insensitive state in non-neuronal tissue
(Stamm et al. 1992; Pley et al. 1995). Here TRA2B might have a tissue-specific function in
mediating vesicular control in response to calcium.
Fibroblast growth factor receptors (FGFRs) mediate multiple biological activities
including development, tissue homeostasis and metabolic processes. FGFRs are
transmembrane proteins that convey signals to the cell depending on the binding of specific
extracellular ligands (i.e. FGFs, fibroblast growth factors). Splicing of FGFR isoforms is a
common mechanism that makes FGFRs very flexible by allowing modulation of their kinase- or
ligand binding-domains (Kalinina et al. 2012; Belov and Mohammadi 2013). TRA2B regulates
the splicing of FGFR2 exons 8 and 9 in a mutually exclusive fashion (Figure 1 (6)) (Chen et al.
2004; Eswarakumar et al. 2005). These two exons both encode the C-terminal half of the D3
extracellular domain. Alternative - but mutually exclusive – usage of these exons modifies the
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extracellular domain, thus changing ligand binding specificity (Chen et al. 2004). This might
enable distinct functionality of FGFR2 in different tissues depending on exon selection.
Smooth musculature can be divided into slow, intermediate and fast phenotype, based
on their rates of contraction. These phenotypes are specified during development depending
on neural input and mechanical load (Somlyo and Somlyo 1994; Owens 1995). Alternative
splicing is a known phenomenon to regulate numerous muscle-related transcripts to allow
diversification of smooth musculature into fast and slow contractile types (Sobue et al. 1999).
TRA2B has been reported to positively control inclusion of exon 23 of the Myosin phosphatase
targeting subunit I (MYPT1). Expression levels of TRA2B are strongly elevated in fast smooth
muscle (as compared to slow smooth muscle) and highly correlate with exon 23 inclusion into
the MYPT1 transcript. This implicates TRA2B in the specification of the fast smooth muscle
phenotype (Shukla and Fisher 2008).
1.6. Spinal muscular atrophy: The role of TRA2B in SMN exon 7 splicing
Spinal muscular atrophy (SMA) is an autosomal recessive disease and the leading
genetic cause of infant death (Crawford and Pardo 1996). SMA is characterized by
degeneration and loss of α-motor neurons in the anterior horns of the spinal cord leading to
increasing weakness and atrophy of the voluntary muscles (Zerres and Rudnik-Schoneborn
1995; Markowitz et al. 2004). For the very most, SMA is caused by homozygous disruption of
the survival motor neuron 1 gene (SMN1) (Lefebvre et al. 1995; Wirth 2000). In humans there
are two copies of the SMN gene termed SMN1 and SMN2. Both encode identical proteins and
genomically only differ by 5 nucleotides that are either intronic, synonymous or located in
untranslated regions (Burglen et al. 1996). Even though encoding the same protein, the SMN2
transcript is spliced differently from the SMN1 transcript which is caused by a C to T transition
at position 6 of SMN2 exon 7 (Figure 5). This results in a dramatically lower inclusion rate of
exon 7 into the SMN2 transcript (Lorson et al. 1999; Monani et al. 1999). Only 10-20 % of
SMN2 transcripts have exon 7 included resulting in the production of functional full-length
SMN protein. The protein produced from SMN2 Δ7 transcripts is truncated and has shown
impaired oligomerization properties as well as reduced protein stability (Lorson et al. 1998;
Burnett et al. 2009).
The intrinsic splice site strengths of SMN exon 7 are rather weak causing generally
poor exon definition (Lim and Hertel 2001; Singh et al. 2004). Caused by this, exon 7 splicing
strongly depends on the function of accessory trans-factors working in concert with
spliceosomal components. The C to T transition in SMN2 exon 7 causes disruption of an exonic
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splicing enhancer (Figure 5, ESE1) and generates an exonic splicing silencer (Lefebvre et al.
1995; Cartegni and Krainer 2002; Kashima and Manley 2003). Binding of the SR-splicing factor
SF2/ASF to ESE1 enhances exon recognition at the 3’ss via interaction with U2AF/U2, but its
binding depends on the cytosine nucleotide at position 6. SF2 cannot bind to the SMN2 pre-
mRNA due to the C to T transition and does no longer antagonize binding of the inhibitory
factor hnRNP-A1. This exerts a strong negative effect on the 3’ss which promotes exon 7
skipping from SMN2 transcripts (Kashima and Manley 2003; Cartegni et al. 2006). By using an
SMN2 minigene it has been demonstrated that TRA2B can revert the SMN2 splicing pattern by
strongly promoting exon 7 inclusion in a concentration-dependent fashion, thereby restoring
the SMN2 splicing pattern up to 80 % to produce functional full-length transcripts (Hofmann et
al. 2000). TRA2B specifically and directly binds a GA-rich sequence motif at the ESE2 in the
central region of exon 7 and acts in concert with SRp30c and hnRNP-G (Hofmann and Wirth
2002). hnRNP-G has been shown to contribute in great extent to exon 7 inclusion but does not
directly associate with SMN2 exon 7 in a sequence-specific manner (Hofmann and Wirth 2002).
Instead hnRNP-G has been demonstrated to interact with TRA2B, which suggested hnRNP-G
being recruited to SMN2 exon 7 via TRA2B. This makes TRA2B a crucial determining factor for
SMN exon 7 inclusion that can act in parallel to SF2/ASF. Indeed, overexpression of TRA2B has
been demonstrated to increase SMN protein levels produced from endogenous transcripts,
which makes TRA2B a potent candidate that could be exploited to correct the splicing pattern
of SMN2 transcripts (Hofmann and Wirth 2002).
Figure 5 | Model of SMN exon 7 splicing.
SMN1 and SMN2 differ in their splicing pattern due to a C to T transition at position 6 of exon 7. SF2/ASF binds to
ESE1 and interacts with U2AF/U2 at the 3’ss (green arrow) to promote splicing of intron 6. In SMN2 ESE1 is
disrupted by the C to T transition and SF2 can no longer antagonize hnRNP-A1, that exerts a negative effect on the
3’ss promoting exon 7 skipping. Thus, SMN2 produces transcripts that in 90 % of the cases lack exon 7 (Δ7). TRA2B
specifically binds GA-rich sequence motifs at the ESE2 and acts in concert with SRp30c and hnRNP-G to promote
exon 7 inclusion. An intronic splicing silencer (ISS-N1) at the beginning of intron 7 exerts a negative effect to the 5’ss
via hnRNP-A1.
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1.6.1. Splicing correction as a therapeutic approach for SMA
The number of SMN2 gene copies in humans is variable between individuals. As full
absence of both SMN1 and SMN2 is incompatible with life, all SMA patients carry at least one
or two SMN2 gene copies. The more SMN2 copies are present, the more functional SMN
protein is produced. For that reason the SMN2 copy number correlates inversely with the SMA
disease severity, which makes SMN2 the major disease determining modifier in SMA (Wirth
2000; Wirth et al. 2006). Splicing correction of SMN2 that is present in every patient could
allow compensating the loss of SMN1. Indeed, numerous approaches aiming to establish a
possible therapy for SMA have been focusing on increasing the amount of functional SMN
protein produced from the SMN2 gene by enhancement of SMN2 expression and splicing
correction.
Histone deacetylase inhibitors (HDACi) are substances inhibiting HDAC function, thus
attenuating chromatin condensation and generally enhancing gene expression. Numerous
substances have been demonstrated to enhance SMN2 expression, among them valproic acid
(Brichta et al. 2003), M344 (Riessland et al. 2006), SAHA (Riessland et al. 2010) and LBH589
(Garbes et al. 2009). A general increase of total SMN2 expression also increases the amount of
functional full-length transcripts accordingly. Interestingly, valproic acid and M344 did further
cause correction of the SMN2 splicing pattern in vitro resulting in increased amounts of full-
length SMN2 transcripts. This has been demonstrated to be attributable to a more than 3-fold
reinforced expression of TRA2B (Brichta et al. 2003; Riessland et al. 2006). Due to their dual
mode of action these results underlined the value of HDACi for possible treatment strategies
for SMA. The combinatorial effect of enhanced transcription from a probably low copy number
of SMN2 genes and the correction of the splicing pattern to yield more full-length SMN2
transcripts constitutes a promising approach. As to its potency in splicing correction of exon 7,
TRA2B holds a central role in such treatment strategy. However, it is not predictable which
other transcripts or exons might be affected by increased TRA2B levels. Knowing that TRA2B
exerts splicing effects depending on its protein concentration (Hofmann et al. 2000; Hofmann
and Wirth 2002) it appears likely that the regulation of TRA2B target exons will change upon its
upregulation. Few TRA2B splicing targets have been described and alteration of their splicing
patterns has been associated with disturbed protein function and probably disease (1.5). HDAC
inhibitors (and especially VPA) are not solely used as a therapeutic approach for SMA, but have
been considered for treatment of other conditions like epilepsy (Davis et al. 1994), bipolar
disorder (Cipriani et al. 2013) and for the prophylaxis of episodic migraine (Linde et al. 2013).
Furthermore, VPA has been found to exert positive impact in fighting cancer (Cha et al. 2013;
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Han et al. 2013). This has mainly been attributed to its ability to transcriptionally upregulate
tumor suppressor genes (Qiu et al. 2013).
In frame of HDACi-related treatment strategies for various conditions, the
identification of TRA2B splicing targets and the characterization of their physiological role as
well as the effect evoked by altered splicing are of major interest and are the central objective
of this study. Previous studies have generally used in vitro approaches involving minigene
constructs. Via this method the impact of a splicing factor on an exon can be safely
determined, but it does not fully reflect splicing under physiological conditions, as it uses
artificial gene constructs and non-physiological splicing factor concentrations (i.e.
overexpression). Therefore, this study is aiming at the identification of novel TRA2B splicing
targets in vivo using conditional knock-out mice. The identity of human TRA2B and murine
Tra2b on protein level implies that splicing targets identified in the mouse are likely also TRA2B
splicing targets in humans. The use of conditional Tra2b knock-out mice will be further
explained in chapter 1.7
Besides the use of HDACi other methods have been researched to correct the splicing
pattern of SMN2. Different strategies using antisense oligonucleotides (ASO) to modulate exon
7 splicing inclusion have been developed. ASO bind sequence-specifically to their target
sequence and block the interaction of trans-factors with mRNA. Successful restoration of the
SMN2 splicing pattern has been shown for an ASO targeting the intronic splicing silencer
ISS-N1 (Figure 5) at the beginning of intron 7 thus blocking the binding of the inhibitory factor
hnRNP-A1. This could restore SMN2 splicing in a humanized SMA mouse model (Hua et al.
2008). Other ASO designs have been aiming to modulate competition of exon joining to
promote exon7 inclusion. An ASO targeting the 3’ss of SMN2 exon 8 has been shown to
incapacitate exon 8 to compete for joining with the exon 6 5’ss, thus promoting exon 7 joining
(Lim and Hertel 2001). As to the limitations of ASO to only block binding sites, bifunctional
RNAs have been developed to not only block inhibiting factors but also actively promote
exon 7 inclusion. Like ASO, bifunctional RNAs comprise an antisense sequence for specific
sequence targeting but further contain enhancing sequence elements (ESE) that constitute a
basis for the recruitment of enhancing factors like HTRA2B or SF2 (Skordis et al. 2003; Baughan
et al. 2006; Baughan et al. 2009). In general, ASO-based approaches appear highly specific as
modulation of splicing is restricted to transcripts that are specifically targeted by the
complementary ASO sequence. As a treatment strategy these methods harbour the potential
of having an unmatched low number of off-targets as opposed other drugs that affect splicing
of many transcripts.
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As an ASO-independent approach the use of modified cantharidins has been proposed
to modulate TRA2B phosphorylation (Zhang et al. 2011). Cantharidins are protein phosphatase
(PP) inhibitors and inhibition of PP1 has been demonstrated to reduce TRA2B phosphorylation
at Thr-33. Thus, the use of modified cantharidins has been demonstrated to enhance exon 7
inclusion in SMN2 minigenes and SMA patient fibroblasts by increased TRA2B activity (Zhang
et al. 2011). However, cantharidins and their derivatives are not very specific and both protein
phosphatase 1 and 2 are essential for the maintenance of general splicing processes.
1.7. Mouse genetics
During the past decades the mouse has become the most frequently used laboratory
animal model organism. Its high genetic similarity to humans and broad opportunities of
genetic manipulation of the mouse has allowed the study of versatile biological processes and
diseases. The mouse, with 99 % of its genes having direct counterparts in humans, hold the key
for the study of human biology and disease (Gunter and Dhand 2002).
As introduced previously (1.6.1), this study is aiming at the identification of novel
TRA2B splicing targets in vivo using a conditional Tra2b knock-out mouse model. The
generation of ubiquitous Tra2b knock-out mice has been previously performed and mice fully
depleted of Tra2b were found to be early embryonically lethal (Mende 2008; Mende et al.
2010). In anticipation of that the applied targeting strategy for the generation of these mice
included the introduction of loxP sites at the Tra2b locus. This allows for conditional knock-out
that is mediated by tissue-specific expression of Cre-recombinase (1.7.1). In an attempt to
analyze Tra2b-related splicing processes especially in the context of SMA (1.6), motoneuron-
specific knock-out mice have been generated using Cre-recombinase expressed under control
of the Hb9 promoter. These mice did not develop an SMA-like phenotype. Changes in FL-Smn
transcripts have not beed detected upon Tra2b depletion, even though the Δ7 isoform has
been found to be upregulated by up to 4-fold (Mende et al. 2010). In this study a conditional
knock-out mouse depleted of Tra2b in the central nervous system should be generated. By
expression of Cre-recombinase under control of the rat Nestin promoter and enhancer
(Tronche et al. 1999) the Tra2b locus gets disabled in neuronal and glial precursor cells of the
developing central nervous system (1.7.1.). This allows to study Tra2b-related splicing
processes in a broader cell variety of neuronal origin.
More detailed information about Cre-mediated recombination and the generation of
neuronal-specific knock-out mice is given in the chapters 1.7.1 and 4.2.2. As severe
developmental brain defects were encountered during the analysis of neuronal-specific Tra2b
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knock-out mice, chapter 1.7.2 gives a short overview about the neuronal and cortical
development in the mouse.
In 2011 the group of Elizabeth Patti has independently generated a Tra2b knock-out
mouse using the gene trap technology (Pihlajamaki et al. 2011). In concordance with the
results obtained during mouse breedings by our workgroup (Mende et al. 2010), homozygous
Tra2b knock-out pups could not be detected indicating early embryonic lethality. Expression of
TRA2B has been demonstrated to be reduced in human obesity and has been suggested to be
involved via splicing of the LPIN1 gene (Pihlajamaki et al. 2011).
1.7.1. The Cre/loxP system of site-directed recombination
The mouse is the most frequently used mammalian model organism. Genetic
manipulation is relatively easy and a great number of genes and their functions are being
studied in knock-out mouse models. In a knock-out mouse the gene of interest is disabled to
reversely study its function. Knock-out is usually achieved by gene targeting (homologous
recombination) of gene loci and their disruption (Capecchi 1989; Mansour et al. 1990).
Numerous studies yield limited success, as mice might not tolerate absence of some genes
during development resulting in early lethality (Lewandoski 2001).
Conditional knock-out strategies emerged to overcome that problem allowing gene
depletion that is limited to a specific tissue or are set to occur at a defined time point. A
commonly used system to achieve tissue specific knock-out is the Cre-loxP system, which
allows targeted recombination upon expression of Cre-recombinase. Cre-recombinase
originates from bacteriophage P1 and belongs to the integrase family of specific recombinases
(reviewed by (Nagy 2000)). The 38 kDa integrase catalyzes the recombination between two of
its specific recombination sites, so called loxP sites (Hamilton and Abremski 1984; Sauer and
Henderson 1989). LoxP sites are 34 bp consensus sequences that contain an 8 bp core spacer
sequence flanked by 2 palindromic 13 bp sequences. The orientation of the loxP site is
determined by the asymmetric core sequence. Cre-recombinase does not require additional
co-factors to operate. That makes it well-suited for the use in a foreign cellular environment as
it can perform recombination independently (Hamilton and Abremski 1984; Lewandoski 2001).
During the reaction of recombination one Cre-recombinase molecule binds to each
palindromic half of a loxP site. Cre-recombinase forms a tetramer combining two loxP sites
located at different genomic locations. Recombination occurs within the central spacer region
of the loxP site causing the post-recombination site to be assembled by each two halves of the
complementary pre-recombination sites (Voziyanov et al. 1999). As a result of recombination
the sequence in between of two loxP sites is excised. The first use of Cre-recombiase-mediated
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recombination to generate conditional knock-out mice was reported in 1994 by the group of
Prof. Klaus Rajewski (Gu et al. 1994).
In the present study the effect of Tra2b depletion in the central nervous system was
analyzed. Neuronal-specific knock-out mice were generated by cross-breeding Tra2bfl/fl
animals with a Cre-recombinase transgenic mouse line expressing Cre-recombinase under
control of the rat Nestin promoter and enhancer, which is active in neuronal and glial
precursor cells (Tronche et al. 1999). It is first activated at 10.5 dpc in the neural tube, the
somites and in migrating cells of the neural crest. At 15.5 dpc it has been reported to be
strongly expressed in the ventricular and subventricular zone of the cortex (Dahlstrand et al.
1995). Generation of the Tra2b mouse line by targeting the murine Tra2b locus via
homologous recombination facilitating insertion of loxP sites was performed as described
previously (Mende 2008; Mende et al. 2010).
1.7.2. Cortical development in the mouse
Neuronal development in the mouse starts with the induction of ectodermal cells to
form the neuroectoderm that develops to the neural plate. These steps occur during
gastrulation between 6.5 – 9.5 dpc. During neurulation the neural plate undergoes multiple
folding steps to finally form the neural tube. The neural tube will develop to form the central
nervous system, while its lumen will form the ventricular system. First brain structures start to
develop at around 9 dpc at the anterior end of the neural tube and can be subdivided into
prosencephalon (forebrain), mesencephalon (midbrain) and rhombencephalon (hindbrain).
These basic structures will later form distinct brain areas (Figure 6). The prosencephalon
subdivides into diencephalon and telencephalon. The diencephalon will form all thalamic
structures, while the most anterior part of the neural tube, the telencephalon, will give rise to
the cerebral cortex. The ventricular system consisting of 4 cavities that are interconnected by
the aqueduct allows the transport of cerebrospinal fluid. Both hemispheres of the
telencephalon comprise one ventricle termed lateral ventricle. A third and fourth ventricle is
located within the diencephalon and rhombencephalon, respectively (Kaufman and Bard
1999).
The mammalian cortex is divided into functionally distinct areas, which strongly differ
between species and are considered to be determining for mental and perceptive
performance. The formation of these areas is referred to as regionalization or arealization. To
date, it is not fully understood how aeralization is regulated. However, traits like individual
gene expression patterns that are autonomous to a specific region appear equally important as
extrinsic input from thalamocortical afferents (O'Leary et al. 1994; O'Leary and Nakagawa
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2002). The latter are neuronal connections that link a thalamic nucleus to a specific cortical
region. Thalamic input shows a high level of specificity with regard to the cortical area and
cortical layer that are targeted by the afferents. Most thalamic input terminates in layer IV of
the neocortex. Layers V and VI send reciprocal connections back to the thalamic nuclei (Lopez-
Bendito and Molnar 2003).
The six-layered neocortex is the largest and the most specialized region of the cerebral
cortex (Krubitzer and Huffman 2000). Most cortical neurons emerge from the ventricular and
subventricular zones (VZ/SVZ) of the lateral ventricles. The first fully differentiated, post-
mitotic neurons form the pre-plate. Subsequently generated neurons coming from the VZ/SVZ
migrate to the outside along radial glia to later form the different layers of the cortex
(Krubitzer and Huffman 2000; Lopez-Bendito and Molnar 2003). Thalamic and cortical
development occur synchronously and the time frames of neurogenesis in cortex and
thalamus strongly overlap. In mice the most significant changes in cortical patterning occur
during the second and third week of gestation. Between 13 and 18 dpc the neocortex and
nuclei of the dorsal thalamus build up reciprocal connections. In mammals thalamic afferents
reach their cortical destination area before their actual target neurons are generated. It has
been proposed that thalamic projections are homing in on their target area sensing specific
signals. Continuous interactions and signaling between the thalamus and the cortex is
necessary to organize cortical patterning, for arealization and for the development of an intact
cortical circuitry (Lopez-Bendito and Molnar 2003).
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Figure 6 | The early murine brain development.
Subdivision of specializing areas of the neural tube can first be observed at around 8.5 dpc. The neural tube splits
into Prosencephalon, Mesencephalon and Rhombencephalon. Telencephalon and Diencephalon emerge from the
Prosencephalon. Formation of the ventricular system is observable at around 11 dpc, as the lateral ventricles form
at the Telencephalon, the third ventricle at the Diencephalon and the aqueduct at the Mesencephalon. The
cerebral cortex will emerge from the Telecephalon at subsequent developmental stages. (Modified from (Kaufman
and Bard 1999))
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2. Aims
SMA is the leading genetic cause of infant lethality and is caused by functional absence
of the SMN1 gene. Every patient carries at least one copy of the almost identical SMN2 gene.
Caused by alternative splicing SMN2 produces only 10 % of functional transcripts, which
depending on the SMN2 copy number can ameliorate the SMA phenotype but is insufficient to
prevent disease onset. Based on this, modulation of the SMN2 expression and correction of
SMN2 splicing have been major subjects of research in developing a therapy for SMA.
The use of HDAC inhibitors has proven itself to be a promising approach as a treatment
strategy for SMA. HDACi treatment has been demonstrated to not only enhance general
expression of SMN2 but also to correct the SMN2 splicing pattern to primarily produce
functional full-length transcripts. This has been shown to occur via massive upregulation of
TRA2B expression, which in turn results in effective inclusion of exon 7 into SMN2 transcripts.
Despite the beneficial effect of TRA2B upregulation on SMN2 splicing, it can be
assumed that the splicing of other transcripts targeted by TRA2B will be affected by its
upregulation. Indeed, few TRA2B targets have been described and their missplicing has been
associated with aberrant function and disease. For that reason it is of utmost importance to
identify target transcripts of TRA2B, which constitute off-targets in SMA-related and general
HDAC inhibitor treatment strategies.
This study aims at the in vivo identification of Tra2b splicing targets using a neuronal-
specific knock-out mouse model. Therefore, Tra2b was depleted in neurons of the central
nervous system by using Nestin-Cre transgenic mice. Neuronal-specific knock-out mice were
viable until birth, but showed severe developmental defects of the brain. This allowed full
developmental analysis as opposed to ubiquitously depleted Tra2b knock-out mice, which died
very early during development.
Firstly, brains of conditional knock-out mice should be morphologically and
histologically analyzed to identify the underlying reasons for the observed developmental
defects. Secondly, differentially spliced Tra2b targets should be identified using whole
transcriptome sequencing and exon arrays. In preparation to that and as a proof of concept,
bona fide Tra2b target transcripts should be validated in vivo using whole brain RNA of
neuronal-specific knock-out mice. Newly identified candidate transcript should be confirmed
by quantitative PCRs. Thirdly, the splicing mechanism of respective exons and the effect of
increased or decreased Tra2b levels should further be investigated in minigene splicing assays.
Lastly, the identified splicing targets and their missplicing should be evaluated as to their
physiological role and possible impact on neuronal development.
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3. Materials
3.1. Devices and Utilities
Type of device Designation Manufacturer
Balance ER Kern
Balance (fine scale) ARJ 120-4M Kern
Centrifuge Allegra X22-R Beckmann Coulter
Centrifuge Avanti J-20XPI Beckmann Coulter
Centrifuge 5415R Eppendorf
Centrifuge 5415D Eppendorf
Centrifuge 5804 Eppendorf
Centrifuge Galaxy Mini VWR
Electrophoresis chamber MGV-620T C.B.S & Scientific
Electrophoresis chamber SGE-020-02 C.B.S & Scientific
Electrophoresis chamber E-H6 Febicon
Electrophoresis chamber Mini-Protean 3 cell BioRAD
Freezer (-80°C) HERA freeze Heraeus
Gel documentation ChemiDoc XRS BioRAD
Heating block HTMR132 HLC
Heating cabinet Function Line Heraeus
Heating magnetic stirrer MR3001 Heidolph
Homogenizer T10 basic, Ultra Turrax IKA
Incubator Innova 44 New Brunswick Scientific
Incubator Innova 4230 New Brunswick Scientific
Incubator, tissue culture HERA cell 150 Heraeus
Laminar airflow cabinet HERA safe Heraeus
Light source (Fibre optic) KL 1500 LCD Leica
Microplate reader Safire² Tecan
Microscope (Fluorescence) Imager M2 Zeiss
Microscope (stereo) S8AP0 Leica
Microscope camera AxioCam MRm Zeiss
Microscope camera AxioCam ICc 1 Zeiss
Microscope camera AxioCam ERc 5s Zeiss
Microtome RM2255 Leica
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Type of device Designation Manufacturer
Microwave R-898(AL)-A Sharp
Orbital Shaker 3015 GFL
pH meter inoLab pH level 1 WTW
Photometer BioPhotometer Eppendorf
Photometer NanoDrop 1000 Peqlab
Pipette Research (2.5/10/20/100/
200/ 1000/5000 µl)
Eppendorf
Pipette (automatic) Research Pro (10/100 µl) Eppendorf
Pipette (repetitive) Multipette Plus Eppendorf
Pipettor Easypet Eppendorf
Power supply PowerPac Basic BioRAD
Power supply PowerPac HC BioRAD
Power supply PowerPac 1000 BioRAD
real-time Thermocycler 7500 Real Time PCR System Applied Biosystems
real-time Thermocycler Light Cycler 1.5 Roche
Roll incubator SRT9 Stuart
Safety gas-burner Fireboy Plus IBS
Shaker Type 3015 GFL
SpeedVac Concentrator 5301 Eppendorf
Thermocycler DNAengine Tetrad2 MJ Research
Thermocycler DNAengine Dyad MJ Research
Thermocycler S1000 BioRAD
Thermocycler C1000 Touch BioRAD
Tissue processor TP1028 Leica
Vacuum pump PM12640-026.3 Biometra
Vortex 444-1372 VWR
Water bath 1083 GFL
Water bath FBC620 FisherBrand
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3.2. Chemicals
Chemical Manufacturer
2-Mercaptoethanol (99 %, p.a.) AppliChem
2-Propanol  (≥ 99.5 %) AppliChem
Acetic acid AppliChem
Acetone AppliChem
Agarose (low melting) Biozym
Agarose for routine use Sigma-Aldrich
Ammonium persulfate AppliChem
Ampicillin AppliChem
Bacto Agar AppliChem
Bovine serum albumin (BSA) Sigma-Aldrich
Bromophenol blue AppliChem
Citrate AppliChem
Coomassie Brilliant Blue R-250 AppliChem
D-glucose AppliChem
Diethylpyrocarbonate (DEPC) AppliChem
Dimethyl sulfoxide (DMSO) Sigma-Aldrich
Disodium hydrogen phosphate (p.a.) AppliChem
Dithiothreitol (DTT) AppliChem
Emetine dihydrochloride hydrate Sigma-Aldrich
Ethanol (≥ 99.5 %, p.a.) AppliChem
Ethidium bromide (1 % in H2O) AppliChem
Ethylenediaminetetraacetic acid (EDTA) AppliChem
Formaldehyde (37 %, p.a.) Sigma-Aldrich
Glycerol (86 %, p.a.) AppliChem
Glycine AppliChem
Hydrochloric acid (37 %, fuming) AppliChem
Hydroxymethylaminoethane (Tris) AppliChem
Kanamycin AppliChem
Magnesium chloride hexahydrate Merck
Magnesium sulfate Merck
Methanol (≥ 99.9 %, p.a.) AppliChem
Milk powder (low fat) AppliChem
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Chemical Manufacturer
Mowiol Roth
Paraformaldehyde Fluka
Potassium chloride (p.a.) AppliChem
Potassium dihydrogenphosphate AppliChem
Sodium chloride (p.a.) AppliChem
Sodium dihydrogen phosphate dihydrate (p.a.) AppliChem
Sodium dodecyl sulfate (SDS, 10 % in H2O) AppliChem
Sodium hydroxide AppliChem
Tertramethylethylenediamine (TEMED) AppliChem
Triton X-100 AppliChem
Trizma base Sigma-Aldrich
Tryptone (microbiology grade) AppliChem
Tween-20 (Polysorbate 20) AppliChem
Water (HPLC grade) Sigma-Aldrich
Xylene AppliChem
Xylene cyanol AppliChem
Yeast extract (microbiology grade) AppliChem
3.3. Kits
Unless noted otherwise, all kit-related procedures have been performed according to
the manufacturer’s instructions.
Name Manufacturer
BigDye Terminator V1.1 Sequencing Kit Applied Biosystems
DNeasy Blood and Tissue Kit Qiagen
EndoFree Plasmid Maxi Kit Qiagen
gDNA Blood & Tissue Kit Qiagen
GeneChip WT Terminal Labelling and Hybridization kit Affymetrix
Hybridization Wash and Stain Kit Affymetrix
Light Cycler Fast Start DNA Master SYBR green I Roche
Mouse Exon 1.0 ST Array Affymetrix
pcDNA 3.1 GFP-TOPO TA Expression Kit Life Technologies
pcDNA 3.1/V5-HisTOPO TA Expression Kit Life Technologies
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Name Manufacturer
Phase Lock Gel (Heavy 2 ml) 5 Prime
Pure Yield Plasmid Midiprep System Promega
QIAprep Spin Miniprep Kit Qiagen
QIAquick Gel Extraction Kit Qiagen
QIAquick PCR Purification Kit Qiagen
QIAshredder Qiagen
Quant-iT RiboGreen RNA assay Kit Life Technologies
QuantiTect Reverse Transcription Kit Qiagen
RNase-free DNase Kit Qiagen
RNeasy Mini Kit Qiagen
Superscript II Reverse Transcription Kit Life Technologies
Superscript VILO Reverse Transcription Kit Life Technologies
Vectastain ABC Vector Laboratories
WT Expression Kit Ambion
3.4. Reagents and equipment
3.4.1. Reagents
Reagent Manufacturer
1kb DNA ladder Life Technologies
AquaPlus Mix 30% (29:1 Acrylamide/Bisacrylamide) AppliChem
Bradford reagen AppliChem
Chloroform/Isoamylalcohol (24:1) AppliChem
Complete Mini Protease Inhibitors Roche
dATP Peqlab
dCTP Peqlab
dGTP Peqlab
dTTP Peqlab
Eosin-Y solution Sigma-Aldrich
Eukitt mounting medium Fluka
GeneRuler 100bp DNA Ladder Plus Thermo
Mayer’s Hematoxylin Sigma-Aldrich
Pager Ruler Prestained Protein Ladder Thermo
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Reagent Manufacturer
PBS (10x) VWR
Ponceau S Sigma Aldrich
QIAzol Lysis Reagent Qiagen
Restore Western Blot Stripping Buffer Thermo
Ripa buffer Sigma-Aldrich
Super Signal West Pico ECL Substrate Thermo
TBE (10x) AppliChem
3.4.2. Enzymes
Enzyme Manufacturer
Accu Prime DNA Polymerase Life Technologies
BamHI (Endonuclease) New England Biolabs
EcoRI (Endonuclease) New England Biolabs
EcoRV (Endonuclease) New England Biolabs
NotI (Endonuclease) New England Biolabs
Platinum Taq DNA Polymerase Life Technologies
Proteinase K AppliChem
PstI (Endonuclease) New England Biolabs
Recombinant Taq DNA Polymerase Life Technologies
RNase A Sigma-Aldrich
T4 DNA Ligase Promega
XhoI (Endonuclease) New England Biolabs
3.4.3. Cell culture reagents and media
Type Name Manufacturer
Antibiotic Penicillin/Streptomycin Life Technologies
Antibiotic G418 (Geniticin) Sigma-Aldrich
Antibiotic Zeocin Life Technologies
Fungicide Amphotericin B Promocell
Medium PBS Life Technologies
Medium DMEM Life Technologies
Medium Opti MEM Life Technologies
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Type Name Manufacturer
Medium Trysin / EDTA Life Technologies
Serum Fetal Bovine Serum Biochrom
Transfection DharmaFECT I Thermo
Transfection Lipofectamine 2000 Life Technologies
Transfection Mirus TransIT LT Mirus
3.4.4. Equipment for laboratory mouse work
Type Name Manufacturer
Ear tag applicator 1005-s1 National Band & Tag Co.
Ear tags 1005-1 National Band & Tag Co.
Forceps FM002R Aesculap
Forceps DB047R Aesculap
Scissors BC321R Aesculap
Scissors BC8641R Aesculap
Scissors BC100R Aesculap
3.5. Solutions and media
Name Composition
Ampicillin stock solution 50 mg/ml in 50 % EtOH
Citrate buffer 10 mM citrate; pH 6
Coomassie destaining solution 10 % acetic acid; 30 % Methanol in water
Coomassie staining solution for
acrylamide gels
0.25 % Coomassie Brilliant Blue R-2500; 10 % acetic
acid; 50 % Methanol in water; filter
DEPC H2O 0.1 % (v/v) DEPC in H2O; stir over night; autoclave
DNA sample buffer, 10x
100 mM EDTA (pH 8); 1 % (w/v) SDS;
50 % (v/v) Glycerin; 0.1 % (w/v) Bromophenol blue;
0.25 % (w/v) Xylene cyanol
dNTP Mix (1.25 mM per dNTP) 5 µl dATP; 5 µl dCTP; 5 µl dGTP; 5 µl dTTP; 480 µl H2O
Kanamycin stock solution 50 mg/ml in H2O
LB agar 3.75 g Bacto Agar in 250 ml LB-medium
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Name Composition
LB medium 5 g Bacto-Trypton; 2.5 g Bacto-yeast-extract;2.5 g NaCl; ad 500 ml ddH2O
Lysis buffer (tissue) 200 mM NaCl; 100 mM Tris-HCl; 5 mM EDTA;0.2 % (w/v) SDS; pH 8.5; 200 µg/ml proteinase K (fresh)
Paraformaldehyde (4 %)
4 % paraformaldehyde, dilute in 30 ml H2O at 60°C;
add 1 M NaOH to clear the solution; cool down and
filter; add 50 ml 2x PBS, pH 7.4
Resolving gel (SDS-PAGE), 12 %
3.3 ml H2O; 4 ml 30 % acrylamide mix;
2.5 ml 1.5 mM Tris pH 8.8; 100 µl 10 % SDS;
100 µl 10 % APS; 4 µl TEMED
SDS Electrophoresis buffer, 10x 0.25 M Tris; 1.92 M Glycine; 1 % (w/v) SDS; pH 8.3
SDS sample buffer (2x)
0.757 g Tris-base; 20 ml glycerol;
10 mg Bromophenol blue; 6 g SDS; ad 90 ml H2O;
add 1/10 Vol. -ME before use
SOC medium
2 % (w/v) Tryptone, 0.5 % (w/v) yeast extract,
10 mM NaCl, 2.5 mM KCl, 10 mMMgCl2,
20 mM D-Glucose, pH 7
Stacking gel (SDS-PAGE), 4 %
1.4 ml H2O; 330 µl 30 % acrylamide mix;
250 ml 1.5 mM Tris pH 6.8; 20 µl 10 % SDS;
20 µl 10 % APS; 2 µl TEMED
TBST 0.5 % (v/v) Tween-20 in TBS
TE buffer 10 mM Tris; 1 mM EDTA; pH 8
TE-4buffer 10 mM Tris-HCl; 0.1 mM EDTA; pH 8
Transfer buffer (Western Blot) 15 mM Tris-base; 150 mM Glycine; 20 % (v/v) Methanol
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3.6. Cell culture
3.6.1. Cell lines
The following cell lines were employed in this study:
 HEK293T cells: Cells are derived from human embryonic kidney and were originally
transformed by using sheared adenovirus 5 DNA (Graham et al. 1977). HEK 293T cells
carry the SV40 large-T antigen.
 NSC34 cells: Cells were produced by fusion of neuroblastoma cells with embryonic
spinal cord cells. NSC34 cells display a neuron-like phenotype are considered to
resemble many aspects of motoneuron development (Cashman et al. 1992).
3.7. Mouse inbread strains
The Tra2b knock-out mouse model has previously been generated by Dr. Ylva Mende
(Mende et al. 2010). The genomic Tra2b locus was altered by homologous recombination to
insert loxP recombination sites flanking the exon 4 of Tra2b. Cre-recombinase-mediated
recombination results in deletion of exon 4 causing a shift in the codon frame. This results in
multiple premature termination codons in the downstream sequence. Here the Tra2b mouse
line was crossbread with a Nestin-Cre transgenic mouse line (Tronche et al. 1999) to achieve
neuronal-specific knock-out of Tra2b. All animals were maintained on a >96 % C57BL/6N
background.
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3.8. Antibodies
3.8.1. Primary antibodies
Antibody Host species Blockingreagent Dilution
Incubation
time Supplier
Product
number
α-Caspase3 rabbit, polyclonal milk IHC: 1:1,000 o.n. R&D Systems AF835
α-Tra2b rabbit, polyclonal IHC: milk
WB: milk
IHC: 1:8,000
WB: 1:2,000
o.n.
o.n.
Epigentech Produced
α-Ki67 rabbit, polyclonal milk IHC: 1:1,000 o.n. Abcam Ab15580
α-p21 rabbit, polyclonal milk WB: 1:1,000 o.n. ProteinTech 10355-1-AP
α-GFP mouse, monoclonal milk WB: 1:250 o.n. N/A N/A
α-β-actin mouse, monoclonal milk WB: 1:30,000 1 hours Sigma-Aldrich A5316
3.8.2. Secondary antibodies
Antibody Host species Blockingreagent Dilution
Incubation
time Supplier
Product
number
α-rabbit IgG
(biotinylated) goat milk 1:2,000 30 min
Vector
Laboratories PK-6101
α-mouse IgG
(HRP conjugate) goat milk 1:5,000 1 h
Jackson
Immuno
Research
N/A
α-rabbit IgG
(HRP conjugate) goat milk 1:5,000 1 h
Cell
Signaling 7074S
3.9. Oligonucleotides and PCR conditions
All oligonucleotides used and optimized in this study are listed. Amplicon defines the
target of the PCR including the species or the exon if applicable. Oligonucleotide sequences are
listed in 5’ to 3’ direction, while forward primers are designated as fw, reverse primers as rev.
The given identification number corresponds to the inhouse primer database. Product gives
the length of the PCR product(s) in base pair. Platform states the kit, polymerase or PCR
system that has been used for the respective primer pair. AccuPrime and Platinum Taq refer to
the respective proof reading polymerase kits from Life Technologies. PCR refers to
Recombinant Taq DNA Polymerase (Life Technologies). RT-PCR refers to semi-quantitative PCR
on a cDNA template using Recombinant Taq DNA Polymerase (Life Technologies). Roche LC
indicates primer usage for quantitative real-time PCR on the Roche Light Cycler 1.5. The
column °C indicates the optimal annealing temperature. MgCl2 or MgSO4 gives the optimal
concentration of MgCl2 or MgSO4 in the respective PCR. Cycles indicate the typical number of
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PCR cycles used. In quantitative real-time PCRs the cycle number is indicated as RTQ, as the
cycle number is irrelevant.
3.9.1. Oligonucleotides for cloning
Amplicon Oligonucleotide 5'>3' product [bp] Platform °C MgSO4[mM] Cycles
mmSgol2
ex4
minigene
4537 fw AAAAAACTCGAGGTTTTGGACTCTCCATTTAAATGG
2138 AccuPrime 55
0.4 mM
MgSO4
35
4538 rev AAAAAAGGATCCCTTAGCAGTTAGGGAAGGAAACC
hsSGOL2
ex4
minigene
4533 fw AAAAAACTCGAGCCATGTAAGTCTATGTCAAAGTAC
1977 AccuPrime 55
0.4 mM
MgSO4
35
4534 rev AAAAAAGGATCCATCCTGATGGGAATAATCCAGAAG
mmTubd1
ex4
minigene
4539 fw AAAAAACTCGAGAGCTCTTGCCCAGTAGTTCC
1238 AccuPrime 55
0.4 mM
MgSO4
38
4540 rev AAAAAAGGATCCCTCTAGTGAGTATTTACCAAGGAG
hsTUBD1 ex
4 minigene
4535 fw AAAAAACTCGAGCACATATCCAAATATCACATGTACC
1123 AccuPrime 55
0.4 mM
MgSO4
38
4536 rev AAAAAAGGATCCCATTCTGGAAGCCATAACTTAAC
mm tNasp
4594 fw AAAAAACTCGAGCTATGGCCACAGAGTCTACAGC sNasp: 1347 Platinum
Taq 60
2 mM
MgSO4
38
4595 rev AAAAAAGGATCCTTAACATGCAGTGCTTTTAATTGTAG tNasp: 2322
pSPL3 Exon
trap vector
sequencing
primers
4508 fw TCTGAGTCACCTGGACAACC seq - - - -
4541 fw GTGAACTGCACTGTGACAAGCTGC seq - - - -
4542 fw CAACCTCAAAGGCACCTTTGC seq - - - -
4544 fw AAATTGTGGGTCACAGTCTATTATGG seq - - - -
4509 rev ATCTCAGTGGTATTTGTGAGC seq - - - -
4543 rev CACCTTCTTCTTCTATTCCTTCG seq - - - -
4545 rev ATCTGATGCACAAAATAGAGTGGTG seq - - - -
NLS-Cre-
recombinase
4083 fw ATGAAGAAGAAGAGGAAGGTGTCC 1060 Taq 56 1.5 34
4084 rev GGTGCTCGAGCTGATCGCCATCTTCC
NLS-Cre
sequencing
4085 fw ACTGGTTATGCGGCGGATCC seq - - - -
4028 rev GGACAGGGCCATCGCCAATTGG seq - - - -
3.9.2. Oligonucleotides for genotyping
Genotyping of mice was performed as previously described using the following primers
and conditions (Mende et al. 2010).
Amplicon Oligonucleotide 5'>3' product [bp] Platform °C MgCl2[mM] Cycles
Nestin-Cre
transgene
3478 fw CGCTTCCGCTGGGTCACTGTCG
tg: 500 PCR 58 1.5 35
3479 rev TCGTTGCATCGACCGGTAATGCAGGC
mmTra2b
(floxed/wt)
3482 fw AAGGCGTTCTAGATCAAAGTCCAG wt: 821
flox: 950 PCR 60 1.5 352340 rev CGAGAGGGCACGAGAGGACAATC
mmTra2b
(wt/-)
2507 fw GTAGTGAAGGTCTGTTACCC wt: 827
KO: 256 PCR 58 1.5 383263 rev CACCAGAAAATTTAACAAATTAAAC
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3.9.3. Oligonucleotides for semi-quantitative RT-PCR and quantitative PCR
Amplicon Oligonucleotide 5'>3' product [bp] Platform °C MgCl2[mM] Cycles
mmAppbp2
E4
4277 fw GGCTGGTACAGTGATGCTGAAAAGG 118 Roche LC 61 3 RTQ
4278 rev GCACATGAAGCAACCTCACACAACACTCC
mmAppbp2
∆4
4279 fw CATTTGCTCCACCACTGTTTTCAGG 166 Roche LC 61 3 RTQ
4280 rev CGCACATGAAGCAACCTAAGACAAAGC
mmCasp1 4565 fw TTATTTCTCAATCTGTATTCACGCC
FL: 541
RT-PCR 60 2.5 32
4566 rev CTCTGAAGGATTTTCTTTCCATAAC ∆2: 274
mmCasp1
∆2
4567 fw ACGCCATGGCTGCTCCATC 186 RT-PCR 58 1.5 32
4566 rev CTCTGAAGGATTTTCTTTCCATAAC
mmCdkn1a 4491 fw GAGCAAAGTGTGCCGTTGTCTCTTCG 414 RT-PCR 60 1.5 30
4492 rev CTGCGCTTGGAGTGATAGAAATCTGTCAG
mmCdkn1a 4493 fw AGGCCCAGTACTTCCTCTGCCCTG 195 Roche LC 62 1.5 RTQ
4492 rev CTGCGCTTGGAGTGATAGAAATCTGTCAG
mmCltb E5
(CltbII)
3939 fw ATGGAGATGTGTTTCAGGAGGCTAAC 276 Roche LC 63 3 RTQ
3941 rev GCTGCTGGTAGAACGCTTTGTC
mmCltb ∆5
(CltbIII)
3939 fw ATGGAGATGTGTTTCAGGAGGCTAAC 258 Roche LC 64 3 RTQ
3940 rev CTTCCGATGCCCTGTTGTTGATC
mmEomes
E4
4494 fw ATAAGATGTACGTTCACCCAGAATC 161 RT-PCR 60 1.5 32
4495 rev AGCCTCGGTTGGTATTTGTGC
mmEomes
∆4
4496 fw ACAACAACAACACACAGATCACC 118 RT-PCR 60 1.5 32
4497 rev GATGGAGTTAACCTGTCATTTTCTG
mmEomes 4502 fw ATCAGATTGTCCCTGGAGGTC 322 RT-PCR 60 1.5 34
4503 rev AAGGTCGGGTCAGGGTAATAC
mmEzh2
∆17
4596 fw AGAATACTGTGGGGAGATTTTGTG 281 RT-PCR 60 1.5 30
4597 rev GCAGCTGTTTCAGAGAGAAGG
mmFgfr2
IIIb
3992 fw CCTGAAGCACTCGGGGATAAATAGC 155 Roche LC 65 3 RTQ
3993 rev CTTGCTGTTTGGGCAGGACAGTG
mmFgfr2
IIIc
3611 fw CAGCATCGGAGCCTTATTATGG 365 Roche LC 65 3 RTQ
3612 rev GTTACATTCCGAATATAGAGAACC
mmGapdh 3999 fw GGCTGCCCAGAACATCATCC 169 Roche LC 63 3 RTQ
4000 rev GTCATCATACTTGGCAGGTTTCTC
mmGca 4569 fw GTTATTCTGACAGCTACTCCCCTG
FL: 257
RT-PCR 60 1.5 32
4570 rev GTTCTGCTTCCAGGCATTAAGAG ∆4: 213
hsHPRT 4262 fw GCTATTGTAATGACCAGTCAACAGGGGAC 168 Roche LC 62 3 RTQ
4263 rev CCTTGACCATCTTTGGATTATACTGCC
mmHprt 2811 fw AAGGAGATGGGAGGCCA 209 RT-PCR 60 1.5 >26
2812 rev GTTGAGAGATCATCTCCACCAAT
mmHtt E60 4273 fw CCCAGTTTGAAATGATGTATCTGACGC 136 Roche LC 63 3 RTQ
4274 rev GCCACAGTTTTGTCCATTCCAAGGACAGC
mmHtt ∆60 4275 fw GAAGTGGTTCGATCTGACAAAACTGTGGC 186 Roche LC 63 3 RTQ
4276 rev GGACAGCAGATAGTCACTAACAACTGG
mmKif11
E12
4498 fw AAGTTTTAGAGCCATGAATGGAAAG 367 RT-PCR 60 1.5 32
4499 rev CTCATCGATTGCTCTCTTGCG
mmKif11
∆12
4500 fw AGGAGCTCAGTAAGTTGCTTAAC 179 RT-PCR 58 2.5 32
4501 rev ACTGCCATCCTTAATCAATTCTTC
mmMapt
E10 (4R)
3990 fw TATCAAACACGTCCCGGGTGGAGGC 257 Roche LC 67 3 RTQ
3991 rev CATTCTCCCTGAAGGTCAGCTTGTGG
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Amplicon Oligonucleotide 5'>3' product [bp] Platform °C MgCl2[mM] Cycles
mmMapt
∆10 (3R)
3931 fw GAGGTGGCAAGGTGCAAATAGTCTAC 291 Roche LC 61 3 RTQ
3934 rev CCACGGGTGACTTATACACAATTTCTGC
mmNasp
E7
4049 fw GGAGTGCATGTAGAAGAGG 115 Roche LC 65 1 RTQ
4042 rev CGTCATAAACCTGTTCTCTC
mmNasp
∆7
4037 fw AATGGAGTGTTGGGAAATGC 118 Roche LC 62 3 RTQ
4043 rev CTGAGCCTTCAGTTTCATCTAC
mmNrg1 E5 4504 fw GAAGTCAGAGCTTCGAATCAAC 238 RT-PCR 60 2.5 32
4505 rev GGATGTAGATGTGGATGAAGAAG
mmNrg1 ∆5 4506 fw CTATGTGTCCTCAGCCACATC 176 RT-PCR 60 1.5 32
4507 rev GGCAACGATCACCAGTAAACTC
mmPrkd3
E18
4577 fw TGCGTTTATGTACCCACCAAATC
172 RT-PCR 60 2.5 30
4578 rev AGTTTCAAATTCTCTGAGGTCAAGC
mmPrkd3
Δ18
4580 fw GAGAAATTTCCAGTGAAGGATTATC 156 RT-PCR 62 2.5 32
4579 rev CATAATGAAATGCTTTGGGTATTCC
mmRcor2
E4
4581 fw GCTATAGCAACAAGGAGCTGAAG 168 RT-PCR 60 2.5 32
4582 rev GTGATTTCTCCACATCGTGTTTATG
mmRcor2
Δ4
4584 fw GTGTATCAGATGCCAAACGCAC 198 RT-PCR 60 2.5 32
4583 rev AATCACCTTGTCAGGGAGCATC
pSPL3
minigene
4508 fw TCTGAGTCACCTGGACAACC 262 + exon
size RT-PCR 62 1.5 284509 rev ATCTCAGTGGTATTTGTGAGC
mmSgol2
E4
4510 fw TCGAAGAATTACTACCGAAAAGATG 182 RT-PCR 60 1.5 32
4511 rev CTTGGTGGAACTCAGAAAGACTG
mmSgol2
∆4
4510 fw TCGAAGAATTACTACCGAAAAGATG 113 RT-PCR 60 3 34
4521 rev GAAAAGAACCTTGGTGGAACAAG
mmSlu7
E15
4512 fw TGGTGCGACTGCAGAAGAG 145 RT-PCR 60 2.5 32
4513 rev CTTCCGTTCCTCATCGTCG
mmSlu7
∆15
4522 fw CCTCCTGGAGGCACTGAATG 152 RT-PCR 60 2.5 32
4523 rev TCTGCCGTTTCATCCTGTAGG
mmSox6
E5
4514 fw AATGAACAGTGTTACTTTTGGAACC 259 RT-PCR 60 2.5 30
4515 rev CTGGGTAATCATGGTGGAGAG
mmSox6 ∆5 4524 fw CGTCTACCTCACCACATAAGC 176 RT-PCR 60 2.5 32
4525 rev CTCTCAGGTGTACCCTCTTG
mmSt18 4587 fw ATGGTCTGGGTCATGTAAACAAC
FL: 313
RT-PCR 60 2.5 32
4588 rev AGCAGACTCTCATTGCTCTGTTC Δ22: 209
mmTcf4
E18
4516 fw GAACTAGTCTTCTCTCAGCCAACAG 443 RT-PCR 60 2.5 30
4517 rev GTTGATATCTCGGACCCTCAG
mmTcf4
∆18
4526 fw AAGACCCTTACAGAGCAATAACG 129 RT-PCR 60 2.5 32
4518 rev AAAGCCTCGTTGATATCTCGGAC
mmTop2a
E11
4519 fw GCTTTGGATCAACATGTCAATTAAG 231 RT-PCR 60 2.5 30
4520 rev AGTCTCCCTCAGTCAGGATAAGTG
mmTop2a
∆11
4527 fw GAAAAGTTCATCAAAGCTGGAGC 154 RT-PCR 62 2.5 32
4528 rev ACATTGAGTATCTTTCCTCTAAGAG
hsTRA2B
E2
4563 fw GGAAGATGAAAGAAGTCAGAATTTG 250 Roche LC 64 3 RTQ
4564 rev AGACCTAGATTCAGATCGGGAC
hsTRA2B
∆2
4562 fw CTACGGCGAGCGGGAATC 151 Roche LC 64 3 RTQ
4564 rev AGACCTAGATTCAGATCGGGAC
mmTra2a
E2
4040 fw GTTGTAGCCGTCGCCTTCT 206 Roche LC 64 3 RTQ
4044 rev CTTGATTTATCTTCCACATTCTTGG
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Amplicon Oligonucleotide 5'>3' product [bp] Platform °C MgCl2[mM] Cycles
mmTra2a
∆2
4040 fw GTTGTAGCCGTCGCCTTCT 155 Roche LC 66 3 RTQ
4046 rev GAGACTCTCTGCCCTCGAAG
mmTra2b
E2
4269 fw GAACTACGGCGAGCGGGTTAATG 161 Roche LC 64 3 RTQ
4270 rev CAAGTGGGACTTCTGGTCTGATAATTAGC
mmTra2b
∆2
4271 fw AGAACTACGGCGAGCGGGAATC 191 Roche LC 64 3 RTQ
4272 rev CCTTGTATAATGCCTTCTAGAACTTCTTC
mmTra2b 3218 fw TAGAAGGCATTATACAAG 186 Roche LC 63 3 RTQ
3219 rev CTCAACCCAAACACGC
mmTubd1
E4
4529 fw CAGTACTCCAGTTCCTTGAAAATG 157 RT-PCR 60 1.5 34
4531 rev AGATCTTATGGACAGCGTCATTCTC
mmTubd1
∆4
4532 fw GGACAACGAGGCATATCAAGC 225 RT-PCR 60 1.5 36
4530 rev GTTCTGCACAATGACCCGTATG
mmHoxa3 4546 fw GTCTCTCCCCCTCAAAGTGC 340 RT-PCR 60 1.5 32
4547 rev AGATCTTGATCTGGCGCTCG
mmHoxa4 4548 fw GCGCCGTCAACTCCAGTTAT 255 RT-PCR 60 1.5 32
4549 rev CCGAGGCAGTGTTGGAAGAT
mmHoxa5 4550 fw AATGGCATGGATCTCAGCGT 473 RT-PCR 60 1.5 32
4551 rev GTCTGGTAGCGAGTGTAGGC
mmHoxa6 4552 fw CACCGACCGGAAGTACACAA 249 RT-PCR 60 1.5 32
4553 rev CACTTCATGCGCCGATTCTG
mmHoxb5 4554 fw CTCTGAGCGGCTCTTACAGG 496 RT-PCR 60 1.5 32
4555 rev CCGTCTGGCCCAGTCATATC
mmHoxb6 4556 fw ACAAGAGCGTGTTCGGAGAG 262 RT-PCR 60 1.5 32
4557 rev CGCCGGTTCTGAAACCAAAT
mmHoxb7 4558 fw GCTCGAACCGAGTTCCTTCA 303 RT-PCR 60 1.5 32
4559 rev TGTCTTTCGGTGAGGCAGAG
mmHoxb8 4560 fw ACTTCTACGGCTACGACCCT 294 RT-PCR 60 1.5 32
4561 rev CGTGCGATACCTCGATCCTC
mmHoxc5 4562 fw AGCTAAGAGCAGTGGGGAGA 298 RT-PCR 60 1.5 32
4563 rev CCACTTCATCCTGCGGTTCT
mmHoxc6 4564 fw ACCGGATCTACTCGACTCCC 337 RT-PCR 60 1.5 32
4565 rev TCCTTCTCCAGTTCCAGGGT
mmHoxd3 4566 fw TATGAGACCTGGCACTGGGA 385 RT-PCR 60 1.5 32
4567 rev GCGGTTGAAGTGGAACTCCT
SV40 T-
antigen
4052 fw CCAGGATTTAAGGAAGAAGC 142 RT-PCR 58 1.5 30
4053 rev GGAGTTTCATCCTGATAAAGG
3.10. Small interfering RNAs
Target transcript Gene accession no. Sense strand Supplier Cat. No.
hTRA2B NM_001243879 5’-GGACUACUAUAGCAGAUCATT-3’ Qiagen SI02653252
hTRA2B NM_001243879 5’-CGAUCUGAAUCUAGGUCUATT-3’ Qiagen SI02653504
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3.11. Software, web applications and databases
3.11.1. Routinely employed software
Name Purpose Manufacturer
AutoStitch 2.2 Image processing (panoramic assembly) University of Britsish
Columbia
EndNote X3 Reference management Thomson Reuters
Excel 2003/2007 Plots, charts, data processing, statistics Microsoft
Image J 1.40g Densitometric analysis NIH
Lasergene Suite Sequence analysis DNAstar Inc.
Light Cycler Software Quantitative real-time PCR analysis Roche
Paint Shop Pro Photo XII Image processing Corel
Power Point 2003/2007 Image illustration Microsoft
Quantity One 4.5.1 Densitometric analysis BioRAD
Word 2003/2007 Word processing Microsoft
ZEN Blue Edition Fluorescence imaging and analysis Zeiss
Mausoleum Laboratory animal management Dr. Hanns-Eugen Stöffler
PyRAT Laboratory animal management Scionics
3.11.2. Routinely consulted databases and web applications
Name URL
AnalyzerSpliceTool http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm
Ensembl http://www.ensembl.org/index.html
ESE Finder http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home
ExonPrimer http://ihg.gsf.de/ihg/ExonPrimer.html
Genecards http://www.genecards.org/
Ingenuity Systems http://www.ingenuity.com/
MGI http://www.informatics.jax.org/
NCBI http://www.ncbi.nlm.nih.gov/
OligoCalc http://basic.northwestern.edu/biotools/OligoCalc.html
PrimerBLAST http://www.ncbi.nlm.nih.gov/tools/primer-blast/
Pubmed http://www.ncbi.nlm.nih.gov/pubmed
UCSC http://genome-euro.ucsc.edu/
UniProt http://www.uniprot.org/
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3.12. Plasmids
Vectors that were produced in frame of this study are labeled with an asterisk and a
reference to the section describing the generation of the respective vector. For amplification
chemicompetent E. coli (TOP10 or DH5α) were transformed with the respective vector using
heat shock transformation (4.3.1). Vectors were conserved as bacterial glycerol stocks (4.3.3).
Vector Insert Resistance
(in bacteria)
pBABE-zeo-largeT (Hahn et al. 2002b) SV40 large-T antigen Ampicillin
pcDNA3.1-CT-GFP-NLS-Cre *(5.2.2) NLS-Cre-recombinase Ampicillin
pEGFP-C2 (Clontech Laboratories) none Kanamycin
pEGFP-C2-HTRA2B (Hofmann et al. 2000) HTRA2B Kanamycin
pEGFP-C2-tNasp *(5.8.2) tNasp Kanamycin
pMAX-GFP (Amaxa Biosystems) GFP Kanamycin
pSPL3 (Life Technologies) none Ampicillin
pSPL3_hsSGOL2_770nt-ex4-1129nt *(5.7.1) hsSGOL2 exon4 minigene Ampicillin
pSPL3_hsTUBD1_468nt-ex4-438nt *(5.7.1) hsTUBD1 exon4 minigene Ampicillin
pSPL3_mmSgol2_1062nt-ex4-998nt *(5.7.1) mmSgol2 exon4 minigene Ampicillin
pSPL3_mmTubd1_468nt-ex4-553nt *(5.7.1) mmTubd1 exon4 minigene Ampicillin
pTriEx-1-HTNC (Peitz et al. 2002) His-TAT-NLS-Cre-recombinase Ampicillin
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4. Methods
4.1. Eukaryotic cell culture
All cell culture procedures were performed under sterile conditions using a laminar
flow workbench. To prevent contamination with bacteria or fungi the growth medium was
routinely complemented with penicillin, streptomycin and amphotericin B unless noted
otherwise. Eukaryotic cells were grown in sterile incubators at 37°C, 5 % CO2 and 95 % relative
humidity.
4.1.1. Cultivation of eukaryotic cells
HEK293T, NSC34 and murine fibroblasts were cultivated in D-MEM (Dulbeccos’s
Modified Eagle Medium) complemented with 10 % fetal bovine serum. Routinely, cells were
cultivated in 75 cm² or 25 cm² tissue culture flasks and split into new flasks when reaching
confluence. Cells were washed with 1x PBS without Mg2+ and Ca2+ and trypsinized using
Trypsin-EDTA until cells detached from the surface. Trypsinization was stopped with at least
1 volume of culture medium. The cell suspension was homogenized and evenly distributed to
new tissue culture flasks. Depending on the cell type and proliferation rate cells were
distributed at different density. Routinely, HEK293T cells were split 1:40, NSC34 cells 1:5,
primary fibroblast 1:5 and immortalized murine fibroblasts cell lines 1:20.
4.1.2. Counting cells using a Neubauer cytometer
Some applications require defined cell numbers and growth densities to work
optimally. To determine the number of cells in a suspension, a Neubauer counting chamber
was used. After trypsinization of cells (4.1.1) cells were well homogenized in excess of culture
medium. Roughly 40 µl of the homogenized suspension were applied to the counting chamber.
Under a standard microscope the cell number was determined in 4 quadrants of the counting
chamber and the mean was calculated. The cell concentration in the cell suspension is mean x
104 cells per ml.
4.1.3. Generation of murine embryonic fibroblasts (MEF)
Murine embryonic fibroblasts were isolated from 13.5 dpc mouse embryos. Mice of
the desired genotype were crossbred in a timed breeding (4.2.4) to determine the progression
of pregnancy. Pregnant female mice were sacrificed by cervical dislocation and embryos were
prepared from the uterus under sterile conditions and washed in PBS. Visible organs like heart
and liver were removed from the embryos. The heads were used for the isolation of DNA for
genotyping purposes. The embryo was ground in a 70 µm nylon cell filter using a plunger of a
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20 ml syringe. The ground material was flushed through the cell filter with 25 ml of cell culture
medium freshly complemented with antibiotics. Cells were pelleted by spinning for 5 minutes
at 200 x g. Cells were resuspended in 6 ml of culture medium and plated into a 6 cm tissue
culture plate. After 24 h cells were 3 times carefully washed in PBS to remove cellular debris.
Cells were expanded while providing fresh culture medium daily.
4.1.4. Transfection of HEK293T and NSC34 cells
For transfection of HEK293T and NSC34 cells, best efficiency and lowest cytotoxicity
was achieved using the DharmaFECT I transfection reagent (Thermo). Cells were either
transfected with plasmid DNA (3.12), siRNA (3.10) or both simultaneously. Experiments were
carried out in 6-well tissue culture plates with a final cultivation volume of 2 ml. To transfect
2 µg of plasmid DNA and/or 50 pmol of siRNA, 4 µl of DharmaFECT I transfection reagent were
routinely used. 2.5 x 105 HEK293T or NSC cells were plated per 6-well 1 day prior to
transfection in D-MEM complemented with fetal bovine serum without antibiotics. For
transfection experiments assayed after 72 h or 96 h the cell number was reduced down to 1.8
x 105 cells to prevent overgrowth during the experiment. Transfection mixes were prepared
according to the manufacturer’s instructions using OptiMEM to pre-dilute nucleic acids and
transfection reagent. The completed transfection mix was complemented to 2 ml with culture
medium without antibiotics. For RNA analysis cells were harvested after 24 h, 36 h or 48 h.
Proteins were isolated after 48 h, 72 h or 96 h.
To survey transfection efficiency cells were transfected with the pMAX-GFP vector
allowing for easy assessment of the transfection rate via GFP fluorescence. As a negative
control for RNAi experiments the AllStars negative siRNA (Qiagen) was used.
4.1.5. Stable transfection of primary murine embryonic fibroblasts
In this study MEFs were stably transfected with pBABE-zeo-largeT and pcDNA3.1-CT-
GFP-NLS-Cre. This allowed stable expression of the SV40 large T-antigen (immortalization)
(Hahn et al. 2002a) and stable expression of Cre-recombinase. Best results for the transfection
of primary MEFs were obtained using the Mirus TransiT LT transfection reagent (Mirus). 1 x 105
cells were plated to a 6-well tissue culture plate 18 h prior to transfection. Transfection mixes
were prepared as recommended by the manufacturer. Best result were achieved using 2.8 µl
transfection reagent per µg of plasmid DNA and a total of 2.5 µg of plasmid DNA per 6-well.
Transfection efficiency was surveyed by transfecting pMAX-GFP to assess the rate of
transfection by GFP fluorescence. Selection for stably transfected cells was started one to two
days after transfection. Routinely, selection was continued for 2 months using an appropriate
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antibiotic. Cells transfected with pBABE-zeo were selected with 200 µg/ml Zeocin and cells
transfected with pcDNA3.1 were selected with 2,000 µg/ml G418.
4.1.6. Treatment of cells with emetine
To allow detection of transcripts undergoing nonsense-mediated decay (NMD) cells
were treated with the protein synthesis inhibitor emetine. Immortalized MEFs were grown in
culture medium until reaching ~90 % confluence. Emetine was provided to the cells at a
concentration of 100 µg/ml for 10 h. Cell were harvested directly and RNA was isolated for
quantitative analysis.
4.1.7. Cryoconservation of cells
Confluent cell layers were detached from the surface by trypsinization (4.1.1). Cells
were pelleted by centrifugation at 200 x g for 5 minutes and resuspended in cryo-medium
containing DMSO as a cryoprotective agent. For all cell types used in this study a cryomedium
containing 10 % DMSO in fetal bovine serum was applicable. Cells from a growth area of 25
cm² were resuspended in 1 ml of cryo-medium and transferred to a cryo-tube. These were
frozen to -80°C using an isopropanol-based freezing aid, which allowed controlled cool down
rates of approx. 1°C per minute. For long term storage cells were transferred to liquid nitrogen
storage.
To take frozen cells back to culture the frozen cryo-tube was quickly thawed in a 37°C
water bath. The thawed cell suspension was transferred to pre-warmed culture medium and
immediately plated to a 25 cm² tissue culture flask.
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4.2. Working with laboratory mice
4.2.1. Mouse experiments
All procedures involving laboratory animals were performed according to the German
laws of animal welfare and were approved by the ‘Landesamt fuer Natur, Umwelt und
Verbraucherschutz NRW’ under the reference numbers 50.203.2-K 38, 19/05 and 8.87-
51.05.20.10.106. Animals used in this study were kept in the animal facility of the Institute for
Genetics at the University of Cologne and in the central animal facility if the Center of
Molecular Medicine Cologne (CMMC).
4.2.2. Generation of conditional knock-out mice
Mice breedings performed in this study are based on the Tra2bflneo/+ and Tra2bfl/+ lines
generated by Ylva Mende (Mende et al. 2010). These lines have previously been backcrossed
to achieve >96 % C57BL/6N background. To maintain this background all Cre-lines used in this
study were also on C57BL/6N background.
Homozygously floxed Tra2b animals were generated by crossbreeding Tra2bfl/+ animals
with each other. To generate neuronal-specific Tra2b knock-out mice Tra2bfl/fl mice were first
crossbred with Nestin-Cretg/0 animals to obtain Tra2bfl/+; Nestin-Cretg/0 animals. Nestin-Cre
transgenic mice express Cre-recombinase under control of the rat nestin promoter and
enhancer and enable expression of Cre-recombinase in neuronal and glial precursors
(Dahlstrand et al. 1995; Tronche et al. 1999; Mignone et al. 2004). Nestin expression is first
activated at 10.5 dpc in the neural tube, the somites and in migrating cells of the neural crest.
At 15.5 dpc it has been reported to be strongly expressed in the ventricular and subventricular
zone of the cortex (Dahlstrand et al. 1995). To obtain neuronal-specific Tra2b knock-out
animals Tra2fl/fl animals were crossbred with Tra2bfl/+; Nestin-Cretg/0 animals. This
crossbreeding allowed generation of control mice (Tra2bfl/+ and Tra2bfl/fl), heterozygous
conditional knock-out mice (Tra2bfl/+; Nestin-Cretg/0) and homozygous conditional knock-out
mice (Tra2bfl/fl; Nestin-Cretg/0) in a single litter (Figure 8 A).
4.2.3. Tagging and genotyping
Offspring of a breeding was weaned 3 weeks after birth and animals were separated
by sex. To allow accurate animal management each animal was tagged with a numbered ear
tag. For genotyping purposes a biopsy of the tail tip was taken (approx. 3 mm) according to the
German laws for animal welfare (TierSchG §6). Oligonucleotides and genotyping conditions are
listed in 3.9.2.
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4.2.4. Timed breedings
Many applications like the generation of MEFs (4.1.3) or the detailed analysis of
murine development require precise knowledge about the developmental stage of the
analyzed embryo. For this purpose controlled timed matings were performed. Two non-
pregnant females were routinely mated with one male over night. The following morning
females were surveyed for the presence of a vaginal plug indicative of copulation during the
night. Vaginal plugs are remnants of the male ejaculate that can be present up to 24 h after
mating. Positively tested females were isolated and were considered to carry embryos at the
stage of 0.5 dpc assuming fecundation in the middle of the night.
4.2.5. Isolation of prenatal mouse embryos
Mouse embryos were prepared following a time breeding (4.2.4). The pregnant
mother was sacrificed at the desired developmental stage by cervical dislocation. The uterus
harboring embryos was fully transferred to PBS. Embryos were prepared from the uterus and a
tail biopsy was performed for genotyping purposes. Isolated embryos were either fixated in
PFA (4.7.1) or embryonic brains were isolated and frozen in liquid nitrogen for subsequent RNA
(4.4.2.3) analysis.
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4.3. Microbiology Methods
All procedures involving cultivation of bacteria were performed under sterile
conditions. Unless indicated otherwise bacteria were always cultivated under selective
pressure depending on the plasmid propagated. In this study the endA deficient E. coli strains
TOP10 and DH5α were used to amplify the plasmid of interest. Both were obtained as
chemically competent stocks from Life Technologies.
4.3.1. Heat shock transformation of chemically competent bacteria
Chemically competent cells are sensitive to temperature as to their ability to take up
plasmid DNA. Cells were stored at -80°C and were thawed on ice directly before usage.
Routinely, 2 µl of ligation product or approx. 100 ng of plasmid DNA were added to the
bacterial vial and mixed gently by flicking the tube. Bacteria were incubated on ice for 20
minutes and then heat shocked for 30 seconds at 42°C in a water bath. Bacteria were directly
chilled on ice for 2 minutes and 250 µl of pre-warmed S.O.C medium was added. The mix was
incubated for 1 h at 37°C in a shaking incubator to allow expression of resistance genes.
Various amounts (e.g. 20 µl and 200 µl) were plated on selective agar and incubated at 37°C
over night.
4.3.2. Selection of positive clones
Colonies from a selective agar plate were picked using a sterile pipette tip. Routinely,
the bacterial material obtained from one colony was resuspended in 20 µl of sterile H2O. 10 µl
of this water was used as a template in a colony PCR. The colony PCR is a standard PCR
(4.4.3.1) that is supposed to detect the presence of the desired insert cloned into a vector
using specific primers that are optimally positioned in the vector and the insert sequence.
Screening of PCR products via agarose gel-electrophoresis allowed selection of clones with the
supposedly correct insert in correct orientation. The remaining bacteria-containing water of
correctly tested clones was used to inoculate 5 ml selective LB-cultures to generate bigger
amounts of plasmid for further analysis.
4.3.3. Preparation of bacterial glycerol stocks
Generation of glycerol stocks from bacterial cultures allows long term storage of
plasmids within bacteria without the need of re-transforming and screening of clones. Glycerol
stocks were prepared by growing bacteria in a 5 ml culture of selective media. Cultivation was
stopped in the exponential phase of growth (i.e. the culture medium becomes slightly
opaque). 750 µl of bacterial culture were mixed with 250 µl of sterile glycerol as a
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cryoprotective agent. Cryo vials were stored at -80°C. Bacterial cultures were inoculated from
a frozen glycerol stock by transferring a minor piece of ice into selective culture media.
4.4. Molecular Biology Methods
4.4.1. Isolation of DNA
In the following chapter different methods of DNA purification will be explained. All
methods vary in the obtained purity of DNA and the method of DNA isolation was chosen
according to the downstream application. All isolated DNAs were routinely stored at -20°C.
4.4.1.1. Isolation of genomic DNA from murine tail biopsies
A single tail biopsy sample was lysed in 500 µl tissue lysis buffer (3.5) complemented
with 200 µg/ml Proteinase K at 55°C in a shaking heating block at approx. 500 rpm. Hair and
insoluble debris were removed by 15 minute centrifugation at 16,100 x g. The supernatant was
mixed with 1 volume isopropanol in a new reaction tube to precipitate the DNA. Precipitation
was continued for 30 minutes at room temperature. DNA was pelleted for 30 minutes at
16,100 x g and washed with 1 volume of EtOH. After repeated centrifugation the EtOH was
discarded and the DNA was dried in a 37°C heated cabinet or in the Concentrator device. At
last the pellet was resuspended in 80 µl TE-4 (3.5) containing 50 µg/ml RNase A to degrade
possible RNA contamination.
4.4.1.2. Isolation of genomic DNA from tissues and cells
To obtain DNA of good purity from cells and animal tissues the gDNA Blood & Tissue kit
(Qiagen) was used according to the manufacturer’s instructions. For routine use, genomic DNA
from pelleted cells and small amounts of tissue was isolated as previously described for tail
biopsies (4.4.1.1). Depending on the tissue size the lysis step was increased in length. To
improve DNA purity the lysate was optionally subjected to phenol-chloroform extraction
(4.4.1.3).
4.4.1.3. Isolation of genomic DNA from tissues (Phenol-Chloroform)
Following tissue lysis in lysis buffer with proteinase K cellular debris was pelleted for
20 minutes at 16,100 x g. To minimize material loss during phenol-chloroform extraction a
gel-based phase separating system was employed. Phase Lock Gel Heavy (5 Prime) tubes were
prepared by spinning 1 minute at 16,100 x g. The cleared lysate was transferred to the Phase
Lock tube. 1 volume phenol-chloroform was added (i.e. ½ vol. phenol + ½ vol.
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chloroform/isoamylalcohol (24:1) and mixed by vortexing. The Phase Lock tube was rotated for
5 minutes and then spun for 5 minutes at 16,100 x g. The upper aqueous phase was
transferred to a fresh Phase Lock tube and previous steps were repeated with 1 volume of
phenol-chloroform. The procedure was finally repeated with 1 volume of pure
chloroform/isoamylalcohol. After centrifugation the aqueous phase was mixed with 3 volumes
of ice cold 100 % EtOH and 0.1 volumes of 3M NaAc (pH 5.2). DNA was precipitated over night
at -20°C and afterwards pelleted for 20 minutes at 16,100 x g. DNA was washed in 70 % EtOH
and repeatedly centrifuged. After drying in a heating cabinet the pellet was resuspended in
TE-4 with 50 µg/ml RNase A.
4.4.1.4. Preparation of plasmid DNA from bacteria
Depending on the sensitivity and the needs of downstream applications a high purity
and large amounts of plasmid DNA were required. For routine analysis of cloning products a
small yield of plasmid DNA was sufficient. For this purpose the Spin Miniprep Kit (Qiagen) was
used with a culture volume of max. 10 ml. Transfection experiments in eukaryotic cell culture
require high amounts of plasmid DNA and a solid endotoxin removal. To obtain transfection
grade plasmid DNA the PureYield Plasmid Midiprep System (Promega) was routinely employed
with a culture volume of 200 ml. For highest amounts of transfection grade plasmid DNA the
Endo-free Plasmid Maxi Kit (Qiagen) was used with culture volumes of up to 500 ml. Purified
plasmid DNA was stored at -20°C.
4.4.1.5. Determination of DNA concentration via spectrophotometry
Concentrations of DNA solutions were determined using a NanoDrop ND-1000
spectrophotometer (Peqlab). From the measured absorption at the wavelengths of 260 nm and
280 nm the software calculated the DNA concentration and determined the 260nm/280nm ratio,
which is an indicator for DNA purity. A value of 1.8 is indicative of high purity. Lower values
point to possible remnants of ethanol, while higher values indicate the presence of RNA.
4.4.2. Isolation of RNA
RNA was handled under RNase-free conditions including appropriately treated
reaction tubes and stuffed pipette tips. RNA in aqueous solution was always kept on ice and
was stored at -80°C.
4.4.2.1. Isolation of RNA from eukaryotic cells
RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. Depending on the amount of RNA needed, RNA was isolated from 6-well or 6 cm
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tissue culture plates. The culture medium was removed from cells and cells were directly lysed
in RLT buffer (Qiagen) and collected using a cell scraper. Cell lysates were homogenized using
QiaShredder (Qiagen). The on-column RNase-free DNAse digestion was routinely performed in
all RNA isolations to prevent contamination with genomic DNA interfering with downstream
applications. RNA was eluted in RNase-free ddH2O.
4.4.2.2. Isolation of RNA from tissues
Isolation of RNA from small tissue fragments or from tissues with low fat content was
equally performed using the RNeasy Mini Kit (Qiagen) and QiaShredder (Qiagen). To ensure
optimal breakup of organ tissue, specimens were homogenized using a rotor-stator
homogenizer (Ultra Turrax, IKA) before proceeding with the RNA extraction as described in
4.4.2.1.
4.4.2.3. Isolation of RNA from fatty tissues
Isolation of RNA from tissues with high fat content (e.g. brain) requires additional
phenol-chloroform extraction to reduce fat and protein content and to maintain high RNA
purity. 100 mg of fatty tissue were broken up and homogenized in at least 1 ml of QIAzol Lysis
Reagent (Qiagen) using a rotor stator homogenizer (Ultra Turrax, IKA). The suspension was
repeatedly homogenized using QiaShredder (Qiagen) and incubated for 5 minutes at room
temperature to allow dissociation of nucleoprotein complexes. To minimize material loss
during phenol-chloroform extraction a gel-based phase separating system was employed.
Phase Lock Gel Heavy (5 Prime) tubes were prepared by spinning 1 minute at 16,100 x g. Up to
750 µl of the homogenized lysate were transferred into the Phase Lock tube and mixed with
200 µl of chloroform/isomalyalcohol (24:1). Tubes were rotated at room temperature for 5
minutes and centrifuged for 10 minutes at 16,100 x g. If the lysate volume exceeded 750 µl the
process was repeated in a fresh Phase Lock tube. The upper aqueous phase containing RNA
was transferred into a new tube and mixed with 1 volume of RNA-grade 70 % EtOH. The
mixture was then applied to RNeasy (Qiagen) columns and RNA extraction was continued
according to the manufacturer’s instructions and as described in 4.4.2.1.
4.4.2.4. Determination of RNA concentration via spectrophotometry
Concentrations of RNA solutions were initially determined using a NanoDrop ND-1000
spectrophotometer (Peqlab). From the measured absorption at the wavelengths of 260 nm and
280 nm the software calculated the RNA concentration and determined the 260nm/280nm ratio,
which is an indicator for RNA purity. A value of 2.0 is indicative of high purity. The
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determination of RNA concentrations with a standard spectrophotometer is insufficiently
precise to allow reliable quantification of transcripts via real-time PCR. For quantitative
downstream applications RNA concentrations need to be determined more accurately
(4.4.2.5).
4.4.2.5. Determination of RNA concentration (Ribo-Green method)
Accurate determination of RNA concentrations was performed using the Quant-IT
RiboGreen RNA assay (Life Technologies) as described in the manufacturer’s instructions. This
technique is based on the RiboGreen dye, which increases its fluorescence when bound to
RNA. This allows RNA quantification that is unbiased by compounds absorbing at similar
wavelengths. The assay was carried out in dark 96-well plates (#655076, Greiner) on a Safire²
microplate reader (Tecan). RiboGreen allows absolute RNA quantification using an included
RNA standard series ranging from 0 to 100 ng/µl. Therefore, the measured samples were pre-
diluted to match the standard range. By fluorescence measurement of the standard series a
standard curve was established by linear regression. The linear equation was used to
determine absolute concentrations from fluorescence values obtained from samples.
4.4.2.6. Evaluation of RNA integrity (Experion gel-electrophoresis system)
For highly sensitive applications (e.g. exon array analysis) the purity and integrity of
RNA samples was further analyzed on the Experion gel-electrophoresis system (BioRAD) using
the Experion RNA StdSens Kit (BioRAD) according to the manufacturer’s instructions. This
system analyzes RNA integrity by assessing band sizes of the 18S and 28S ribosomal RNAs.
These molecules should appear at distinct sizes of 1874 nt and 4718 nt, respectively. Gross
deviation from these values or smear is indicative of impaired RNA integrity. Degraded
samples or samples with impaired integrity have been excluded from exon array analysis or
have been replaced by intact RNA samples.
4.4.3. Polymerase chain reaction
The polymerase chain reaction (PCR) was developed by Kary Banks Mullis in 1983
(Mullis et al. 1992). PCR utilizes thermostable DNA polymerases to extend 3’-OH ends of DNA
oligonucleotides specifically binding to a DNA matrix molecule. Primer extension leads to cyclic
amplification of the template, as each extension product serves as a new template in the
subsequent cycle.
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In this study PCR was a fundamental tool that many applications were based on. PCR was used
for the genotyping of mice, for the generation of protein encoding sequences during cloning
and for the quantification of transcripts from single stranded cDNA.
4.4.3.1. The standard PCR
For routine PCR, as applied for genotyping purposes but also for semi-quantitative PCR from a
single stranded cDNA, the Recombinant Taq DNA Polymerase kit (Life Technologies) was used.
A typical PCR setup on a 25 µl scale is shown in Table 1.
Table 1 | Typical PCR setup.
PCRs using the recombinant Taq DNA polymerase (Life Technologies) were routinely performed in a 25 µl scale. 10x
PCR buffer and a 50 mM MgCl2 solution were provided with the kit.
component amount
H2O (ad 25 µl) 14.35 µl
PCR buffer (10x) 2.5 µl
MgCl2 (50 mM) 0.75 µl (1.5 mM)
dNTP Mix 4 µl
fw oligonucleotide (10 µM) 1 µl
rev oligonucleotide (10 µM) 1 µl
Taq DNA polymerase 0.4 µl
Template (20-200 ng) 1 µl
A starting point to assess performance of a PCR included MgCl2 concentrations of
1.5 mM and primer concentrations of 0.4 µM. Amplification of targets that were difficult to
amplify or that yielded unspecific products was enhanced by adaption of PCR conditions.
Increasing the MgCl2 concentration boosts polymerase performance on cost of primer binding
specificity. Decreasing the MgCl2 concentration can make primer binding very specific, but the
amplification reaction might become very ineffective. Similar effects can be achieved by
adjustment of the annealing temperature. Low temperatures cause primers to effectively bind
the template but allow unspecific primer binding. High temperatures increase binding
specificity but might also reduce the number of primers binding the template, thus decreasing
PCR efficiency. The annealing temperature of a PCR program should be adjusted according to
the oligonucleotide properties. Melting temperatures of oligonucleotides were calculated
using the OligoCalc web application as listed in 3.11.2. A typical PCR program is shown in Table
2.
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Normal Taq DNA polymerase is prone to insertion of wrong nucleotides and usually
causes insertion of mutations into the amplified sequence. For that reason, proof reading
polymerases were used for cloning procedures to preserve the original sequence. Proof
reading polymerases used were AccuPrime Polymerase and Platinum Taq Polymerase (Life
Technologies) as stated in 3.4.2. These polymerases vary from recombinant Taq DNA
polymerase as they use different buffer systems and work best at 68°C. Proof reading PCRs
were performed as suggested by the manufacturer.
Table 2 | Standard PCR program.
The usual PCR begins with an initial denaturation step melting the double stranded DNA template followed by 38
cycles of denaturation, annealing and extension. Finally, incomplete product are complemented for 10 minutes at
72°C. The annealing temperature varies between PCRs and depends on the oligonucleotide properties. The
extension temperature is chosen according to the enzymes optimum temperature (i.e. 72°C for Taq polymerase)
which may vary between enzymes). Extension time depends on the amplicon length and processing speed of the
polymerase.
initial denaturation 5 min 95°C
denaturation 30 sec 95°C
38 cyclesanneling 30 sec 50-68°C
extension ~1min/kb 72°C
final extension 10min 72°C
4.4.3.2. Colony PCR
Colony PCR was used to identify bacterial clones that have successfully taken up a
vector during transformation. Furthermore, the orientation of an insert within the vector was
analyzed. Colony PCR is based on a standard PCR setup as described in Table 1 and Table 2.
Bacteria of a colony were resolved in 20 µl of sterile water as described in 4.3.2. 10 µl of this
solution served as a template for colony PCR. As template DNA was enclosed within intact
bacteria the initial denaturation step of the PCR was increased to 10 minutes to allow effective
lysis of the bacteria. Primers used for colony PCR were located on the vector sequence and
within the insert. This allowed not only detecting the presence but also the orientation of the
insert.
4.4.3.3. Clean-up of PCR products
Applications like ligations, digests by endonucleases and sequencing reactions require
removal of PCR buffer, enzymes and free nucleotides from PCR products. For PCR clean-up the
QIAquick PCR Purification Kit (Qiagen) was used according to the manufacturer’s instructions.
PCR products were eluted in ddH2O.
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4.4.3.4. Design of oligonucleotides
The design of oligonucleotides can significantly determine PCR specificity and
efficiency. There are some guidelines for oligonucleotide design that were roughly followed to
design primers for this study. Oligonucleotides used in PCRs are usually 18-30 nucleotides long
and should have a GC content between 30 % and 70 %. Primers should end on at least 1 but at
maximum 3 consecutive G or C nucleotides at the 3’ end. Forward and reverse primers should
have similar melting temperatures to be compatible in a PCR. Both primers should not be
complementary with themselves or with each other to prevent formation of hairpins or primer
dimers. Many of these molecular features were analyzed during primer design using the
OligoCalc web application (3.11.2). To minimize the number of unspecific but as to their
sequence similar targets Primer BLAST was performed (3.11.2). All oligonucleotides used in this
study, their sequences and optimal PCR conditions are listed in 3.9. Oligonucleotides used in
this study were produced by Metabion and Integrated DNA Technologies (IDT).
4.4.3.5. Reverse Transcription
cDNA synthesis was routinely performed using SuperScript VILO (Life Technologies) or
the QuantiTect Reverse Transcription kit (Qiagen) according to the manufacturers instructions.
For quantitative real-time PCR the QuantiTect kit (Qiagen) was used exclusively. Prior to cDNA
synthesis the RNA concentration was determined by the RiboGreen method (4.4.2.5). For
quantitative real-time PCR 150 ng of RNA was reversely transcribed in a 10 µl setup. For
generation of a standard series 600 ng of RNA was used in 20 µl.
4.4.3.6. Semi-quantitative Reverse Transcription PCR
Semi-quantitative Reverse-Transcription PCR uses single-stranded cDNA as a template.
After amplification of a specific cDNA copy of a transcript, original transcript amounts can be
estimated by measuring band intensities on an agarose gel. This method is an end-point assay
and evaluates amounts of PCR products at the end of a PCR. Reaction kinetics in every PCR
include an exponential amplification phase followed by a saturation phase in which product
amounts are no longer increasing. Therefore, in semi-quantitative RT-PCRs the cycle number
has to be reduced as far as possible to allow valid densitometric band analysis, while the
reaction was still performing exponentially. Running semi-quantitative PCRs for too many
cycles will mostly result in equal band intensities, as all PCRs reached saturation, even though
original cDNA levels might have been different. To overcome inaccuracies in quantification
based on unequal loading of PCR template or unequal loading of the gel, all semi-quantitative
PCRs were performed as multiplex PCR with a housekeeping gene.
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Semi-quantitative RT-PCR was performed using Recombinant Taq DNA Polymerase (Life
Technologies). PCR conditions of all applied PCRs were thoroughly optimized and the cycle
numbers were reduced until bands became clearly weak but were still measurable.
Densitometric analysis was performed using the ChemiDoc XRS system (BioRAD) in
combination with the QuantityOne Software (BioRAD) or ImageJ (3.11.1).
4.4.3.7. Quantitative real-time PCR
Quantitative real-time PCR (qPCR) overcomes the limitations of semi-quantitative
RT-PCRs. Even though it underlies the same reaction kinetics as any other PCR, template
amounts can be robustly determined. In contrast to the semi-quantitative PCR, qPCR measures
product amplification as it happens during exponential phase. In this study qPCRs were
performed on the Roche Light Cycler 1.5 using the Light Cycler Fast Start DNA Master SYBR
green I kit (Roche) according to the manufacturer’s instructions. The SYBRgreen I dye
preferentially binds to DNA but also to RNA. Its absorption maximum is at 494 nm (blue).
When excited SYBRgreen emits green light (521 nm). The fluorescence is strongest when
bound to double stranded DNA but is much weaker when bound to single stranded DNA or
RNA. After each primer extension step of a qPCR, SYBRgreen fluorescence is measured at 80°C.
At this temperature double stranded DNA caused by primer dimmers or cDNA hairpins is
denatured but longer PCR products are stable allowing a precise determination of PCR product
amounts in every PCR cycle. As SYBRgreen binds double stranded DNA independently of the
sequence, all PCR products including unspecific side products are measured. Therefore,
specific product amplification is vital for SYBRgreen-based systems. Product specificity was
surveyed by dissociation curve analysis and subsequent agarose gel electrophoresis. All qPCR
primers used in this study amplify their target specifically at the indicated conditions (3.9.3).
For use as a template for qPCR, cDNA was produced as described in 4.4.3.5. The template
solution was generated by diluting cDNA 1:5 in TE-4 buffer (e.g 8 µl of cDNA (from 150 ng RNA
in 10 µl) + 32 µl of TE-4). A standard series was generated from a 600 ng RNA reverse
transcription reaction as shown in Table 3. The cycle threshold of each standard concentration
was plotted against the concentraton (log) and the standard curve was extrapolated by linear
regression. This curve was then reversely used to calculate the concentrations of samples from
their respective cycle threshold value. Samples were routinely measured as duplicates and
averaged using the arithmetic mean. For a 10 µl qPCR setup 3 µl of template solution were
routinely used. The composition of a typical qPCR is shown in Table 4.
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Table 3 | Dilution of a cDNA standard series for qPCR.
cDNA was diluted 1:2.5 in TE-4 buffer to generate templates with different concentrations ranging from 64 (i.e.
64/64) to 1 (i.e. 1/64 of the starting cDNA concentration)
Standard sample cDNA diluent
standard 64 (1:2.5) 16 µl cDNA (from 600 ng RNA in 20 µl) 24 µl TE-4
standard 32 (1:5) 20 µl standard 64 20 µl TE-4
standard 16 (1:10) 20 µl standard 32 20 µl TE-4
standard 8 (1:20) 20 µl standard 16 20 µl TE-4
standard 4 (1:40) 20 µl standard 8 20 µl TE-4
standard 2 (1:80) 20 µl standard 4 20 µl TE-4
standard 1 (1:160) 20 µl standard 2 20 µl TE-4
Table 4 | Typical qPCR setup for the Roche LightCycler 1.5.
qPCRs in the Roche Light Cycler 1.5 using the SYBRgreen I Master Mix were routinely performed in a 10 µl scale.
H2O, MgCl2 solution, SYBRgreen Master Mix and Fast Start enzyme were provided in the kit. A MgCl2 concentration
of 3 mM was suitable for most applications but was decreased in some reactions to improve primer specificity.
component amount
H2O (ad 10 µl) 2.8 µl
MgCl2 (25 mM) 1.2 µl (3 mM)
fw oligonucleotide (10 µM) 1 µl
rev oligonucleotide (10 µM) 1 µl
SYBRgreen Master Mix 0.833 µl
LC Fast Start Enzyme 0.166 µl
diluted cDNA template 3 µl
4.4.4. Agarose gel electrophoresis
DNA fragments of different sizes were separated by agarose gel-electrophoresis for
analytical and preparative purposes. Different concentrations of agarose (e.g. 0.5 % - 3 %)
were used according to the size of DNA fragments to analyze. For agarose concentrations
higher than 1.5 % an agarose mix consisting of 1/3 standard agarose and 2/3 low melting
agarose was used. For preparative applications including in-gel ligation of DNA 0.8 % of pure
low melting agarose was used. Before loading, the gel was chilled to 4°C to become fully solid.
Low melting gels were run at low voltage (e.g. 60 Volts) to prevent melting. For preparation
agarose was melted in TBE buffer and supplemented with ethidium bromide (1:10,000). This
allowed visualization of DNA when exposed to UV-light. DNA samples were mixed with 6x
loading buffer, transferred to the gel and separated at 60 Volts to 180 Volts depending on the
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gel size and agarose concentration. Results were documented using the ChemiDoc XRS
documentation system (BioRAD).
4.4.5. Cloning Procedures
4.4.5.1. TOPO TA cloning
Cloning of DNA fragments into the eukaryotic expression vectors pcDNA3.1 was
performed using the pcDNA3.1 TOPO TA Expression Kits (Life Technologies). Different versions
of the pcDNA3.1 vector allow expression of fusion proteins with either GFP or V5-His tag.
Vectors used for cloning are listed in 3.12. The TOPO TA ligation method uses 3’-adenine
overhangs produced by Taq polymerase during PCR or previous 3’-adenylation for the ligation
of a PCR product into the pcDNA vector. Topoisomerase coupled to the linearized vector
allows effective but non-directional ligation of insert and vector. Ligation and transformation
procedures were performed according to the manufacturer’s instructions. Also the ligation of
in-gel DNA fragments obtained from low melting agarose gels (4.4.4 and 4.4.5.4) was
successfully performed using TOPO TA vectors.
4.4.5.2. Restriction Digest of DNA
Digestion of DNA with endonucleases was performed using restrictions enzymes and
buffer systems from New England Biolabs (3.4.2). Digests were performed as a preparative
step for directional ligation of DNA fragments into a vector or for analytical purposes. Nucleic
acids used for digestion were either purified plasmids in ddH2O (4.4.1.4) or purified PCR
products in ddH2O (4.4.3.3). Double digests were performed depending on buffer
compatibility.
4.4.5.3. Extraction of DNA from agarose gels
DNA was routinely extracted from agarose gels using the QIAquick Gel Extraction kit
(Qiagen) according to the manufacturer’s instructions. DNA was eluted in ddH2O.
4.4.5.4. DNA ligation and in-gel ligation
Ligation procedures were performed using T4 DNA ligase (Promega) as suggested by
the manufacturer. Ligation was performed in a 20 µl reaction scale when using purified vector
and insert sources. For ligation of in-gel vector and insert fragments the volume was increased
to 50 µl to compensate for changes in the buffer system caused by the presence of TBE from
the gel buffer. Digested PCR products and plasmids were resolved on a 0.8 % low melting
agarose gel as described in 4.4.4. Bands were excised using a sharp scalpel while minimizing
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the amount of total agarose cut. Agarose containing DNA was transferred to reaction tubes
and heated to 70°C for 5 minutes to allow homogenization of the DNA agarose mixture.
Depending on band intensities observed on the gel a total of up to 30 µl of agarose solution
(including insert and vector) was used in a 50 µl ligation setup. Ligation was either performed
at 14°C over night or for 2 hours at room temperature. 2 µl of a completed ligation reaction
were used for heat-shock transformation of chemically competent bacteria as described in
4.3.1.
4.4.6. DNA sequencing
Sequencing of purified plasmid DNA and purified PCR products was performed at GATC
Biotech. PCR products were routinely sequenced using custom made primers. Inserts of
vectors were sequenced using custom primers and vector-primers provided by GATC.
Sequence alignment and analysis was performed using the SeqMan application from the
Lasergene Suite (DNAstar).
4.5. High throughput screening for alternatively spliced exons
Aiming on the discovery of alternatively spliced exons regulated by Tra2b in the
murine developing central nervous system, two high throughput screening approaches have
been performed. In both approaches relative abundances of single exons were compared to
the abundance of the respective whole transcript to allow detection of differences in exon
inclusion between control (Tra2bfl/+) and conditional knock-out aimals (Tra2bfl/fl; Nestin-Cretg/0).
4.5.1. Whole transcriptome sequencing
Whole transcriptome sequencing was performed by the Cologne Center for Genomics
(CCG) using a RNA-sequencing approach from reversely transcribed cDNA. mRNA was isolated
by poly-A selection. Sequencing was performed as a paired-end sequencing run with 2 x 95 bp
of read length. Sequence data was aligned to the murine transcript database at Ensembl. All
bioinformatic analyses and data processing was performed by Dr. Peter Frommolt (CCG). Exon
and transcript abundances were estimated using a RPKM (reads per kilobase per million
mapped reads) based model. Statistically, the number of reads mapping to an exon reflects the
relative abundance of that exon. To exclude effects of differential gene expression, exon-
specific RPKM-values were normalized to the RPKM-value of the respective whole transcript.
In total 3 control animals have been compared to 3 conditional knock-out animals using whole
brain RNA. Normalized RPKM-values for each exon were grouped according to the genotype
and statistically compared. Candidate exons were sorted according to differences in RPKM,
which suggested a differential usage of that exon in control and knock-out animals. Candidate
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exons obtained in this approach were analyzed for validation of alternative splicing events by
qPCR.
Many methodological details of the transcriptome data analysis and their variations
had direct effect on data and outcome. Therefore, numerous items are described in detail in
chapter 5.5 of the result section.
4.5.2. Mouse exon arrays
Mouse exon arrays were performed in the laboratories of Prof. A. Sachinidis at the
Institute of Neurophysiology at the University of Cologne. Array analysis and preparative work
was carried out by Dr. Kesavan Meganathan. The main workflow of mouse exon array
preparation and labeling procedures is shown in Figure 7. All procedures have been carried out
according to the manufacturer’s instructions as described in the respective manuals of the WT
Expression Kit (Ambion) and the WT Terminal Labeling and Hybridization Kit (Affymetrix).
Whole brain RNA samples of Tra2bfl/+ and Tra2bfl/fl; Nestin-Cretg/o mice were prepared as
follows:
RNA samples were used as starting material and their quality and concentration was
analyzed on the Experion gel-electrophoresis system (BioRAD) as described in 4.4.2.6. From
mRNA first strand cDNA synthesis was performed using T7 promoter-coupled oligo(dT) primers
and 100 ng of total RNA. The mRNA template was digested by RNAse H digest and the
complementary DNA strand was synthesized using DNA-polymerase to produce ds cDNA. In an
overnight in vitro transcription reaction antisense cRNA was produced using T7 RNA-
polymerase. cRNA was purified using a magnetic bead system provided with the kit to remove
enzymes, salt and free nucleotides. The total cRNA yield was determined using the Nanodrop-
1000 spectrophotometer as described in 4.4.1.5. More than 20 µg of cRNA should have been
produced from 100 ng RNA. 10 µg cRNA was used to generate single sense strand cDNA using
random primers and a nucleotide mix containing dUTP. The cRNA template was digested by
RNAse H and sense strand cDNA was purified using the provided magnetic bead system. The
cDNA yield was determined using the Nanodrop-1000 spectrophotometer (4.4.1.5). More than
6 µg of cDNA should have been produced from 10 µg cRNA. Single stranded sense cDNA was
fragmented using uracil-DNA-glycosylase (UDG) and apurinic/apyrimidinic endonuclease
(APE1) cleaving DNA at positions of incorporated dUTP. cDNA ends were labeled using
terminal deoxynucleotidyl transferase (TdT) with the DNA labeling reagent provided with the
WT labeling kit. Labeled cDNA was hybridized to the array for 16 h and subsequently processed
using an Affymetrix fluidics station for washing, staining and repeated washing, while using
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components provided with the Hybridization Wash and Stain kit (Affymetrix). Arrays were
scanned using an Affynetrix GeneChip scanner.
Bioinformatic analyes were carried out by Dr. John Antonydas Gaspar. In short: Both
gene level and exon level analysis were performed using R, Bioconductor package and Partek
Genomic Suite tools. Preprocessing of exon array data included background correction using
RMA (Bolstad et al. 2003), adjusting for GC-content, Quantile normalization and probeset
summarization using mean and setting log probes using base 2. The probeset class, Gene
extended was used. Preprocessing was performed by Partek Genomic Suite. Gene level
analysis was performed in core extended mode. Transcripts showing very low expression signal
values of less than 25 across arrays were eliminated and only 23,331 transcripts (annotated
and non-annotated) were taken for statistical analysis. Moderated t statistics of linear model
analysis (Smyth 2004) was employed to filter the differentially expressed transcripts. Threshold
values of t score-p value of ≤0.05 and fold-change value 1.5 were used to generate a significant
gene list. Partek Genomic Suite was used for statistical filtering of the alternatively spliced
variants. Prior to alternative splicing calculation the probe sets with signals <3 (at log 2 scale)
were excluded. The threshold values used for statistical filtering were set to p-value ≤0.05 and
fold-change values of 1.5 for high confidence (personal communication with Dr. Gaspar).
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Figure 7 | Whole transcript sense target labeling workflow.
The Ambion® WT Expression Kit (Ambion) was used to amplify and generate sense strand cDNA with unbiased
coverage of the transcriptome. cDNA was labeled and prepared using the GeneChip® WT Terminal Labeling and
Hybridization Kit (Affymetrix). The array used was GeneChip® Mouse Exon 1.0 ST Array (Affymetrix). The figure is
based on the Affymetrix product information.
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4.6. Proteinbiochemistry
4.6.1. Extraction of proteins
Proteins were generally isolated in RIPA buffer (Sigma-Aldrich) containing a mix of
protease inhibitors (Complete Mini Protease Inhibitors, Roche). 1 tablet of protease inhibitors
was resolved in 10 ml of RIPA buffer. All isolation steps were carried out at 4°C and proteins
were routinely stored at -80°C.
4.6.1.1. Extraction of proteins from eukaryotic cells
Cells were detached from growth surface by trypsinization and pelleted as described in
4.1.1. Cells were washed in PBS without Ca2+ and Mg2+ and transferred to new reaction tube.
Depending on cell type and cell number the pellet was resuspended in an appropriate amount
of ice cold RIPA buffer (e.g. 40 µl RIPA for a confluent 6-well of HEK293T or NSC34 cells). For
efficient lysis cells were incubated on ice for 30 minutes. Lysate was centrifuged for 30 minutes
at 16,100 x g and 4°C to sediment cellular debris. The supernatant containing soluble proteins
was transferred to a new pre-chilled reaction tube. Isolated proteins were snap-frozen in liquid
nitrogen and stored at -80°C.
4.6.1.2. Extraction of proteins from tissues
Lysis and protein extraction from animal tissues requires additional steps for efficient
tissue break up and lysis. To obtain protein from organs (e.g. brain, liver, lung, spleen or testis)
the tissue was homogenized in RIPA buffer containing protease inhibitors using a rotor stator
homogenizer (Ultra Turrax, IKA). The homogenizer was cleaned after each homogenization
step in 1 % SDS, 70 % EtOH and ddH2O. Depending on tissue size 200 µl to 400 µ of RIPA buffer
was used. Tissues with high protein content (e.g. brain) generally required a larger lysis
volume. For effective lysis the homogenate was incubated on ice for 30 minutes. Subsequent
steps were performed as described in 4.6.1.1.
4.6.1.3. Determination of protein concentration via Bradford protein assay
Protein concentrations were determined using the protein assay according to Bradford
(Compton and Jones 1985). The Bradford reagent contains the dye Coomassie-Brilliant-Blue
G-250, which forms complexes with cationic and nonpolar amino acids in acidic environment.
This stabilizes the dye in its non protonated form which causes a shift of light absorbance
maximum from 470 nm to 595 nm. 1 µl of protein lysate was mixed with 499 µl of Bradford
reagent (Applichem) and incubated at room temperature for 10 minutes. The concentration
62 Methods
was determined by measuring the absorption at 595 nm on a standard spectrophotometer
(Eppendorf) using a standard of 0.5 µg to 5.0 µg of BSA for calibration.
4.6.2. Discontinuous SDS-PAGE
During SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel-electrophoresis) proteins
are resolved according to their molecular weight within an electric field. Proteins of different
size or molecular weight proceed through the polyacrylamide gel with different velocities.
Furthermore, the anionic detergent SDS is applied, which adapts the mass to charge ratio of
proteins. Proteins become negatively charged and their speed in the gel is almost exclusively
determined by their mass. SDS also denatures secondary and tertiary structures. Thus proteins
of similar mass proceed towards the anode at same velocities without being impaired by their
innate conformation. Hydrogen- and disulfide-bonds are severed due to boiling in presence of
reducing compounds like dithiothreitol or β-Mercaptoethanol (Laemmli 1970).
In this study discontinuous SDS-PAGEs were carried out. Routinely, a 4 % stacking gel
and a 12 % resolving gel was used to separate most target proteins. Discontinuous SDS-PAGE
allows proteins to focus in a sharp band within the stacking gel and to simultaneously start
resolving in the resolving gel. This effect is based on a discontinuous buffer system with low pH
of 6.8 in the stacking gel and higher pH of 8.8 in the resolving gel. Proteins traveling through
the stacking gel have the same charge and their speed is hardly biased by their size, as the gel
matrix is insufficiently dense (4 %). In the stacking gel proteins are focused between two ion
fronts: The quickly moving Cl- and the slowly moving glycine, which has its isoelectric point pI
at 5.97 and therefore close to pH 6.8. As the ion front approaches the resolving gel (pH 8.8)
glycin overtakes the proteins, which are then no longer focused and resolve according to their
size caused by interaction effects with the dense gel matrix.
SDS gels were prepared between two vertical glass plates. First, the resolving gel (3.5)
was prepared and isopropanol was pipetted on top to produce a sharp edge. After
polymerization was complete, isopropanol was removed and the stacking gel (3.5) was poured
on top.
The total protein concentration of lysates was determined according to Bradford
(4.6.1.3). 7.5 µg to 20 µg of total protein were supplemented with 1 volume of 2x SDS sample
buffer and boiled for 5 minutes before being loaded to the gel. As a protein ladder 10 µl of the
PageRuler™ Prestained Protein Ladder (Thermo) were loaded. Electrophoresis was performed
at low initial voltage of 80 Volts while proteins were moving through the stacking gel. Voltage
was increased up to 180 Volts while resolving.
63Methods
4.6.3. Transfer of proteins to PVDF blotting membranes
Proteins that have been resolved by SDS-PAGE (4.6.2) were electrophoretically
transferred to PVDF (polyvinylidene fluoride) blotting-membranes. All transfers have been
performed via wet-blot (tank–blot) according to Towbin (Towbin et al. 1979). Protein transfer
was carried out at 4°C for 2 hours at 100 Volts or over night at 30 Volts. Successful transfer of
proteins could be recognized due to pre-stained protein ladders that were visible on the
blotting membrane.
4.6.4. Immunostaining of proteins on PVDF membranes
The immunoblot or Western Blot utilizes antibodies to specifically detect proteins.
Primary antibodies specifically bind epitopes of the target protein. The primary antibody is
then detected by secondary antibodies, which are conjugated to HRP (horseradish peroxidase).
The desired protein can finally be detected by chemiluminescence using Super Signal West
Pico ECL Substrate (Thermo). This substrate contains H2O2 and luminol. As HRP cleaves H2O2,
luminol will luminesce.
After blotting (4.6.3) the membrane was shortly washed in TBST and blocked with
6 % milk powder in TBST at 4°C for 2 h or overnight. Primary antibodies were applied in TBST
with 2 % milk powder and incubated at 4°C. Concentration and the duration of incubation time
for each antibody are stated in 3.8.1. The membrane was washed 5 times for 5 minutes in
TBST to remove non-bound antibodies. The secondary antibody was applied in TBST with
2 % milk powder at concentrations indicated in 3.8.2. All secondary antibodies used for
immunoblots were HRP-conjugates. To remove non-bound secondary antibody the membrane
was washed 5 times for 5 minutes in TBST. To visualize the protein of interest the membrane
was incubated for 5 minutes in chemiluminiscence substrate. Results were recorded using the
ChemiDoc XRS system (BioRAD). Densitometric analysis was performed using the QuantityOne
Software (BioRAD) or ImageJ (3.11.1).
4.6.5. Restoring of PVDF membranes for re-blotting
For repeated immunological detection of proteins on previously used PVDF
membranes bound antibodies were removed by shaking the membrane for 7 to 15 minutes in
Restore Western Blot Stripping Buffer (Thermo). Afterwards the membrane was washed twice
in TBS before proceeding with a new immunostaining.
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4.7. Histological Methods
In this study brains of conditional knock-out mice were histologically analyzed at
various developmental stages. To obtain mice of the desired genotype at the desired stage
timed breedings were performed as described in 4.2.4.
4.7.1. Histological preparation of animal tissues
Pregnant females were sacrificed by cervical dislocation and embryos were isolated as
described in 4.2.5. Isolated embryos were washed in PBS and fixated in PBS with 4 % PFA at
4°C for 1 day or longer to prevent tissue decay. Embryos at developmental stages later than
15.5 dpc were skinned prior to fixation to allow efficient uptake of PFA. Preparation of the
specimen for micro-dissection included fully automated dehydration and paraffin embedding
using a tissue processor (TP1028, Leica). After micro-dissection, paraffin sections were
flattened in a water bath and dried over night at 37°C.
4.7.2. Haematoxylin/Eosin staining of paraffin-embedded sections
HE staining (haematoxylin and eosin staining) was used as an initial standard staining
procedure to allow gross histological analysis. Upon HE staining nuclei are stained dark blue
while most parts of the cytoplasm (i.e. proteins) are stained red to pink.
Paraffin-embedded sections were first deparafinized for 2 x 15 minutes in xylene and
rehydrated in a series of EtOH solutions of decreasing concentrations (each 2 min in
100 % EtOH, 96 % EtOH, and 70 % EtOH). Sections were shortly washed in PBS and H2O.
Staining with haematoxylin was performed for 6 minutes. Specimens were shortly rinsed in
water and then washed for 15 minutes in fresh water. Finally, sections were shortly rinsed in
ddH2O. Eosin staining was performed for 1 minute before shortly washing in H2O. At the end
specimens were dehydrated with an EtOH series of increasing concentration (each 1min in
70 % EtOH, 96 % EtOH and 100 % EtOH). For sample preparation sections were incubated for
1 minute in xylene and mounted with Eukittmounting medium.
4.7.3. Immunostaining of paraffin-embedded sections
Paraffin-embedded sections were first deparafinized in xylene and rehydrated in a
series of EtOH solutions of decreasing concentrations (each 2 min in 100 % EtOH, 96 % EtOH,
and 70 % EtOH) followed by 10 minutes incubation in ddH2O. To improve epitope accessibility
antigen retrieval was performed by boiling specimens 3 times for 5 minutes in citrate buffer in
a microwave at 600 W. Specimens were left 45 minutes for cool down before washing for 5
minutes in TBS. Sections were blocked for 45 minutes at room temperature in a moist chamber
(20 % goat serum, 1 % BSA in TBS) and afterwards washed 3 times for 5 minutes in TBS. The
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primary antibody was applied in a moist chamber over night at 4°C in TBS with 3 % milk
powder. Concentrations of primary antibodies for immunohistochemistry are stated in 3.8.1.
To remove non-bound antibodies sections were washed 3 times in TBS. Biotinylated secondary
antibodies were applied in a moist chamber for 30 minutes in TBS with 3 % milk powder and
samples were repeatedly washed 3 times for 5 minutes in TBS. In a 30 minute reaction
avidin-conjugated peroxidase was coupled to biotinylated antibodies using the Vectastain ABC
kit (Vector Laboratories) according to the manufacturer’s instructions. Specimens were washed
3 times for 5 minutes with TBS were then incubated with DAB (diaminobezidine) staining
solution. Enzymatic turnover of H2O2 causes DAB to produce a brownish stain. After sufficiently
strong staining was achieved, sections were rehydrated and mounted as previously described
(4.7.2).
4.7.4. Microscopy
Parffin-embedded brain sections were microscopically analyzed. Images were recorded
on a Zeiss AXIO microscope and the Zeiss M2 imaging system using the ZEN software (Zeiss,
Jena, Germany). Routinely, whole mount overview images were taken using 1.25x
magnification. For high resolution analysis multiple images have been taken to finally cover the
whole sample using 10x magnification. Images were merged and blended using the Demo
version of the Autostitch software. Overlap of image recording at the microscope allowed
perfect panoramic assembly of single images. Images used for brain analysis that are shown in
this work are high resolution panoramic assemblies consisting of multiple 10x magnification
shots.
4.8. Statistical analyses
Data obtained in this study was generally undertaken to statistical evaluation to
analyze the technical error of a measurement or to determine the significant difference
between groups of biological replicates. All statistical analyses were carried out using Excel
2007 (Microsoft). Some measurements were recorded as duplicates (e.g. qRT-PCR, Light Cycler
1.5, n=2) or triplicates (RiboGreen method of determining the RNA concentration, n=3) to
allow calculation of the mean to minimize the technical error caused by device inaccuracies or
inaccurate pipetting. To assess biologically significant differences, groups of biological
replicates (e.g. mice of a specific genotype or equally transfected but individual cell cultures)
were compared to each other. N gives the number of biological replicates; i.e. the number of
individuals per group observed. The average of each group was calculated by the arithmetic
mean, while the dispersion of readout values within a group was represented by the standard
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error of the mean (s.e.m.). Error bars within bar charts represent the s.e.m. unless indicated
otherwise. Student’s t-Test was employed to determine the statistical significant difference
between groups. The probabilities for data points belonging to indifferent groups are are 0.05
(*), 0.01 (**) or 0.001 (***).
The statistical analyses of raw data obtained in high throughput screening approaches
are described in the sections 4.5.1 and 5.5.1 for whole transcriptome sequencing and in the
sections 4.5.2 and 5.6.2 for mouse exon arrays. All candidate filtering strategies explained in
these sections were performed using filtering and sorting functions of Excel 2007 (Microsoft).
Analyses of exon sequences for the detection of GAA-binding motifs was performed by Dr.
Radu Wirth using custom made scripts.
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5. Results
5.1. Generation and validation of neuronal-specific Tra2b knock-out mice
Tra2b is a potent modifier of SMN2 exon 7 splicing, which makes it an extremely
promising candidate to ameliorate the SMA phenotype (Hofmann et al. 2000). HDAC inhibitors
have been demonstrated to effectively increase SMN2 exon 7 inclusion via transcriptional
upregulation of Tra2b ultimately resulting in increased amounts of SMN protein (Brichta et al.
2003; Riessland et al. 2006; Riessland et al. 2010). This makes HDAC inhibitors a potent tool to
establish treatment strategies for SMA. However, splicing factors are not restricted to a single
target, and increased expression levels of Tra2b might alter the splicing pattern of a multitude
of transcripts. This study aims at the identification of physiological Tra2b target transcripts in a
murine in vivo model system. Ubiquitous ablation of Tra2b in the mouse is incompatible with
life and results in early embryonic lethality (Mende et al. 2010). In this study a neuronal-
specific knock-out mouse was generated to allow the analysis of Tra2b-related splicing
processes in neurons, which is the primary affected cell type in SMA.
5.1.1. Identification and initial characterization of neuronal-specific knock-out
animals
The generation of neuronal-specific Tra2b knock-out mice was performed as described
in 4.2.2. By crossbreeding of Tra2bfl/fl mice with Tra2bfl/+; Nestin-Cretg/0 mice, control mice
(CTRL, Tra2bfl/+ and Tra2bfl/fl), heterozygous neuronal-specific knock-out mice (HET, Tra2bfl/+;
Nestin-Cretg/0) and homozygous neuronal-specific knock-out mice (KO, Tra2bfl/fl; Nestin-Cretg/0)
were obtained in a single litter (Figure 8 A). Genotypes were expected to split up according to
Mendelian law with each genotype contributing to approx. ¼ of the offspring.
Offspring of this breeding usually comprised few pups that were found dead in the
cage in the morning after birth or have already been (partly) devoured by the mother. DNA
was isolated from dead pups and genotyping analysis was performed using oligonucleotides as
described in 3.9.2 (Mende et al. 2010). The genotype of the Tra2b allele and the presence of
the Nestin-Cre transgene were determined in separate PCRs. Genotyping indicated that the
dead animals were KO mice of the genotype Tra2bfl/fl; Nestin-Cretg/0, indicating that these mice
were either born dead or died shortly after birth.
To narrow down the time point of death, the mating was performed as a timed
breeding. Embryos were isolated from pregnant females at late developmental stages
(18.5 dpc or later). All isolated embryos were viable and did not show differences in head
morphology or outer appearance (Figure 8 B). Genotyping indicated that those litters also
included KO mice (Figure 8 B). Analysis of 113 prenatal pups at late developmental stages
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showed that KO mice were viable during late embryonic development and contributed as
expected roughly ¼ to the total offspring (Figure 8 C). Later observations showed that KO
animals were born alive. In rare cases KO mice survived up to 36 h. CTRL and HET mice were
fully viable at birth, developed normally and had a normal life expectancy.
Figure 8 | Crossbreeding of Tra2b mouse lines and identification of knock-out animals.
(A) Breeding scheme. Cross breading of Tra2bfl/fl with Tra2bfl/+; Nestin-Cretg/0 mice allowed generation of neuronal-
specific knock-out (KO) animals as well as controls (CRTL) and heterozygous knock-out animals (HET) in one litter.
(B) General development of conditional knock-out mice is not impaired as there are no gross morphological
differences in embryo appearance. The genotype of the Tra2b allele (upper bands) was determined using primers
3482 and 2340 for detection of the floxed (fl) allele (950 bp) and the wild type (+) allele (821 bp). The Nestin-Cre
transgene was detected using the primers 3478 and 3479 yielding a 500 bp product (lower bands). (C) Analysis of
prenatal pups at late developmental stages (>18.5 dpc). KO animals were born alive and all possible genotypes were
detected according to Mendelian law (N=113).
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5.1.2. Analysis of Tra2b expression levels in neuronal-specific knock-out animals
To validate the knock-out of Tra2b in conditional knock-out mice the expression of
Tra2b was analyzed on mRNA and on protein level. Prenatal embryos were isolated on day
16.5 of gestation. Embryonic whole brains were used to isolate total RNA and proteins. RNA
was used for quantitative real-time PCR using specific primers to detect Tra2b. All data was
normalized to Gapdh expression. Brains of KO mice showed highly significantly reduced Tra2b
levels compared to all other genotypes (Figure 9 A). KO mice showed a more than 80 %
reduction of Tra2b expression compared to Tra2bfl/+ mice, but not a total loss of expression.
This was expected, as Cre-recombinase under control of the Nestin promoter is not expressed
in all cells of the brain. The remaining Tra2b expression likely originated from Nestin-negative
cells. Brains of Tra2bfl/fl mice maintained high expression levels that are only slightly but
significantly reduced compared to Tra2bfl/+ mice. HET mice showed an approx. 40 % reduction
Figure 9 |Analysis of Tra2b expression levels in neuronal-specific knock-out mice.
(A) Tra2b expression on RNA level. Tra2b was detected using the specific primers 3218 and 3219 in a quantitative
real-time PCR. Data was normalized to Gapdh (primers 3999 and 4000). Numbers within the bars indicate the
number of biological replicates (N). (B) Tra2b expression on protein level. Tra2b (38 kDa) and beta-actin (42 kDa)
were detected by specific antibodies. Bars show Tra2b expression normalized to beta-actin.
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of Tra2b expression compared to Tra2bfl/+ mice. This was significantly different to CTRL and KO
mice.
Whole brain protein lysates were analyzed by Western Blotting. Immunostaining of
Tra2b showed a clear reduction of protein levels in KO mice compared to controls (Figure 9 B).
Both control genotypes (Tra2bfl/+ and Tra2b fl/fl) and HET mice showed similarly high expression
levels of Tra2b. Despite Tra2b transcript levels in HET mice were reduced by half (Figure 9 A),
protein levels were maintained high. These data indicate that despite the loss of one Tra2b
gene copy in HET mice normal protein levels are maintained in the brain. This suggests that
some regulatory mechanism might compensate lower transcript concentrations on a post-
transcriptional level. Loss of both gene copies in KO animals resulted in a drastic reduction of
Tra2b levels. Despite Cre-mediated recombination did not occur in Nestin-negative cells, the
very low Tra2b expression in KO mice indicates an effective downregulation of Tra2b in the
majority of the brain.
5.2. Generation of Tra2b deficient murine embryonic fibroblasts
Murine embryonic fibroblasts (MEFs) are an easy to generate cell culture model that
finds application in a multitude of experimental strategies. This study aimed at the generation
of a murine embryonic fibroblast cell line that is depleted of Tra2b. Such cell line would allow
the study of Tra2b-related splicing processes in a homogeneous cellular system in a
reproducible environment.
MEFs are typically generated from murine embryos at 13.5 days of gestation. The early
lethality of mice ubiquitously depleted of Tra2b (Mende et al. 2010) precludes MEF generation
from this mouse line. Here MEFs were generated from Tra2bfl/fl pups. Deletion of Tra2b was
achieved by stably transfecting cells with Cre-recombinase including a nuclear localization
signal (NLS-Cre). Transient transfections were unsuccessful generating Tra2b-depleted cell
lines, as transfection efficiencies in fibroblasts were only low to moderate and cells depleted of
Tra2b appeared to have a selective disadvantage which became apparent by decreased
proliferation rates. Thus, Tra2b-depleted cells were quickly repressed by faster proliferating
Tra2bfl/fl cells.
A stable transfection approach allowing for permanent selection for cells expressing
Cre-recombinase using antibiotics to prevent survival of Tra2bfl/fl cells was followed. Therefore,
cells were immortalized by stable transfection of the SV40 (simian vacuolating virus 40) large-T
antigen (Zhu et al. 1991; Tevethia et al. 1998). Immortalization allows cells to evade
senescence and to keep proliferating extensively, thereby evading limitations of murine
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embryonic fibroblasts. The immortalization vector (pBABE-zeo-largeT) was obtained from
Addgene and was originally provided by the lab of Robert Weinberg (Hahn et al. 2002b).
5.2.1. Generation and characterization of murine immortalized fibroblasts (MIF)
Primary murine embryonic fibroblasts were transfected with pBABE-zeo-largeT as
described in 4.1.5. pBABE-zeo propagates resistance to Zeocin. To allow optimal selection of
stably transfected cells, MEFs were previously treated with different concentrations of Zeocin
to determine a low but effective concentration (Figure 10 A). After 7 days of Zeocin treatment
cells were effectively suppressed by 200 µg/ml Zeocin. Lower concentrations failed to
effectively suppress cell growth.
Transfection efficiency was surveyed by GFP-fluorescence using transfection of pMAX-
GFP. Average transfection efficiency was usually lower than 50 %. Zeocin selection using
200 µg/ml was started 48 h after transfection of pBABE-zeo-largeT. While replenishing Zeocin
in a 48 h interval cells were cultivated for 6 weeks. Expression of the largeT-antigen was
analyzed by RT-PCR and transfected cells but not controls showed clear largeT expression.
Figure 10 | Generation and characterization of murine immortalized fibroblasts (MIFs).
(A) Determination of the optimum Zeocin concentration for stable transfection. MEFs were treated for 7 days with
different concentrations of Zeocin. (B) MIF cell morphology 19 passages after immortalization. (C) Detection of
largeT antigen expression via RT-PCR. Primers 4052 and 4053 were used to specifically detect transcripts of the
largeT antigen. MIF, murine immortalized firboblasts; MEF, murine embryonic fibroblast; NC, negative control
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Zeocin selection was suspended and cells were cultivated for further passages.
Immortalized murine firbroblasts (MIFs) showed an increased proliferation rate far superior to
that of non-treated MEFs and tolerated splitting ratios of 1:40. MIFs acquired a more
pronounced spindle-like shape that is usually not observable in MEFs (Figure 10 B).
Furthermore, MIFs did not show any alterations in morphology or proliferation speed at high
passage number (p>50). Non-treated MEFs may enter crisis early after 5 passages, but were
sometimes observed to keep proliferating up to 20 passages. Testing expression of largeT
antigen several passages after Zeocin withdrawal showed solid largeT expression in MIFs
(Figure 10 C). Expression of the largeT antigen was not detected when using cDNA from the
same cell lines before pBABE-zeo-largeT transfection. These analyses indicate that MIFs show
solid expression of the largeT antigen and display enhanced morphological and proliferative
properties. This suggests that MIFs can be classified as immortalized cell lines.
5.2.2. Cloning of NLS-Cre-recombinase to pcDNA3.1.TOPO-CT-GFP
Cre-recombinase including an N-terminal nuclear localization signal (NLS-Cre) was
amplified from pTriEx1-HTNC, which was a gift from the group of Dr. Frank Edenhofer (Peitz et
al. 2002). PCR was carried out using Taq DNA polymerase with the specific primers 4083 and
4084. The NLS-Cre amplicon was cloned into pcDNA3.1-CT-GFP using the pcDNA 3.1 GFP-TOPO
TA Expression Kit. The cloned vector encodes a NLS-Cre-GFP, i.e. Cre-recombinase with an N-
terminal nuclear localization signal and a C-terminal GFP-tag. The insert was validated by
sequencing.
5.2.3. Generation and characterization of Tra2b-depleted MIFs
Murine immortalized fibroblasts (MIFs) were transfected with pcDNA3.1-NLS-Cre-GFP
as described in 4.1.5. pcDNA3.1 propagates resistance to Geniticin (G418). Transfection
efficiency was surveyed by GFP-fluorescence using transfection of pMAX-GFP and was usually
far lower than 50 %. Geniticin selection using 2 mg/ml was started 48 h after transfection of pc
DNA3.1-NLS-Cre-GFP. While replenishing Geniticin in a 4 day interval cells were cultivated for 6
weeks.
To functionally evaluate Cre-recombinase expression, Tra2b levels were determined on
mRNA level using quantitative real-time PCR. Upon Cre-mediated disruption of the Tra2b locus
the expression of Tra2b should drastically decrease. RNA was isolated from cells starting from
3 passages after NLS-Cre-GFP transfection onward. Expression analysis 3 passages after
transfection demonstrated a reduction of Tra2b expression down to ~20 % of its initial values
(Figure 11). By continuation of Geniticin selection Tra2b transcript levels decreased further to
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background levels. This suggests that the transfected Cre-recombinase construct is functional
and effectively abolished Tra2b expression in MIFs.
5.3. Characterization of the brain phenotype and analysis of neuronal
development
Conditional Tra2b knock-out mice die shortly after birth but do not show gross
morphological alterations in outer appearance. As the knock-out mice are depleted of Tra2b in
neuronal and glial precursor cells it is self-evident to investigate the developmental
progression of the brain. To allow comparison of different developmental stages and
genotypes timed breedings were performed to isolate embryonic brains. Histological and
immunohistological analyses were carried out using paraffin-embedded sections.
5.3.1. Histological analysis of neuronal-specific knock-out brains
To understand the underlying cause of perinatal lethality brains of KO mice were first
histologically analyzed at various developmental stages (14.5 dpc until birth) using hematoxylin
and eosin staining on paraffin-embedded brain sections. Compared to control mice KO mice
showed a dilation of both the third and lateral ventricles (ventriculomegaly) (Figure 12). The
dilation of the ventricles had its onset at around 14.5 dpc and progressed until birth. Dilation
at 14.5 dpc was still moderate and cortical patterning was comparable to control animals. At
16.5 dpc the lateral ventricles occupied a big part of the brain hemispheres and the cortical
layers were no longer distinguishable. The ependyma which constitutes the ventricular lining
Figure 11 | Tra2b expression analysis in NLS-Cre-GFP transfected MIFs.
RNA was isolated from MIFs and MIFs transfected with NLS-Cre-GFP at various passages after transfection. Tra2b
expression levels were analyzed using quantitative real-time PCR with the specific primers 3218 and 3219.
Expression levels were normalized to Gapdh (primers 3999 and 4000). After transfection of Cre-recombinase and
persistent selection using Geniticin, Tra2b transcript levels were effectively downregulated.
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appeared to be fully absent or destroyed in KO animals, even though the choroid plexus was
present but being detached as a consequence of ventriculomegaly. Furthermore, late stage
brain morphology (18.5 dpc) showed irregularities in the caudal regions of the septum or the
anterior thalamic area. Heterozygous knock-out animals retained normal cortical patterning
with normal ventricle sizes at all stages of development. This is in line with the finding of Tra2b
expression being comparable to controls on Western Blots (Figure 9) (Grellscheid et al. 2011a).
This suggests that a single gene copy of Tra2b can functionally compensate protein function
without producing an obvious phenotypic effect. These first histological results indicate that
Tra2b is essential for brain development and normal cortical patterning.
5.3.2. Immunohistological analysis of neuronal-specific knock-out brains
5.3.2.1. Immunohistochemical analysis of Tra2b expression
To validate efficient downregulation of Tra2b in KO mice and to identify regions
depleted of Tra2b or preserving Tra2b, paraffin-embedded brain sections were
immunohistochemically stained. The ventricular and subventricular zones of the developing
mouse brain showed notably high Tra2b expression (Figure 13). Further cell populations with
Figure 12 | Conditional ablation of Tra2b causes ventriculomegaly and disturbed cortical patterning.
Hematoxylin/Eosin staining of paraffin-embedded coronal sections at indicated developmental stages. KO animals
but not controls or HET animals show ventriculomegaly of the third and lateral ventricles starting at around 14.5 dpc.
Cortical layers are largely distinguishable at 14.5 dpc but cortical patterning and the ependymal lining of the lateral
ventricle appears highly disturbed at later stages(black arrowheads). 18.5 dpc KO mice show anomalies at the caudal
septum or the anterior thalamic area (empty arrowhead). Scale bar equals 400 µm; ctx, cortex; th, thalamus; cpt,
caudoputamen; cp, cortical plate; iz, intermediate zone; svz, subventricular zone; vz, ventricular zone; sn, septal
nuclei; 3v, third ventricle; lv, lateral ventricle; pc, choroid plexus
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prominent Tra2b expression were found in the outermost layer of the cortex. In contrast,
Tra2b expression was strongly reduced in the ventricular and subventricular zones of KO
animals. In general, brains of KO animals showed reduced levels of Tra2b expression but
clearly retained localized centers of expression that likely comprise Nestin-negative cells
(Figure 13). This was in so far expected as the mosaicism of Cre expression is based on the
natural expression pattern of the Nestin promoter. Stainings of KO brains at 14.5 dpc appeared
slightly more intense than at later stages, which could be indicative for residual Tra2b
expression at this developmental stage. In contrast, cortical cell layers that were still present at
18.5 dpc did not show any remaining Tra2b expression. The absence or decay of the
ventricular cortex layers in KO animals and the fact that these layers are loci of neuronal
differentiation and neuronal outgrowth leading to cortex formation (Rakic 1988; Noctor et al.
2001) suggest that Tra2b plays a pivotal role in cortical development.
5.3.2.2. Immunohistochemical analysis of Ki67 and Caspase-3 expression
To further elucidate the course of the pathological progression we analyzed apoptotic
events and the proliferative potential in KO versus control brains. This was in so far important
as the observed brain phenotype including ventriculomegaly and failure in cortical patterning
Figure 13 | Tra2b expression is drastically reduced throughout the brains of KO mice.
Immunostaining of Tra2b on paraffin-embedded coronal sections shows efficient downregulation of Tra2b protein in
knock-out brains compared to CTRL and HET animals. Cells of the ventricular and subventricular zones of the cortex
show strongest Tra2b expression in controls (black arrowheads). Expression in the according areas of KO brains is
severely reduced. Scale bar equals 400 µm; ctx, cortex; th, thalamus; cpt, caudoputamen; cp, cortical plate; iz,
intermediate zone; svz, subventricular zone; vz, ventricular zone; sn, septal nuclei; 3v, third ventricle; lv, lateral
ventricle; pc, choroid plexus
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can be caused by aberrant development or by the death of already developed structures. The
latter could be caused by increased intracranial pressure that might lead to a normal pressure
hydrocephalus based on reduced resorption of cerebrospinal fluid or duct obstruction in the
ventricular system (Adams et al. 1965).
The proliferative potential and apoptosis were investigated using immunostainings for
cleaved Caspase 3 (Casp3) and Ki-67. Localized presence of Casp3 indicating apoptotic events is
a typical hallmark of neuronal development as each proliferation, differentiation and apoptosis
orchestrate neuronal restructuring (Ikonomidou et al. 1999; Roth and D'Sa 2001). KO brains
showed drastically elevated levels of apoptosis at 14.5 and 15.5 dpc but not at later stages of
development (Figure 14 A). This primarily affected the cortical layers close to the lateral
ventricles and the anterior thalamic region between the cavities of the third ventricle.
Accordingly, the thalamic area presented morphological anomalies at later stages of
development (16.5 dpc). The more dorsally located septal nuclei appeared largely unaffected,
however (Figure 14 A, KO 16.5 dpc).
In concordance with these apoptotic events the proliferative potential of the
ventricular and subventricular zone started to decrease at around 14.5 dpc and was fully lost
at 16.5 dpc and all later stages (Figure 14 B). This temporal occurrence of events suggests
proliferation loss being a direct consequence of initial apoptotic events ultimately leading to
tissue loss and ventriculomegaly. The brain development of HET animals was not affected. In
these brains neither an increase of apoptosis, nor a loss of proliferative potential was
detected.
This demonstrates that haploinsufficiency of Tra2b has no phenotypic consequence
and rules out any secondary effect of the Nestin-Cre transgene on brain development (Forni et
al. 2006). In contrast, depletion of Tra2b in neuronal precursors leads to ventriculomegaly and
aberrant cortical patterning. This appears to be a direct result of massive apoptotic events in
ventricular and subventricular cortical layers and subsequent loss of the proliferative potential
in these neurogenic areas. These findings clearly point out a pivotal role of Tra2b in neuronal
development and survival.
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Figure 14 | Brain malformations are initiated by massive apoptosis in the cortex.
(A) Immunostaining for Caspase-3 on paraffin-embedded coronal sections indicates prominent apoptosis in the
proximal cortical layers and in the thalamic area of 14.5 dpc and 15.5 dpc KO embryos (black arrowheads).
Remaining cortical tissue does not show apoptosis at 16.5 dpc and later stages (light arrowhead).
(B) Immunostaining for Ki-67 shows initial decrease of proliferation at 14.5 dpc which is fully lost at 16.5 dpc in KO
animals (black arrowheads). CTRL and HET animals retain strong Ki-67 signals in the proximal cortical layers at all
indicated developmental stages. Scale bar equals 400 µm; ctx, cortex; th, thalamus; cpt, caudoputamen; sn, septal
nuclei; 3v, third ventricle; lv, lateral ventricle
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5.4. Molecular biological analysis of neuronal-specific knock-out brains
In preparation for high throughput screening approaches as an effort to detect target
transcripts of Tra2b, a detailed molecular biological analysis of Tra2b-depleted brains was
carried out. Splicing targets of Tra2b that are known, have mostly been identified in in vitro
systems. Such experiments have a limited power in stating the physiological relevance of a
splicing process, as standard splicing assays were performed using minigenes while
overexpressing Tra2b. This kind of approach might certainly allow a functional validation of a
splicing process, but does not allow a physiological assessment. This chapter will focus on the
physiological assessment of the splicing processes of well-known Tra2b target transcripts using
conditional Tra2b knock-out mice. Validation of known targets in vivo would be a proof of
concept for the identification of physiological splicing targets in vivo using conditional Tra2b
knock-out mice.
Initial analyses showed correct tendencies in confirming the splicing of known targets,
but these results were not significant. It was assumed that only cell populations in the brain
that were depleted of Tra2b could display an effect in splicing. Cell populations that do not
express Cre-recombinase continue expressing Tra2b and thus retain normal splicing. As whole
brain RNA was used in these experiments, normal splicing in Tra2b expressing cells would
mask altered splicing patterns in depleted cell populations. To assess the extent of mosaicism
in KO brains, Tra2b expression was measured by quantitative real-time PCR and compared
between single embryos and between different developmental stages. Measuring low levels of
Tra2b using whole brain RNA might indicate knock-out in the vast majority of brain areas,
while high levels would indicate a high degree of mosaicism with larger brain fractions
retaining Tra2b expression. Indeed, though all observed KO mice displayed ventriculomegaly
and loss of cortical patterning, the severity of the described brain phenotype appeared to vary
slightly. Mosaicism of Cre-recombinase expression and retained Tra2b expression could well
explain that phenomenon.
5.4.1. Expression analysis of Tra2b during development
Whole brain RNA was first analyzed for expression levels of Tra2b at different
developmental stages by real-time PCR and normalized to the expression of Gapdh (Figure 15).
In control animals the total expression of Tra2b in the brain was largely constant between
16.5 dpc and birth. Expression levels at 18.5 dpc were slightly but non-significantly lower than
at 16.5 dpc or at birth. HET animals showed an approx. 50 % reduction of Tra2b transcript
levels, while Tra2b was effectively down-regulated in brains of 16.5 dpc, 18.5 dpc and PND 1
KO animals (Figure 15 A). Though the reduction of Tra2b expression was significant, 16.5 dpc
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brains of KO mice showed highest residual expression levels. As whole brain RNA was used,
residual Tra2b expression is likely a result of Nestin-negative cells that do not express Cre-
recombinase. To answer whether this high retention of Tra2b expression was a general
phenomenon at 16.5 dpc, individual expression levels were compared (Figure 15 B). Though
average Tra2b downregulation was significant, expression levels were individually different
between single animals. Despite transcript levels were on average gradually reduced according
to the genotype (horizontal lines in Figure 15 B), single animals within each genotype group
showed untypical Tra2b expression levels. In the KO group three animals were found with
expression levels equally high as seen in HET animals. For these animals also the Tra2b protein
expression in the brain was expected to be accordingly higher, which makes it likely that such
pups with high levels of residual Tra2b expression account for the sometimes observable
moderate brain phenotypes.
In an attempt to validate this hypothesis RNA was isolated from paraffin-embedded
brain sections of KO mice displaying severe and moderate brain phenotypes. We aimed to find
a correlation between moderate phenotypes with retained Tra2b levels and between severe
brain phenotypes and very low Tra2b levels. Analysis by quantitative PCR was strongly
hampered by highly impaired quality of RNA obtained from paraffin-embedded sections. Tra2b
transcripts were detected but their amounts varied drastically (data not shown). Therefore, a
precise quantification was not possible, which was likely due to pronounced RNA
fragmentation based on formalin fixation and paraffin embedding.
Aiming at the validation of previously reported Tra2b-related splicing processes in vivo,
quantitative RT-PCRs specifically detecting alternatively spliced exons were performed. This is
discussed in detail in chapter 5.4.3. Initial analyses showed only a tendency of well-known
Tra2b-dependent splicing processes, which was not significant, however. Knowing that a
fraction of KO brains retains significant expression levels of Tra2b this is not surprising, as
splicing processes in Tra2b expressing cells are not impaired. For that reason all KO brains used
in this study were analyzed for Tra2b transcript levels and only brains showing a strong
reduction in Tra2b expression were used for subsequent analyses. To test this, an arbitrary
threshold value of 0.4 in Tra2b/Gapdh expression was selected (dashed line in Figure 15 B).
Using only mice with relative expression levels lower than 0.4 resulted in significant results
when assaying for alternative splicing events (5.4.3). For that reason all KO brains with relative
Tra2b expression levels of higher than 0.4 were excluded from analyses, as incomplete or
highly mosaic knock-out hampers the analysis of Tra2b-related splicing processes.
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Figure 15 |Expression analysis of Tra2b during development.
Quantitative real-time PCR using whole brain RNA of control, HET and KO embryos at 16.5 dpc, 18.5 dpc and
postnatal day 1. All mRNA levels have been normalized to Gapdh expression. Total Tra2b levels were specifically
detected using the primers 3218 and 3219. Primers 3999 and 4000 were used to detect Gapdh. (A) Total Tra2b
expression levels are effectively reduced in KO animals at 16.5 dpc, 18.5 dpc and PND1. (B) Individual expression
levels of total Tra2b in 16.5 dpc brains largely behave accordingly to the respective genotype but are subject of
variation within each group. Horizontal lines indicate the mean of each genotype group. The dashed line indicates a
threshold value of 0.4. Numbers within bars represent the number of biological replicates (N).
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5.4.2. Expression analysis of Tra2b isoforms
Tra2b is known to autoregulate its own expression level via a splicing feedback-loop by
including cassette exon 2 into its own transcript (Stoilov et al. 2004). Exon 2 contains a
premature termination codon rendering the transcript non-functional and thus decreasing the
Tra2b protein concentration. This means that Tra2b balances its own concentration. High
amounts of Tra2b protein facilitate effective inclusion of exon 2, thus rendering the transcript
non-functional and as a consequence decrease the protein concentration. However, Tra2b
auto-splicing might be regulated not solely by its own concentration but also by its
phosphorylation. It has been suggested that phsophorylation of Tra2b regulates interactions
with other splicing factors and also influences the cellular localization of Tra2b (Stoilov et al.
2004; Li et al. 2013).
Auto-splicing of Tra2b has hitherto been demonstrated in in vitro approaches like
minigene experiments, which use artificial constructs and high levels of Tra2b protein. The
following experiment aimed at analyzing the Tra2b self-splicing mechanism in vivo using
conditional knock-out mice. In previous Tra2b quantitifcation experiments of this study the
whole transcript amount of Tra2b was determined without differentiating between the
functional (exon 2 skipped) and non-functional isoform (exon 2 included) (Figure 15). Here the
inclusion of exon 2 was specifically detected using primers individually amplifying the
functional or the non-functional isoform.
Using isoform-specific real-time PCRs on 16.5 dpc brains a significant down-regulation
of both the functional (-78 %) and non-functional (-88 %) Tra2b isoforms was detected (Figure
Figure 16 | Expression analysis of Tra2b isoforms.
RNA from 16.5 dpc brains was analyzed using real-time PCR. Expression levels of both the functional and non-
functional Tra2b isoforms were measured using the primers 4271/4272 and 4269/4270. Expression levels were
normalized to Gapdh (primers 3999/4000). Both isoforms were reduced in KO and HET mice. In HET mice the non-
functional isoform was strongly reduced, while the functional isoform was maintained at almost normal levels.
Numbers within bars represent the number of biological replicates (N).
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16). In general the down-regulation of the non-functional isoform was stronger than for the
functional isoform. Interestingly, in HET mice the levels of functional transcripts were only
mildly but significantly reduced (-24 %) while non-functional transcripts were very strongly and
significantly reduced (-61 %). These data suggest that the auto-regulatory splicing feedback-
loop is functional in a physiological environment in mice (Grellscheid et al. 2011a). The only
mildly altered levels of functional Tra2b transcripts in HET mice are fully consistent with
survival, normal brain development (Figure 12) and Tra2b protein levels being comparable to
controls (Figure 9). Loss of a single Tra2b gene copy resulted in an approx. 50 % reduction of
total Tra2b transcript levels (Figure 15 A), while protein levels were maintained stable (Figure
9). Analysis of Tra2b isoforms demonstrated that both isoforms are not coordinately
downregulated but instead being shifted to preserve higher amounts of functional transcripts.
This suggests that loss of a single Tra2b gene copy can be compensated to a great extent via
this auto-regulatory mechanism in vivo.
5.4.3. Proof of concept splicing analyses in Tra2b knock-out brains
Neuronal-specific Tra2b knock-out mice mostly showed a robust downregulation of
Tra2b in the brain. However, the knock-out efficacy was low in some pups and Tra2b transcript
levels were insufficiently reduced to validate well-known Tra2b-dependent splicing processes.
To allow efficient validation of splicing events, KO mice with relative Tra2b expression levels of
higher than 0.4 were excluded from analyses (as described in 5.4.1). Inclusion of samples with
insufficient Tra2b knock-out prevented a reliable detection of known splicing events.
Besides the already validated Tra2b auto-splicing the following experiments were
aiming at the validation of known Tra2b target transcripts in vivo under physiological
conditions. This analysis included transcripts of the microtubule associated protein tau (Mapt)
and the vesicle coating protein clathrin light chain b (Cltb) (introduced in chapter 1.5).
Knowledge about Tra2b-related exon splicing of these transcripts has been obtained in
minigene or exon trapping approaches (Stamm et al. 1992; Stamm et al. 1999; Jiang et al.
2003; Kondo et al. 2004) but correlations of enhanced Tra2b expression and Mapt exon 10
inclusion have been reported in post mortem Alzheimer’s disease brains as well (Glatz 2005;
Glatz et al. 2006). The validation of known Tra2b-dependent splicing targets would constitute a
proof of concept for the identification of alternative splicing events in vivo using neuronal-
specific KO mice. This would pave the way for the identification of novel Tra2b splicing targets
using high throughput screening approaches.
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Using isoform-specific real-time PCRs the splicing of microtubule associated protein
tau (Mapt) exon 10 and the vesicle coating protein clathrin light chain b (Cltb) exon 5 was
analyzed in 16.5 dpc brains. In Mapt inclusion of the cassette exon 10 was reported to be
promoted by Tra2b (Kondo et al. 2004). Accordingly, quantification ofMapt isoforms showed a
moderate but significant decrease of the 4R isoform containing exon 10 in KO mice (Figure 17
A). HET mice only showed an insignificant decrease in exon 10 inclusion, suggesting that Tra2b
levels previously found to be comparable to controls can also functionally fully compensate
splicing processes. In contrast the 3R isoform displayed a slight but non-significant
upregulation. These data indicate that Tra2b positively regulates Mapt exon 10 splicing under
physiological conditions. These results are in good concordance with increased Mapt 4R levels
in postmortem AD brains, which displayed an increased expression of Tra2b (Glatz et al. 2006).
Furthermore, the splicing of Cltb exon 5 was analyzed. Here Tra2b has been reported
to promote skipping of exon 5 (Stamm et al. 1992; Stamm et al. 1999). Accordingly, absence of
Tra2b promoted inclusion of exon 5 and caused a solid and significant increase of isoform LCbII
expression (Figure 17 B). No changes in expression were detected for the LCbIII isoform, which
as a response to Tra2b depletion was expected to decrease. Also for Cltb no changes in splicing
were detected in HET mice.
To summarize, selection of mice with Tra2b/Gapdh expression in brain lower than 0.4
allowed the in vivo validation of previously described Tra2b target exons in a physiological
situation. Tra2b physiologically promotes inclusion of Mapt exon 10 and promotes skipping of
Cltb exon 5.
Figure 17 | Splicing analysis ofMapt exon 10 and Cltb exon 5.
RNA from 16.5 dpc brains with Tra2b/Gapdh expression lower than 0.4 was analyzed using real-time PCR. Expression
levels of both Mapt and Cltb isoforms were measured using isoform-specific primers: Mapt 4R (3990/3991), Mapt 3R
(3931/3934), Cltb II (3939/3941), Cltb III (3939/3940). Expression levels were normalized to Gapdh (primers
3999/4000). Tra2b promotes inclusion of Mapt exon 10 and promotes skipping of Cltb exon 5.
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5.4.4. Validation of splicing targets identified in HITS-CLIP experiments
In frame of collaboration with the workgroup of Prof. David Elliott novel Tra2b splicing
targets have been identified by HITS-CLIP (high throughput sequencing cross-linking
immunoprecipitation) on murine testis lysates (Grellscheid et al. 2011a). Analysis has shown a
significant increase in exon inclusion of a poison exon of the Tra2a transcript and of a
testis-specific exon of the nuclear autoantigenic sperm protein Nasp. Tra2a and Tra2b are
paralogs and similar to the Tra2b transcript, inclusion of its exon 2 also introduces a premature
termination codon in the Tra2a transcript. This might constitute a post-transcriptional
regulatory mechanism similar to Tra2b (Grellscheid et al. 2011a). Nasp encodes the histone
chaperone nuclear autoantigenic sperm protein, which encodes two isoforms: the somatic
isoform sNasp and the testis-enriched isoform tNasp, which comprises the roughly 1 kb long T-
exon (Richardson et al. 2000). Besides its high expression in testis tNasp is reported to be
highly abundant in embryonic and tumor cells, which are both highly proliferative cell types
(Richardson et al. 2000; Richardson et al. 2006). O’Rand and colleagues have demonstrated
that selective depletion of tNasp in tumor cells abolished proliferation (Alekseev et al. 2011)
and ablation of Nasp causes early embryonic lethality in mice (Richardson et al. 2006). This
data implicates Nasp playing a fundamental role during embryonic development and probably
in highly proliferative cells in general.
In a collaborative effort experiments were aiming at the physiological validation of the
Tra2b-dependent splicing processes of Tra2a exon 2 and the Nasp T-exon (exon 7) in neuronal-
specific knock-out mice. RNA from 16.5 dpc brains was analyzed by real-time PCR using
isoform-specific primer pairs each detecting a single isoform of the Tra2a and Nasp transcripts.
Both the T-Nasp and the somatic isoform of Nasp were detected in the developing murine
brain (Figure 18 A). HITS-CLIP experiments suggested a Tra2b-dependent inclusion of the Nasp
T-exon. Accordingly, expression of the T-Nasp isoform was significantly more than 5-fold
decreased in KO mice compared to controls (Figure 18 A). HET mice displayed a minor and
non-significant downregulation of the T-isoform. These data clearly demonstrate that Tra2b is
an in vivo activator of Nasp T-exon inclusion in the murine developing brain. Given the more
than 5-fold reduction of tNasp expression in Tra2b-depleted brains, Tra2b likely has a
prominent physiological role in regulating Nasp T-exon inclusion. Interestingly, no changes
were detected for the sNasp isoform, which was expected to increase as a response to tNasp
downregulation in KO mice. It cannot be excluded that other transcriptional or post-
transcriptional mechanisms of regulation impact total Nasp expression as a response to the
interference in splicing administered in this experiment.
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Tra2a exon 2 inclusion has been determined to be equally promoted by Tra2b
(Grellscheid et al. 2011a). Supporting this finding, exon 2 inclusion was highly significantly
reduced in KO mice, which resulted in a coordinate approx. 4-fold downregulation of the non-
functional Tra2a isoform (Figure 18 B). HET mice showed a weak and non-significant
downregulation. In contrast and as a response to massive exon 2 skipping in KO mice, a
significant increase of the functional Tra2a isoform was detected. These data indicate that
Tra2a is a physiological in vivo target of Tra2b. Depletion of Tra2b in the murine brain caused a
physiological splicing shift promoting expression of the functional Tra2a isoform. Given that
the two homologous splicing factors Tra2a and Tra2b have a similar domain structure and bind
both to GAA-rich sequence elements (Tacke et al. 1998) a similar function and probably even
an overlap in the spectrum of specific target transcripts can be expected. Thus, the Tra2a
splicing shift promoting its functional isoform might constitute a compensatory mechanism to
counteract the loss of Tra2b. Such mechanism might be true for some common splicing
targets. However, the clearly determined missplicing events caused by absence of Tra2b (5.4.3
and 5.4.4) as well as the severe brain phenotype and perinatal lethality of KO mice indicate
that Tra2b has unique splicing targets that are not compensated by Tra2a or other splicing
factors.
Figure 18 | Splicing analysis of Nasp exon 7 and Tra2a exon 2.
RNA from 16.5 dpc brains with Tra2b/Gapdh expression lower than 0.4 was analyzed using real-time PCR.
Expression levels of both Nasp and Tra2a isoforms were measured using isoform-specific primers: sNasp
(4037/4043), tNasp (4049/4042), non-functional Tra2a (4040/4044), functional Tra2a (4040/4046). Expression
levels were normalized to Gapdh (primers 3999/4000). Tra2b promotes inclusion of Nasp exon 7 and Tra2a exon 2.
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5.5. Whole transcriptome sequencing analysis for the identification of
Tra2b target transcripts
Mice ubiquitously depleted of Tra2b are early embryonically lethal. Here a neuronal-
specific Tra2b knock-out mouse was generated. Mice homozygously depleted of Tra2b in the
central nervous system die perinatally but are viable throughout embryonic development. This
provides a unique chance to study Tra2b-related alternative splicing processes in a
physiological setting during brain development. Conditional Tra2b knock-out mice have proven
to be a potent in vivo model allowing the identification and quantification of alternative
splicing processes in a physiological environment. This study aims at the identification of novel
Tra2b target transcripts using high throughput screening approaches as whole transcriptome
sequencing and exon array analysis. Identification of such targets will disclose putative off-
targets that might be deregulated in treatment strategies using HDAC-inhibitors (1.6) and will
shed light on splicing processes that are essential for neuronal development.
5.5.1. Data summary, analysis and statistics
The transcriptome sequencing was performed at the Cologne Center for Genomics
using 3 RNA samples obtained from control mice and 3 obtained from KO mice. All RNAs were
isolated from 16.5 dpc brains and well known Tra2b-dependent splicing processes have been
reconstituted using these samples. Furthermore, all KO samples had Tra2b/Gapdh levels of
less than 0.4 (as described in 5.4.1). This validation ensured that the used RNA samples can
yield valid data of known splicing processes and are therefore presumably potent in identifying
novel splicing targets.
Whole transcriptome sequencing yielded an average coverage of approx. 53-fold
assuming a 100 Mb transcriptome. The total number of reads obtained and the resulting
coverage were different between the samples, however (Table 5). The main objective of the
whole transcriptome analysis was an unbiased assessment of relative exon abundances and
their changes between CTRL and KO group to allow detection of alternative splicing events.
Different coverage (i.e. different number of total reads) between individual samples and
varieties in coverage depending on the transcriptome region exert significant influence on the
quantification of individual exons. To overcome this bias, RPKM (reads per kilobase and 1
million of reads) analysis was performed allowing normalization of the absolute read number
with regard to the total transcript length and the total number of reads in the respective
region (Figure 19). This allows compensation of variable coverage between samples and makes
the read number independent of the respective transcript length. Moreover, exon abundances
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were normalized to the total expression levels of a transcript. This prevents changes in total
expression between CTRL and KO to influence the assessment of exon inclusion. To achieve
that, RPKM was calculated for each whole transcript (RPKMT) and for each of its exons
(RPKME). The ratio of RPKME/RPKMT gives the normalized abundance of a respective exon. As
shown in Figure 19 the mean of RPKME/RPKMT ratios was calculated for the control and for the
KO group, which allowed a direct comparison of the average exon abundances (x-fold change).
The x-fold change value gives the alteration of exon abundance as observed in the KO group
relative to CTRL group. The significance level (p-value) of the relative change was calculated
using Student’s t-test comparing the 3 ratios of the CTRL group with the 3 ratios of the KO
group.
In this transcriptome sequencing approach a total of 203,324 exons was identified.
Figure 20 gives an overview about the significance and x-fold change distribution. The absolute
majority of identified exons did not display significant changes in their abundances between
CTRL and KO group (Figure 20 A). 198,900 exons were determined with p-values larger than
0.05 classifying them as non-significant; 4,424 exons with a p-value smaller than 0.05 (Figure
20 A, gray pie chart). The latter group of significantly differently abundant exons split up into
50 very highly significant exons with p-values smaller than 0.001 and into 615 highly significant
exons with p-values between 0.001 and 0.01 (Figure 20 A, red pie chart). Most of the
significantly different abundant exons had p-values between 0.05 and 0.01 (3,759 exons).
Table 5 | Whole transcriptome sequencing read coverage.
During whole transcriptome sequencing the average coverage was 53-fold assuming a 100 Mb transcriptome. The
total read number was variable between samples.
sample reads x106 coverage (100 Mb transcriptome)
CTRL A 45.2 42.2x
CTRL B 27.9 53x
CTRL C 39.4 74x
KO D 31.0 58.9x
KO E 26.2 49.8x
KO F 22.2 42.2x
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Figure 19 | RPKM Analysis of whole transcriptome data.
Sequence reads were mapped to the transcriptome database at Ensembl. RPKM was calculated to compensate for
differences in the total number of reads, differences in the local distribution of reads on the transcriptome and for
variable lengths of transcripts. RPKM was calculated for whole transcripts (RPKMT) and for every of their exons
(RPKME). Exon abundance was measured by the ratio of RPKME/RPKMT to allow an assessment unbiased by
differential gene expression. The x-fold change of exon abundance was determined by the mean ratios obtained
from the CTRL and the KO group. The significance of the difference in exon abundances was calculated using
Student’s t-test.
Figure 20 | Statistical distribution of significance levels and differential exon abundances.
Mapping of sequence reads obtained from transcriptome sequencing identified 203,324 exons. (A) Distribution of
statistical significance for differential exon abundance between CTRL and KO group. Most exons were non-
significantly different (gray pie chart, p>0.05). 4,424 exons were identified with p<0.05. These split up into 3,759
exons with 0.01<p<0.05, 615 exons with 0.001<p<0.01 and 50 highly significant exons with p<0.001 (red pie chart).
(B) Distribution of x-fold changes in exon abundances of significantly different exons with p<0.01. 380 out of 665
exons displayed an upregulation in KO vs. CTRL group (i.e. putative inhibition by Tra2b) and 285 out of 665 exons
showed a downregulation (i.e. putative activation by Tra2b). Most exons displayed moderate changes in
abundance; only few showed higher than 3-fold change.
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Exons from the group with p<0.01 (665 exons) mostly showed moderate x-fold
changes between the KO and CTRL group. Figure 20 B gives an overview of changes in exon
abundances. 380 exons were detected to be upregulated in KO mice indicating a putative
inhibition of these exons by Tra2b. 285 exons were found to be negatively regulated in KO
mice indicating a putative activation of these exons by Tra2b. Only a relatively small number of
exons showed changes of larger than 3-fold.
Given that whole brain RNA of Tra2b-depleted mice and controls have been used for
transcriptome sequencing and given the effect that Tra2b ablation has on brain development,
it was expected that genes involved in neuronal function or neuronal development should be
enriched among the identified candidates. All genes identified with alternatively spliced exons
were cross-referenced with the gene ontology database at Ingenuity Systems. Exons that were
detected as being non-significantly different (0.05<p<1.00) were found either associated or not
associated to neuronal processes at highly similar frequencies (Figure 21). Interestingly,
significant exons with p-values lower than 0.05 displayed a 3-fold enrichment of gene
ontologies related to neuronal function or development. This indicates that genes or exons
that were significantly detected to be alternatively spliced, have a 3-fold increased probability
of having a neuron-related function.
To select candidate exons for validation by real-time PCR, identified exons were sorted
according to their significance levels. As exons of high significance levels were shown to have
an increased probability of serving a neuronal-related function, exons with best significance
levels were selected for validation analysis. Table 6 gives an overview of the top 10 ranking
Figure 21 | Enrichment of genes related to neuronal function and development.
Genes identified with alternatively spliced exons were cross-referenced with the gene ontology database at
Ingenuity Systems. Exons are displayed according to their significance levels and the exon number was normalized
per 1,000 exons. Genes related to neuronal function or development were found 3-fold enriched among the group
of significant different exons (p<0.05). There was no enrichment of neuronal-related genes in non-significant
groups.
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candidate genes containing putative alternatively spliced exons. The top ranking 100
candidates are listed in the appendix (Appendix, I).
Previously validated targets were not convincingly identified by whole transcriptome
sequencing. The testis-specific exon of the tNasp transcript was identified as non-alternatively
spliced and also the splicing of Tra2a exon 2 was not detected. To understand why established
targets showing robust alternative splicing in vivo were not detected in transcriptome analysis,
the local coverage was displayed as a custom track using the UCSC genome browser. As an
example Figure 22 shows coverage tracks for Nasp T-exon for all analyzed samples. Inclusion of
the Nasp T-exon is promoted by Tra2b. As expected, KO samples generally displayed fewer
reads mapping to the T-exon, while controls showed many reads mapping to that region. In
contrast to CTRL samples A and C, CTRL sample B showed a drastically reduced number of
reads. This phenomenon was not restricted to the T-exon of the Nasp transcript but was
observed for multiple targets. It is likely that a reduced coverage of CTRL B accounts for the
strongly reduced significance. As the RPKM-based normalization should compensate deviating
coverage of a sample, it appears likely that CTRL B did not suffer from generally low coverage
per se (Table 5). Localized deviations in coverage could probably explain the failure of RPKM-
based normalization. This idea is further supported as top ranking candidates did not show a
comparably strong reduction of the local coverage in CTRL B (Figure 23).
The top ranking candidates Appbp2 (Amyloid beta precursor protein binding protein)
and Htt (Huntingtin) are both related or probably related to neuronal function and disease
(Cisbani and Cicchetti 2012). Whole transcriptome analysis suggested that Tra2b promotes
inclusion of Appbp2 exon 4 and promotes skipping of Htt exon 60 (Table 6). Moreover, local
coverage of these candidate exons did not appear to be severely affected by coverage
anomalies of CTRL sample B (Figure 23). Given the adequate data quality for these candidate
exons and their strong implication in neuronal function Appbp2 exon 4 and Htt exon 60 were
selected for validation experiments using quantitative real-time PCR.
Table 6 | Top 10 candidates obtained by whole transcriptome sequencing
gene designation gene symbol index p-value
amyloid beta precursor protein binding protein 2 Appbp2 -3.24 0.000025
renin binding protein Renbp -4.11 0.000039
Huntingtin Htt 1.52 0.000055
(embryonic lethal, abnormal vision, Drosophila)-like 2 Elavl2 17.30 0.000064
ribosomal protein L34 Rpl34 -1.71 0.000066
expressed sequence AI413582 AI413582 1.25 0.000103
transmembrane 7 superfamily member 2 Tm7sf2 1.28 0.000121
nuclear autoantigenic sperm protein Nasp 5.20 0.000130
zinc finger protein 507 Zfp507 1.47 0.000199
BAH domain and coiled-coil containing 1 Bahcc1 -2.44 0.000210
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Figure 22 | Local coverage data of the Nasp T-Exon.
Coverage data from the whole transcriptome analysis was loaded as a custom track to the UCSC Genome Browser.
Nasp T-exon inclusion is promoted by Tra2b. Accordingly, CTRL samples show a high coverage of that exon, while
KO samples show rather low coverage. CTRL sample B deviates drastically, as its local coverage of the Nasp T-exon
is strongly reduced compared to CTRL samples A and C.
Figure 23 | Local coverage data of Appbp2 exon4 and Htt exon 60.
Coverage data from the whole transcriptome analysis was loaded as a custom track to the UCSC Genome Browser.
Appbp2 exon 4 was predicted to be promoted by Tra2b, while Htt exon 60 was predicted to be blocked by Tra2b.
The local coverage of each of these exons supports this idea. CTRL B did not appear to be severely affected by very
low coverage in the depicted regions.
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5.5.2. Validation of top ranking candidates
Quantitative real-time PCRs were carried out using RNA isolated from 16.5 dpc brains
to validate top ranking candidates obtained from whole transcriptome sequencing. Using
isoform-specific PCRs, isoforms of the Htt transcript (FL and Δ60) and of the Appbp2 transcript
(FL and Δ4) were specifically detected. In contrast to the predictions from whole transcriptome
sequencing, neither of the two candidate exons was confirmed to be differentially spliced in
KO mice (Figure 24). Appbp2 exon 4 inclusion was predicted to be promoted by Tra2b. For Htt
exon 60 Tra2b was predicted to promote exon skipping. Determination of isoform expression
levels by real-time PCR was highly precise and specific as validated by PCR product sequencing.
Both measured isoforms of each transcript are expressed at highly similar levels regardless of
the genotype or Tra2b transcript levels. These results indicate that splicing of Htt exon 60 and
Appbp2 exon 4 is not altered upon Tra2b depletion and suggest that these exons are very likely
not targets of Tra2b.
Figure 24 | Splicing analysis of Appbp2 exon 4 and Htt exon 60.
RNA from 16.5 dpc brains with Tra2b/Gapdh expression lower than 0.4 was analyzed using real-time PCR.
Expression levels of both Appbp2 and Htt isoforms were measured using isoform-specific primers: FL Appbp2
(4277/4278), Δ4 Appbp2 (4279/4280), FL Htt (4273/4274), Δ60 Htt (4275/4276). Expression levels were normalized
to Gapdh (primers 3999/4000). Tra2b is very likely not a slicing regulator of Appbp2 exon 4 and Htt exon 60.
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5.5.3. Further proceedings in WTS data analysis
First experiments aiming at the validation of putative Tra2b target exons by real-time
PCR were fully ineffective. To exclude the possibility of erroneous data analysis and detection
of false candidates based on sequence coverage anomalies in CTRL sample B, the whole
transcriptome sequencing of this CTRL sample was repeated. Data analysis was repeated as
described in 5.5.1. Substitution of the old by new CTRL data caused a drastically increased
number of significantly detected exons. The number of alternatively spliced exons with
p<0.001 increased from 50 to 415, exons with p<0.05 increased from 4,424 to 21,298. This
strongly suggests that data originating from the initial control sample B contained indeed
numerous outliers that were dissimilar from the other control samples. This caused generally
low significance levels and prevented many exons from being significantly detected.
In the initial analysis most changes in splicing were positive (Figure 20 B), meaning that the
majority of significant exons was detected to be repressed by Tra2b as they on average had
higher levels in KO mice. After substitution of CTRL sample B most of the significant splicing
effects were found negative with lower levels in KO mice indicating splicing inclusion by Tra2b.
This shift clearly demonstrates the strong impact that one sample of poor data quality can
exert on the analysis outcome.
The newly obtained data was filtered to increase the probability of picking a true
target exon of Tra2b. Criteria for selecting candidate exons in this second approach included as
before a highly significant detection. Moreover, candidates with a high x-fold change were
preferred. Sequences of the detected exons were analyzed for the total number and the
frequency of AGAA or GAA binding sites. Exons with a high frequency of putative Tra2b binding
sites were preferred. More candidates were selected for validation experiments including
Las1-like (Las1l) exon 6, the cAMP-dependent protein kinase Prkar2b exon 9, Renin binding
protein (Renbp) exon 6 and Asparaginyl-tRNA synthetase (Nars) exon 4. Splicing of these exons
in CTRL and KO mice was analyzed by real-time and semi-quantitative RT-PCR. To summarize,
none of these identified splicing processes could be validated: Of each transcript only the
isoform including the respective exon could be detected. This was equally true in both CTRL
and KO mice. This suggests that isoforms skipping the respective exons do either not exist or
are expressed at extremely low levels. These and previous failures in validation of splicing
targets indicate that neither a highly significant detection, high x-fold change in splicing, or
enrichment of Tra2b binding sites, nor a combination of all criteria yield true Tra2b splicing
targets.
RNA sequencing has become a potent tool to determine whole spectrum gene
expression profiles and it also finds increasing application in the identification and
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quantification of alternative transcript isoforms (Churko et al. 2013; Costa et al. 2013).
However, quantitative expression analysis from whole transcriptome data makes great
demands on sequencing technology and its accuracy. The quantitative accuracy of high
throughput sequencing approaches is the coverage. The higher a region or transcript sequence
is covered, the more precise is the assessment of its expression. Toung and colleagues have
demonstrated that a total number of 100M reads has been sufficient for the sole detection of
the majority of expressed genes. However, for an accurate quantitative assessment of gene
expression about 500M reads or more have been required (Toung et al. 2011). Read numbers
achieved in this study reach from 45.2M down to 22.2M with an average coverage of 53-fold,
which is far below the required coverage to allow solid evaluation of expression levels. With
regard to the failure in validating splicing targets suggested by transcriptome sequencing, very
low coverage as observed here, might be accounting for the detection of false candidates.
Transcripts that are weakly expressed should be even more prone to such effect as low
expression combined with a low coverage can make the smallest difference in expression
appear big and significant. This is in line with the finding, that many isoforms tested during the
validation process could not at all or only very weakly be detected. Furthermore, brains of KO
mice showed a very severe phenotype that included the loss of whole brain areas associated
with apoptosis (Figure 14). This causes changes in the cell-type composition when comparing
CTRL with KO brains. These inert differences between these groups might also be accounting
for a big fraction of artifact results obtained in the whole transcriptome analysis. Using whole
brain RNA for analysis, such artifacts would then not be based on alternative splicing but be a
result of secondary effects and alterations in gene expression based on selective tissue loss in
the brain. This possibility will be revisited and evaluated in the following chapters.
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5.6. Mouse exon array analysis for the identification of Tra2b target
transcripts
Failure of the whole transcriptome sequencing approach to identify novel Tra2b
splicing targets was likely caused by a too low sequencing coverage that made it impossible to
reliably quantify transcript and isoform levels. Moreover, solid and significant identification of
targets was very susceptible to irregularities in a single sample, as due to the high cost of a
whole transcriptome sequencing run three years ago a rather small 3 CTRL versus 3 KO
comparison was performed. As an alternative attempt to identify novel Tra2b splicing targets
quantification was repeated using mouse exon arrays. Compared to whole transcriptome
sequencing exon arrays are rather inexpensive and allow comparison of a larger sample
number. In this approach 5 CTRL RNA samples were compared to 5 KO samples. Procedures
carried out in preparation and during mouse exon array analysis are described in chapter 4.5.2
of the methods section.
5.6.1. RNA quality control assessment
In preparation for exon array analysis RNA samples were checked for good integrity
and quality on the Experion gel electrophoresis system as described in 4.4.2.6. Total RNA as it
was isolated comprises primarily ribosomal RNAs (rRNAs) and mRNAs only contribute a very
small fraction to the total number of RNA molecules. Visualization of rRNAs on agarose gels or
by capillary gel electrophoresis allows assessment of the general RNA integrity. In RNA samples
isolated from eukaryotic cells or tissues the 28S rRNA and the 18S rRNA should be detectable
at sizes of 4,718 nt and 1,874 nt, respectively. Sharp bands or signals of well defined size are
indicative of intact rRNA, which likely is transferable to mRNAs. Blurry bands or smear are
indicative of degraded or fragmented rRNAs.
Results obtained from RNA analysis are shown in Figure 25. All RNA samples isolated
from whole brains of CTRL and KO mice showed sharp bands of the 28S and 18S rRNA (Figure
25 A). For ratio analysis the results of capillary gel electrophoresis were automatically plotted.
This is exemplarily shown for the first control sample in Figure 25 B. Samples displayed clear
peaks for both rRNAs and no or very weak smear and the automated quality assessment
program of the gel electrophoresis system indicated all samples suitable for downstream
analyses. Size deviations observed for the 28S rRNA (it appears smaller than it theoretically is)
are likely due to inaccuracies in ladder calibration of the capillary electrophoresis system that
should not have impaired analysis in any way.
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5.6.2. Data summary, statistics and filtering
To identify novel splicing targets for Tra2b, analyses of 5 CTRL and 5 KO whole brain
RNAs was performed using Affymetrix mouse exon 1.0 ST arrays. This array type detects single
exons via antisense probes and accordingly requires labeled sense-strand targets for detection.
The array represents a total of 1.2 million probe sets including 835,897 probe sets supported
by gene prediction and 266,791 probe sets that are supported by the Ensembl transcript
database (Affymetrix product information). Each probe set represents a single exon and mostly
comprises 4 distinct probes to specifically hybridize to sequences of the respective exon. RNA
samples used for this analysis were tested for integrity as described in 5.6.1 and Tra2b/Gapdh
transcript levels were assured to be smaller than 0.4 as described in 5.4.1. Preparation,
labeling and hybridization were performed as stated in 4.5.2.
Before proceeding with the statistical and bioinformatic analyses of candidate exons,
the quality of the array read out data was assessed by comparing the dispersion of cell
intensities between the arrays. A summary of this analysis is shown in Figure 26. The box plot
Figure 25 | Analysis of RNA integrity.
RNA samples were analyzed on the Experion capillary gel electrophoresis system (BioRAD). (A) The virtual gel
output shows sharp bands of the 28S and 18S rRNA at defined sizes indicating good RNA integrity. (B) The detection
plot of the capillary electrophoresis shows distinct peaks for both ribosomal RNAs. Automated quality assessment
by the Experion software indicated high quality for all tested RNAs.
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indicated that 8 of the 10 arrays performed had a similar dispersion of signal intensities. The
arrays number 5 and 6 displayed median cell intensities that were drastically lower than
intensities of all other arrays. This deviation might have been a result of in part ineffective
hybridization or labeling. To prevent that these deviating samples bias the determination of
exon abundances in CTRL versus KO group, the arrays number 5 and 6 were excluded from the
analysis. Consequently, estimation of changes in exon abundances was based on 4 CTRL versus
4 KO samples.
Data obtained from the exon array was processed in two different ways: First, to
analyze changes in gene expression (i.e. changes in the abundance of whole transcripts) and
second, to analyze changes in splicing (i.e. changes in the abundance of single exons relative to
whole transcripts). To analyze changes in gene expression in general, intensity data of a whole
transcript cluster was combined. A transcript cluster contains all exon clusters (i.e. groups of
probe sets) belonging to a certain transcript. Thus, global changes of intensity within the whole
cluster are indicative of changes in gene expression. To determine changes in splicing, exon
clusters were directly compared between the CTRL and KO group. If differences in cell intensity
within single exon clusters between CTRL and KO were detected, but were not detected for
the whole transcript cluster in general, the probability of exon specific regulation was
considered high.
To filter out all hits (expression and splicing analysis) that did not present any
difference between the CTRL and KO group only such transcripts or exons that showed at least
Figure 26 | Comparative analysis of array cell intensities.
The dispersion of cell intensities of 10 exon arrays was compared. 8 out of 10 arrays showed very similar dispersion of
intensities. Arrays 5 and 6 displayed median intensities drastically reduced compared to all other arrays surveyed.
Data obtained from the arrays 5 and 6 was excluded from analysis. Whiskers indicate the lower and upper quartiles
of distribution; the band in the box represents the median.
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a change of ±1.5-fold in abundance were considered. Furthermore, the Student’s t-test was
applied to analyze the difference between samples of CTRL and KO group which had to yield
p-values smaller than 0.05. This initial filtering resulted in a list of 86 differentially expressed
transcripts (Appendix, II). 24 transcripts were found to be upregulated and 62 transcripts were
identified as being downregulated in KO brains.
Most of the originally identified exons showed no or very little changes in splicing
inclusion (Figure 27 A, gray bars). Filtering out exons with less than ±1.5-fold up- or
downregulation (gray bars) excluded about 97 % of the identified exons. Further, elimination
of exons with significance levels of worse than 0.05 yielded a list of still 1,006 differentially
included exons. The majority of 622 identified exons was found to be downregulated in KO
mice indicating a positive regulation by Tra2b (Figure 27 B). 384 were upregulated in KO mice.
In total most of these differentially regulated exons were changed not more than ±1.5-fold.
Only 31 and 81 exons were more than 2-fold up- or downregulated in KO mice.
Among the 1,006 identified exons, multiple exons from one and the same gene were
identified as being alternatively spliced (132 exons in total). Genes included in the list of 86
differentially expressed transcripts (Appendix, II) were compared with those genes called with
multiple exons. From the list of 132 alternatively spliced exons, 54 matched with the list of 86
differentially expressed genes. A subset of the double-identified transcripts/exons was
analyzed including the transcription factor Eomes exon 4, Kinsesin-like protein 11 (Kif11) exon
12 and Transcription factor 4 (Tcf4) exon 18. CTRL and KO samples were analyzed by
semi-quantitative RT-PCR using primers that either detect the full length isoform or the
isoform in which the exon of interest is skipped. All PCRs were performed as multiplex PCR
using Hprt as a housekeeping gene. Bands were densitometrically quantified and expression
levels of the respective isoforms were normalized to Hprt expression. Analysis revealed
general changes in expression but no exon-specific changes were detected (Figure 28). This
became apparent by equally strong and coordinate downregulation of both isoform levels. The
transcription factor Eomes (Eomesodermin) was analyzed in detail. Cohorts of CTRL, HET and
KO samples were used to quantify levels of total Eomes, the full-length and the Δ4 isoform
using isoform specific primers. Primer positions for the quantification of total Eomes were
independent of exon 4. Quantification demonstrated that both isoforms and the total Eomes
transcript were equally and significantly downregulated in KO mice (Figure 29). This strongly
suggests that these exons being identified to be alternatively spliced are true artifacts caused
by misinterpretation of altered transcript levels. Thus, the 132 exons belonging to this group
were excluded from the candidate list (Figure 27 C).
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Figure 27 | Statistical analysis and filtering of differentially spliced exons from exon arrays.
(A) The x-fold change of exon inclusion is defined as [KOINCLUSION] / [CTRLINCLUSION]. Values were distributed from ~0.2
until ~4.0. Initial filtering strategies comprised exclusion of exons with x-fold changes between 0.66 and 1.5 (grey
bars) as well as restriction to p-values smaller than 0.05 which yielded a total of 1,006 exons. (B) Distribution of
positive and negative inclusion ratios in KO mice. (C) Exons associated with transcripts identified as being
transcriptionally up- or downregulated were excluded from analysis. Ranking of those was further refined using
large x-fold change values and considering presence of putative Tra2b binding sites (AGAA-motifs). Thereby, exons
had to contain at least a single AGAA-site and an AGAA-frequency higher than 1.5.
Figure 28 | Analysis of double candidates for alternative splicing and differential expression.
RNA from 16.5 dpc brains with Tra2b/Gapdh expression lower than 0.4 was analyzed using semi-quantitative RT-
PCR. Expression levels of all shown isoforms was measured using isoform-specific primers: FL Eomes (4494/4495),
Δ4 Eomes (4496/4497), FL Kif11 (4498/4499), Δ12 Kif11 (4500/4501), FL Tcf4 (4516/4517), Δ18 Tcf4 (4526/4518).
Expression levels were normalized to Hprt (primers 2811/2812).
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The overall high number of alternative events and the strong overlap with
differentially expressed transcripts is probably indicative of poor data quality and a high error
rate which strongly increases the number of false positive exons. It cannot be excluded that
the strongly altered brain morphology and misdevelopment in the KO mice and the according
changes in cell type and transcriptome composition cause a large number of artifact results.
Especially whole transcripts that were found to be downregulated in KO mice are extremely
prone to error. Assuming that a transcript is strongly expressed in cortical neurons and is
found downregulated in KO mice, it is very likely that the downregulation is a result of absence
of many cortical neurons in KO mice but is not a result of real transcriptional regulation.
Furthermore, mosaicism of Cre-recombinase expression leads to two distinct cell
populations in the KO brain. First, surviving cells in which Tra2b was depleted and show altered
splicing patterns and, second, cells that express Tra2b and show normal splicing. In such a
mosaic brain the latter cell population masks the splicing effect present in KO cells. That
phenomenon appears to hamper the analytical efforts to reliably call alternative splicing
events.
As an attempt to counteract this problem, exons that do not contain any AGAA binding
motif were excluded from analysis (Figure 27 C). Considering that such motif occurs
statistically once in a 256 bp stretch, the binding site frequency (F) was calculated as the
number of binding sites multiplied with the exon length in bp divided by 256. Exons with FAGAA
< 1.5 were excluded resulting in 481 remaining exons (Figure 27 C). The remaining 481 exons
after applying the described filtering conditions are listed in the Appendix (Appendix, III).
Figure 29 | Quantification of total Eomes and individual isoform levels.
RNA from 16.5 dpc brains was analyzed using semi-quantitative RT-PCR. Expression levels of total Eomes, full-length
and Δ4 Eomes were measured using isoform-specific primers: total Eomes (4502/4503), FL Eomes (4494/4495), Δ4
Eomes (4496/4497). Primers used for the quantification of total Eomes were located independently of exon 4.
Expression levels were normalized to Hprt (primers 2811/2812). Numbers within the bars indicate the number of
biological replicates (N).
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5.6.3. Validation screening of top ranking splicing candidates
Detection of putative alternatively spliced exons on exon arrays required validation by
PCR. Even when using simple semi-quantitative PCRs it was due to the sole quantity of
candidates not feasible to test all or a big fraction of the 481 remaining candidate exons.
Therefore, candidates were individually selected for downstream analysis according to their
x-fold change of splicing inclusion and AGAA binding site frequency. Exons with a big change of
inclusion in KO mice and a high binding site frequency were preferred. Furthermore, exons
that contained binding site clusters were preferred. Additionally, the conservation of the
binding sites in mammals was manually surveyed using the UCSC genome browser. As a high
conservation of binding sites might point to a conserved biological function of that exon, exons
with conserved binding sites or binding site clusters were preferred to others.
As a feasible fast forward screening approach semi-quantitative PCR was performed
using isoform specific primer pairs that either detected the isoform including the candidate
exon or detected the isoform skipping the candidate exon. Up to 2 forward and 2 reverse
primers allowing for 4 possible PCR combinations were used in parallel PCRs. As a template,
cDNA was generated from each a representative CTRL and KO RNA. Semi-quantitative PCR was
carried out for the screening of 11 candidates matching the properties mentioned above.
These were candidate exons of the following transcripts: Casp1, Ezh2, Gca, Nrg1, Prkd3, Rcor2,
Sgol2, Slu7, Sox6, St18 and, Tubd1. All these tested candidates and their scores are also
highlighted in the candidate list in the Appendix (Appendix, III).
Analysis of these candidates was mostly not able to reproduce the tendencies of exon
inclusion detected on the array. In many cases the isoform lacking the exon in question was
not detected at all, suggesting that it either does not exist or is expressed at extremely low
levels. Figure 30 shows representative examples of the candidate screening. Most PCRs were
optimally amplifying the product using multiplex conditions with Hprt as the housekeeping
gene. Normalization and densitometric quantification showed similar downregulation for both
isoforms of the Slu7 and Nrg1 transcripts. Coordinate downregulation is indicative of general
changes in the amounts of transcripts but rather not of an alternative splicing event. The full
length isoforms of the Prkd3 and Sox6 transcripts did not demonstrate any clear changes of
expression between CTRL and KO. The isoforms of both transcripts lacking the respective
candidate exon were not detected at all. However, possible differences in splicing were
detected for the Shugoshin-like2 and Tubulin delta chain transcripts (Sgol2 and Tubd1 are
introduced in chapter 5.6.4). The expression of the Sgol2 isoform including exon 4 was reduced
by approx. 70 % in KO mice compared to CTRL. The isoform skipping exon 4 was not detected
in CTRL mice but was detectable in KO mice. This inverse correlation of isoform expression in
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CTRL and KO mice strongly suggests that Sgol2 exon 4 splicing is a Tra2b-dependent splicing
process. This appeared to be equally true for the splicing of Tubd1 exon 4. Expression of the
full-length isoform including exon 4 was reduced by approx. 20 % in KO mice compared to
CTRL mice. The isoform lacking exon 4 was not detected in either CTRL or KO mice.
Computational analysis showed that removal of exon 4 from the Tubd1 transcript causes a
frame-shift and generates multiple premature termination codons. Therefore, the Tubd1
transcript lacking exon 4 probably undergoes nonsense-mediated decay and might not be
detectable for that reason. Of the 11 initially surveyed putative splicing events only the exons
4 of the Sgol2 and Tubd1 transcripts showed indications for alterations in splicing based on the
absence of Tra2b. Other tested candidates displayed either coordinate up- or downregulation
of both isoforms, which could be an indicator of transcriptional regulation but is most likely an
artifact result based on the severe changes in brain morphology and tissue composition as it is
present in the brains of KO mice. This idea is further supported by the fact that in the absolute
majority of cases a coordinate downregulation but not an upregulation was observed. Failure
in detection of isoforms lacking the respective candidate exon in both CTRL and KO mice
suggests that this isoform is not expressed and is likely not a physiological isoform – at least
not in brain. The sudden appearance of the shorter isoform in KO mice – as it is the case for
Sgol2 exon 4 – indicates that inclusion of this exon at least in part might depend on Tra2b.
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Figure 30 | Fast forward screening of candidate exons for alternative splicing.
RNA from a representative 16.5 dpc brain with Tra2b/Gapdh expression lower than 0.4 was analyzed and compared
to CTRL using semi-quantitative RT-PCR. Gel images show PCR results of the most effective primer combination
used. Isoform-specific PCRs were carried out in parallel using the primers: FL Slu7 (4512/4513), Δ15 Slu7
(4522/4523), FL Nrg1 (4504/4505), Δ5 Nrg1 (4506/4507), FL Sgol2 (4510/4511), Δ4 Sgol2 (4510/4521), FL Prkd3
(4577/4578), Δ18 Prkd3 (4580/4579), FL Sox6 (4514/4515), Δ5 Sox6 (4524/4525), FL Tubd1 (4529/4531), Δ4 Tubd1
(4532/4530). Expression levels were normalized to Hprt if multiplex PCR was applicable (primers 2811/2812).
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5.6.4. Validation of positive splicing candidates
Mouse exon array analysis and candidate screening identified exons of the Sgol2 and
Tubd1 transcripts as likely targets of Tra2b, as both exons showed differential inclusion ratios
in CTRL versus KO mice. Sgol2 encodes the Shugoshin-like 2 protein that protects the integrity
of the cohesin-complex, which regulates sister chromatid cohesion during meiosis I (Llano et
al. 2008; Clift and Marston 2011). It has been demonstrated to be essential for meiosis but not
for mitosis and Sgol2-deficient mice are viable but infertile. The Tubd1 gene encodes the
tubulin delta 1 protein. It is highly expressed in testis and is a component of the perinuclear
ring of the manchette, which helps to translocate and elongate the nucleus during sperm cell
maturation (Smrzka et al. 2000; Kato et al. 2004). The somatic function of delta tubulin is
poorly understood and expression levels in brain are rather low. Still it has been detected on
exon arrays using brain RNA and the transcript was identified in subsequent screening PCRs.
To validate splicing of the respective candidate exons of the Sgol2 and Tubd1
transcripts in vivo, semi-quantitative RT-PCRs were performed using cohorts of CTRL, HET and
KO whole brain RNAs for a comparative analysis. As before, primers were selected to
specifically amplify either the isoform including or skipping the respective exon. All PCRs were
performed as multiplex PCRs using Hprt as a housekeeping gene. Band intensities were
densitometrically determined and expression levels were normalized to Hprt expression.
The isoform of Sgol2 including exon 4 showed a modest and non-significant decrease
in KO and HET mice compared to controls (Figure 31 A,C). This is in contrast to the results
shown in Figure 30 in which full-length Sgol2 appeared to be drastically downregulated in KO
mice. However, this result was based on a single KO sample compared to a CTRL sample and
was therefore statistically non-significant. Quantification of the Sgol2 Δ4 isoform showed weak
but consistent expression in CTRL and HET mice (Figure 31 B,D). Strikingly, Sgol2 Δ4 expression
was significantly increased by 2.75-fold in KO animals. This quantification fully resembles the
results obtained in exon array analysis, where a 2.7-fold loss of exon inclusion was detected in
KO mice (Appendix, III). These data demonstrate that the inclusion of exon 4 into the Sgol2
transcript is promoted by Tra2b. The mild decrease of full-length Sgol2 transcripts might be a
consequence of Sgol2 Δ4 upregulation. Very likely the decrease of FL Sgol2 expression is
minimal, because - regardless of the presence of Tra2b – FL Sgol2 is the major isoform and
even drastic changes of the inferior Δ4 isoform do not strongly affect the prominent FL
isoform. Thus, in vivo validation of Sgol2 exon 4 splicing constitutes a proof of concept for this
in vivo candidate approach to detect Tra2b-related splicing processes under physiological
conditions.
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Figure 31 | Validation of Sgol2 exon 4 and Tubd1 exon 4 splicing.
RNA from 16.5 dpc brains with Tra2b/Gapdh expression lower than 0.4 was analyzed using semi-quantitative RT-
PCR. Expression levels of all shown isoforms was measured using isoform-specific primers: (A,C) FL Sgol2
(4510/4511), (B,D) Δ4 Sgol2 (4510/4521), (E,G) FL Tubd1 (4529/4531), (F) Δ4 Tubd1 (4532/4530). Δ4 Tubd1 was not
detectable in vivo. Skipping of exon 4 causes a frame-shift generating numerous premature termination codons.
(H) Analysis of Tubd1 Δ4 expression in emetine treated fibroblasts that either express or do not express Tra2b. FL,
full length; ∆4, transcript lacking exon 4, (-) PCR negative control; numbers within the bars indicate the number of
biological replicates (N), asterisks indicate premature termination codons.
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Tubd1 exon 4 was further demonstrated to be dependent on Tra2b by semi-
quantitative RT-PCR (Figure 31 E,F). The Tubd1 isoform including exon 4 showed a significant
decrease by 1.46-fold in the brains of KO animals compared to CTRL. Expression of the full-
length isoform in CTRL and HET animals was at similar levels and non-significantly different.
The reduction of full-length isoform expression in KO mice verifies the 1.7-fold loss of exon
inclusion detected on the microarray (Appendix, III). Similar to the initial candidate screening
approach, the 4 isoform of Tubd1 was not detectable in brains of either CTRL or KO mice.
Tubd1 exon 4 is 217 nucleotides long and thereby comprises 72 nucleotide triplets plus a single
nucleotide. Computational analysis showed that skipping of exon 4 from the Tubd1 transcript
causes a frame-shift that results in at least 10 premature termination codons that would likely
lead to transcript degradation by nonsense-mediated decay (Figure 31 F). This hypothesis was
tested using previously generated murine immortalized fibroblasts that were either depleted
of Tra2b or expressed Tra2b. The generation and characterization of these cell lines is
described in 5.2. Cells were treated with emetine to block NMD in Tra2b-depleted and
Tra2b-expressing cells (as described in 4.1.6). RNA isolated from treated and non-treated
fibroblasts was used to detect the Tubd1 Δ4 isoform using isoform specific primers. Strikingly,
the Tubd1 Δ4 isoform was exclusively detectable in Tra2b-depleted cells that were treated
with emetine (Figure 31 H). Tra2b-depleted cells that were not treated with emetine did not
show expression of the Δ4 isoform, strongly suggesting that the Tubd1 Δ4 transcript is highly
effectively degraded via the NMD-mechanism. Furthermore, fibroblasts expressing Tra2b
(Tra2bfl/fl) did not allow detection of Tubd1 Δ4 neither without, nor with emetine treatment.
This clearly indicates that ablation of Tra2b is directly causative for the generation of this
isoform. Moreover, Tubd1 exon 4 inclusion can obviously not be fully compensated by other
factors, an idea which is supported by reduced full-length Tubd1 levels in KO mice (Figure 31
G).
Which functional or physiological implications the observed Tra2b-dependent splicing
processes have in vivo cannot be answered with certainty. The question whether the Tubd1 Δ4
isoform is expressed in presence of Tra2b under physiological conditions cannot be resolved as
the inability to abolish NMD in vivo precludes this analysis. In vivo splicing regulation of Tubd1
exon 4 could constitute a mechanism to regulate the amount of Tubd1 protein levels on a
post-transcriptional level. Whether and which functional role the skipping of exon 4 from the
Sgol2 transcript has and which consequences this has for the protein function and stability
remains to be determined.
To summarize, splicing processes of two candidate exons of the Sgol2 and Tubd1
transcripts identified on mouse exon arrays were successfully verified in vivo. This proofs the
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neuronal-specific Tra2b knock-out mouse to be a functional model to study Tra2b-related
splicing processes in vivo under physiological conditions. High throughput analyses have also
uncovered weaknesses of the system. These will be discussed in detail in section 6.3.
5.7. Functional splicing analyses
The Shugoshin-like 2 exon 4 and the Tubulin delta 1 exon 4 were shown to be spliced
in dependency of Tra2b in the murine developing brain. Both were identified on exon arrays
and were validated by RT-PCR using RNA from murine brains. For the identification of splicing
targets most previous studies have been focusing on approaches involving artificial or biased
systems like cross-linking of RNA-protein interactions, overexpression of splice factors and
minigene experiments (Stamm et al. 1999; Hofmann et al. 2000; Kondo et al. 2004; Stoilov et
al. 2004; Grellscheid et al. 2011a; Grellscheid et al. 2011b). The identification of the Sgol2 and
Tubd1 exons 4 using murine whole brain RNA is a proof of concept for the in vivo identification
of novel splicing relationships.
Though the in vivo analysis allowed detection of these splicing events on a
physiological background, it cannot be excluded that results obtained from the neuronal-
specific knock-out system are inertly biased by massive changes in brain physiology. It was
demonstrated that Tra2b-depleted brains develop a very severe phenotype including
ventriculomegaly and loss of cortical cells and patterning. Thus the final ratio of cell types is
different between CTRL and KO brains. This is in so far important as different cell types with
diverse function might have different patterns of global gene expression but also different
patterns in alternative splicing of transcripts.
To assure that the splicing effects of Sgol2 exon 4 and Tubd1 exon4 are truly Tra2b-
related but not a product of a shift in cell type composition, minigene experiments were
performed. Even though minigene approaches are non-physiological with regard to splice
factor concentrations and substrate mRNA concentrations, experiments are performed in a
controlled environment that allows direct comparison. The human and murine versions of
Sgol2 exon 4 and Tubd1 exon 4 were tested for splicing inclusion as a response to increased or
abolished Tra2b expression in HEK293T cells using the pSPL3 exon trapping system as
described in chapter 5.7.1.
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5.7.1. Generation of Sgol2 and Tubd1 minigene constructs
For testing of Sgol2 exon 4 and Tubd1 exon 4 in minigene experiments the human and
murine versions of the exons with approx. 0.5 – 1 kb flanking intronic regions were cloned into
the pSPL3 exon trapping vector. Genomic regions were amplified from human and murine DNA
using restriction-overhang primers as listed in 3.9.1. The PCR amplified insert was cloned to
the multiple cloning site of pSPL3 using 5’XhoI and 3’BamHI restriction ligation. The whole
genomic insert was validated by sequencing. In total 4 distinct minigene constructs were
generated (Figure 32 B): the human and murine versions of each Sgol2 exon 4 and Tubd1
exon 4. Their genomic inserts are somewhat variable in size as to the length of their flanking
introns. These were chosen to be shorter for the Tubd1 genomic insert due to a GC-rich
genomic vicinity which made specific amplification by PCR laborious. Once transfected into
eukaryotic cells the pSPL3 vector produces mRNA containing the genomic insert with the
respective exon of interest flaked by the tat a and tat b exons of HIV. These flanking exons are
constitutively spliced and  have the potential to link with foreign exons resulting in a specific
mRNA (Buckler et al. 1991). Inclusion of the exon of interest results accordingly in a longer
mRNA that can be detected and compared by size differences using RT-PCR (Figure 32 A).
Figure 32 | The pSPL3 exon trapping system: Sgol2 and Tubd1 minigene constructs.
(A) Functional structure of transcripts generated from the pSPL3 vector. Tat a and tat b are constitutive exons of
HIV that form a 262 bp transcript. The genomic insert containing the exon of interest was cloned in between them.
Depending on exon recognition and the used conditions the exon of interest will be spliced or skipped. The
transcript can be detected using specific primers within the tat a and tat b exon producing a 262 bp product.
Inclusion of the exon of interest results in an accordingly longer product. (B) Genomic inserts containing human
and murine versions of Sgol2 exon 4 and Tubd1 exon 4. Exons are surrounded by their flanking intronic sequences.
The length of the intronic sequences is given.
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5.7.2. Minigene splicing assay
The minigene splicing assays using the previously described pSPL3 exon trapping
constructs were carried out in HEK293T cells. HEK293T cells were transfected using the
DharmaFECT I transfection reagent to deliver plasmid DNA, siRNA or both. Splicing of the
human and murine versions of Sgol2 exon 4 and Tubd1 exon 4 was tested while
overexpressing HTRA2B from pEGFP or depleting HTRA2B using siRNAs in parallel to
transfection with a minigene in pSPL3. As control experiments proteins were isolated from
HEK293T cells. Immunological detection of TRA2B indicated that TRA2B expression is
effectively abolished upon siRNA treatment and the TRA2B-GFP fusion-protein is strongly
expressed upon pEGFP-TRA2B transfection (Figure 33 A). RNA was isolated 48 h after
transfection and pSPL3-derived transcripts were detected by semi-quantitative RT-PCR using
the tat a and tat b specific primers 4508 and 4509. The typical transcript product of 262 bp was
specifically detected. PCR products with the Sgol2 or Tubd1 exon included were accordingly
longer (Figure 33 B).
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Figure 33 | Minigene splicing assay of Sgol2 exon 4 and Tubd1 exon 4.
HEK293T cells were co-transfected with the pSPL3 minigene vector and siRNA specific for Tra2b or a TRA2B-GFP
expression vector. (A) Western Blot analysis shows efficiently reduced TRA2B protein levels and solid
overexpression of TRA2B-GFP. (B) RNA was analyzed for exon inclusion after 48h by semi-quantitative RT-PCR using
the primers 4508/4509. (C-F) RT-PCR results were densitometrically quantified. Exon 4 of murine but not human
Sgol2 was responsive to increased concentrations of TRA2B as splicing inclusion significantly increased from 43 % to
89 %. Knock-down of TRA2B was insufficient to reduce Sgol2 exon4 splicing inclusion. Exon 4 of human but not
murine Tubd1 was responsive to increased concentrations of TRA2B as splicing inclusion significantly increased
from 79 % to 94 %. Knock-down of TRA2B decreased inclusion of exon 4 from 79 % to 71 %. nt, non-treated; scr,
scrambled siRNA; si, siRNA against Tra2b; n.s., non significant; all transfections were performed in triplicates
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PCR results indicate that only the murine Sgol2 but not the human SGOL2 is responsive
to HTRA2B overexpression in HEK293T cells (Figure 33 C,D). Under normal conditions (scr)
Sgol2 exon 4 was included in 43 % of the transcripts. After overexpression of HTRA2B exon 4
was included in 89 % of the transcripts suggesting that HTRA2B effectively promotes inclusion
of murine Sgol2 exon 4 (Figure 33 D). On the contrary, HTRA2B overexpression had no effect
on the human SGOL2 transcripts (Figure 33 C). The human exon 4 is included in 93 % of the
transcripts under normal conditions (scr) (Figure 33 C). This suggests that HTRA2B
overexpression is unable to further enhance SGOL2 exon 4 inclusion. As human embryonic
kidney cells (HEK293T) were used for minigene splicing assays the intrinsic splice site strengths
of the tested exons was analyzed by comparison to the primate splice site consensus
(http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm). Splicing machineries of rodent organisms
might process exons differently than in primate organisms with regard to their optimal
consensus sequence of the major spliceosome. Indeed, scores of both the 3’ and 5’ splice sites
of Sgol2 exon 4 were higher for the human sequence compared to the murine version (Figure
34). Furthermore, ablation of endogenous HTRA2B in HEK293T cells by RNAi did not decrease
Figure 34 | Comparative splice site analysis of human and murine Sgol2 exon 4.
3’ and 5’ splice sites of human and murine Sgol2 exon 4 were rated by comparing to the primate consensus
sequence using the AnalyzerSpliceTool available online (http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm). (A)
Alignment of 3’ splice sites. The relevant nucleotide stretch from -14 (intonic) to +1 (exonic) is labeled blue. (B)
Alignment of 5’ splice sites. The relevant nucleotide stretch includes the last 3 exonic nucleotides and the first 6
intronic nucleotides (labeled red). Both the 3’ and 5’ splice site of human SGOL2 achieve higher scores than the
murine version.
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exon 4 inclusion (Figure 33 C,D). These results suggest that the high intrinsic splice site
strength of the human SGOL2 exon 4 is sufficient to constitutively splice that exon. Therefore,
results obtained for Sgol2 in the mouse might probably not be transferable to humans.
The alternative splicing of Tubd1 exon 4 in the minigene is HTRA2B dose-dependent
(Figure 33 E,F). Under normal conditions (scr) 79 % of transcripts show exon 4 inclusion.
Ablation of HTRA2B slightly but significantly reduced exon 4 inclusion to 71 % while
overexpression significantly increased inclusion to 94 % (Figure 33 E). This indicates that
HTRA2B promotes TUBD1 exon 4 inclusion, confirming the results obtained in the mouse
model. Surprisingly, the murine version of the minigene failed to respond to altered HTRA2B
concentrations in HEK293T cells (Figure 33 F). Under normal conditions (scr) exon 4 was
included in 92 % of the transcripts and splicing inclusion did not change upon knock-down or
overexpression of HTRA2B. This finding is in so far intriguing as the Tubd1 exon 4 splicing event
was originally detected in mouse (Figure 31 E-H). The splice site strengths of human and
murine Tubd1 exon 4 are very similar and analysis suggests that the murine 3’ and 5’ splice
sites are presumably equally well recognized by the human splicing machinery in HEK293T
cells. However, there are minor differences in number and position of well-known binding sites
(e.g. SF2/ASF and SRp40) that might be attributable to a more efficient inclusion of exon 4 in a
human cellular system compared to native conditions in the mouse.
Analysis of Sgol2 exon 4 and Tubd1 exon4 splicing using minigene analyses could in
part confirm both exons being responsive to different concentrations of TRA2B.
Responsiveness to HTRA2B overexpression clearly demonstrated that both exons are regulated
by TRA2B. However, it appears like TRA2B exerts a rather modulating effect on the inclusion of
Sgol2 exon 4 and Tubd1 exon 4. A basic and often solid recognition of both exons was even
detectable in absence of TRA2B, suggesting that these exons are well recognized by the
general splicing machinery and / or other factors. The human TUBD1 minigene was the only
construct that was responsive to reduced TRA2B concentrations and accordingly showed less
exon inclusion. In how far the result obtained in vivo using neuronal-specific knock-out mice
can be compared to results from minigene experiments is difficult to determine. HEK293T cells
are of human origin and their spliceosome matches best the primate consensus sequence. This
consensus sequence in rodents is different, however. For that reason, responsiveness of a
minigene construct in human cells might not be fully transferable to a splicing effect observed
in mice.
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5.8. Functional analysis of Tra2b-mediated p21-upregulation
In frame of exon array analysis of murine brain RNA, total expression levels of genes
were studied besides performing analyses regarding differential exon inclusion. As underlined
in previous chapters severe morphological changes and alterations in cell type composition
take place in brains of neuronal-specific knock-out mice. This impacts the analysis of splicing
events and the determination of transcript levels in general (see 5.7). The identification of
decreased transcript levels might be a direct result of tissue loss in the brain and might
therefore not reflect a real transcriptional downregulation. However, the identification of
increased transcript levels is more likely to reflect real and solid transcriptional upregulation,
as the increase is counteracted but not supported by the general loss of transcripts caused by
tissue loss. Accordingly, many more transcripts have been significantly identified as being
downregulated than being upregulated (Appendix, II).
Among the candidates with increased expression levels the cyclin-dependent kinase
inhibitor 1A (Cdkn1a), also known as p21, attracted most attention for two reasons. First, p21
is an important regulator of cell cycle progression that can inhibit the activity of the cyclin-
dependent kinases CDK2 and CDK4, thereby blocking cell-cycle progression (Harper et al.
1993). This was in so far intriguing as massive apoptosis and a loss of the proliferative potential
was detected in Tra2b-depleted murine brains. As CDK inhibition by p21 leads to cell-cycle
arrest at the G1-S-phase transition (Harper et al. 1993) and inability to proliferate might cause
apoptosis in parts of the developing brain, expressional upregulation of p21 might be causative
for apoptosis in Tra2b-depleted murine brains.
Second, the histone chaperone Nasp was shown to be spliced by Tra2b in mouse testis
and the developing brain (Grellscheid et al. 2011a) (Figure 18 A). Ablation of Tra2b decreased
the inclusion rate of the Nasp T-exon which resulted in a decreased expression of the tNasp
isoform (Figure 18 A). Ablation of Nasp has been shown to cause early embryonic lethality in
mice (Richardson et al. 2006). Astonishingly, selective ablation of tNasp via RNAi in tumor cells
has previously been demonstrated to induce apoptosis via expressional upregulation of p21
(Alekseev et al. 2011).
Apoptosis in the Tra2b-depleted brains, early embryonic lethality in mice ubiquitously
depleted of Tra2b (Mende et al. 2010), aberrant splicing of tNasp in Tra2b-depleted brains,
and tNasp ablation causing p21-mediated apoptosis in tumor cells (Alekseev et al. 2011)
possibly form a common ground to explain p21 upregulation and apoptosis observed in
neuronal-specific knock-out mice. Therefore, p21 upregulation identified on exon arrays
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became the major subject of further investigations. First experiments included the validation
of p21 upregulation in brains of neuronal-specific knock-out mice.
5.8.1. p21 is upregulated in brains of conditional knock-out mice
To validate the expressional upregulation of p21 found on exon arrays semi-
quantitative RT-PCR was carried out specifically detecting p21 transcripts in whole brain RNA.
Cohorts of CTRL, HET and KO mice were compared and expression data were normalized to
Hprt expression levels. In agreement to the 1.5-fold upregulation of p21 detected on exon
arrays (Appendix, II), p21 was found significantly upregulated by 1.4-fold in KO mice compared
to CTRL (Figure 35). HET mice did not show any changes in p21 expression levels compared to
controls. Due to Cre recombinase-related mosaicism and the spatial limitations of apoptotic
areas in the brain of KO mice (Figure 14) it was expected that apoptotic cells likely contribute
only with a small fraction to the whole brain. Still the detection of p21 upregulation was
possible in whole brain RNA indicating a solid upregulation in the affected cell populations.
Expressional upregulation of p21 likely occurred in brain regions that showed
increased Caspase 3 levels indicative of apoptosis. These regions were primarily the ventricular
and subventricular zone of the cortex (Figure 14), which are neurogenic areas and origin of
neuronal outgrowth to form different cortical layers (Lopez-Bendito and Molnar 2003). P21-
mediated cell-cycle arrest in this population of neuronal precursor cells could very likely
Figure 35 | Expression analysis of p21 in neuronal specific knock-out mice.
(A) RNA from 16.5 dpc brains was analyzed using semi-quantitative RT-PCR. Expression levels of p21 were
measured using specific primers (4491/4492). P21 expression was normalized to Hprt (primers 2811/2812). (B) P21
levels were found 1.4-fold significantly upregulated in KO mice compared to CTRL and HET mice. Numbers within
the bars indicate the number of biological replicates (N).
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abolish cell differentiation and heavily disturb cortical development. To test whether p21
upregulation is a direct result of Tra2b depletion, NSC34 cells were used to analyze the effects
of Tra2b depletion in a homogeneous cellular system. The use of this neuronal precursor cell
line further allowed assessing the cellular response to p21 upregulation.
5.8.2. Tra2b knock-down experiments in NSC34 cells
To test the consequences of Tra2b-depletion in a homogeneous cellular system murine
neuronal stem cells (NSC34 cells) were used, as their neuronal fate resembles the neuronal
identity of affected cells found in the ventricular and subventricular cortical layers of KO mice.
NSC34 cells were depleted of Tra2b using specific siRNAs. RNA and protein levels of Tra2b and
p21 were determined by quantitative real-time PCR and immunoblot. RNA levels of the
functional Tra2b 2 isoform (Figure 37 A) and Tra2b protein levels (Figure 36) were markedly
reduced within 24, 48 and 72 hours after siRNA transfection. Transfection with a scrambled
control siRNA did not cause significant changes of the Tra2b protein level (Figure 36). As
expected, depletion of Tra2b caused changes in splicing of the Nasp transcript. The tNasp
isoform was significantly downregulated by at least 50 % within 24 to 48 hours after
transfection (Figure 37 B) suggesting that Tra2b activity is functionally abolished upon siRNA
transfection. To test whether p21 elevation found in KO mice (Figure 35) can be reconstituted
in NSC34 cells, p21 expression was measured via real-time PCR using the specific primers 4493
and 4492. The p21 expression on protein level was determined via Western Blot. Within 48
hours after transfection, p21 did not increase on protein level (Figure 36). However, a modest
but significant increase of p21 expression was detected on mRNA level (Figure 37 C). To asses
long term effects of Tra2b ablation on p21 expression RNA levels were assayed 72 and 96
hours after transfection. Notably, after 72 hours about 20 % of the Tra2b-depleted cells had
died (data not shown) and p21 was strongly and highly significantly upregulated by +2.2-fold
on mRNA and protein level (Figure 37 C, Figure 36). Strikingly, after 96 hours the majority of
transfected cells had died indicating a massive loss of proliferative potential and possible cell
cycle arrest and apoptosis. The succession of events suggested that the downstream effects
originally triggered by Tra2b ablation do not occur instantly but rather require time to
establish. This is in line with the findings in KO mice, in which onset of Cre-recombinase
expression and thus Tra2b depletion starts at around 10.5 dpc. Abnormalities in brain
development cannot be observed before 14.5 to 15.5 dpc, however. These findings strongly
indicate that Tra2b deficiency leads to p21 activation and suggest p21 activation to be a major
contributor to apoptosis and developmental defects observed in neuronal-specific Tra2b KO
mice.
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As depletion of Tra2b reduced the inclusion rate of the Nasp T-exon, the expression of
the tNasp isoform was accordingly reduced in the performed experiment (Figure 37 B). Like
mentioned previously, p21 has been demonstrated to be upregulated in tumor cells upon
selective depletion of tNasp (Alekseev et al. 2011); a situation that is very similar to the
experiment performed in this study. One could argue that Tra2b-depletion mediates p21
upregulation via depletion or downregulation of tNasp. This indirect signal transmission finally
leading to p21 upregulation includes the probably time-consuming degradation of tNasp
protein, which fits to the delayed cellular response in NSC34 cells. To approach functional
testing of this hypothesis, follow-up experiments were aiming to rescue p21 expression to
normal levels by overexpressing tNasp from a vector while depleting Tra2b using siRNAs.
Figure 36 | Tra2b depletion in NSC34 cells: Analysis on protein level.
NSC34 neural stem cells were transfected with siRNAs specific to Tra2b or scrambled siRNAs using the DharmaFect I
transfection reagent. (A) Immunoblots of NSC34 cell lysates at the indicated time points. (B) Densitometric analysis
of immunoblot band intensities. All data were normalized to β-actin expression. siRNA treatment but not scr-
treatment effectively reduced Tra2b protein levels 48h and 72h after transfection. P21 protein levels are
unchanged after 48h but are significantly increased by 2.2-fold in Tra2b-depleted cells 72h after transfection.
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In preparation to rescue experiments a tNasp expression vector was produced. tNasp
was amplified from murine adult testis cDNA using the primers 4594 and 4595 and cloned into
pEGFP-C2 using XhoI and BamHI restriction ligation. The pEGFP vector used here has an
N-terminal EGFP tag. This was chosen as the tNasp protein physiologically localizes to the
nucleus and the nuclear localization signal is predicted at the C-terminal end of the protein
(UniProt). Linking the EGFP tag to the N-terminal end of tNasp should prevent any interference
of the tag with the nuclear localization signal. Identity of the cloned tNasp insert was validated
by sequencing. Vectors used for transfection experiments were prepared using low-endotoxin
plasmid purification kits.
NSC34 cells were co-transfected with scrambled or Tra2b-specific siRNA and pEGFP-
tNasp or the pEGFP vector without any insert. RNA and proteins were isolated 48h and 72h
after transfection. GFP-immunoblot analysis showed that transfection of the pEGFP or pEGFP-
tNasp vector results in solid expression of EGFP (28 kDa) or EGFP-tNasp (111 kDa) with specific
bands at the expected molecular weight (Figure 38). This indicated that intact EGFP-tNasp
fusion-protein is produced from the generated pEGFP-tNasp vector. However, most cells
Figure 37 | Tra2b depletion in NSC34 cells: Analysis on RNA level.
NSC34 neural stem cells were transfected with siRNAs specific to Tra2b or scrambled siRNAs using the DharmaFect I
transfection reagent. Expression levels of the functional Tra2b Δ2 isoform (A), tNasp (B) and p21 (C) were
determined using quantitative real-time PCR. All data were normalized to Gapdh expression. Specific primers were:
Tra2b Δ2 (4271/4272), tNasp (4049/4042), p21 (4493/4492), Gapdh (3999/4000). siRNA treatment effectively
reduced Tra2b mRNA levels 24h, 48h and 72h after transfection. Tra2b ablation caused reduction of tNasp isoform
expression by approx. 50 %. P21 mRNA levels were slightly but significantly increased after 48h but are highly
significantly increased by 2.2-fold in Tra2b-depleted cells 72h after transfection.
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subjected to this experiment died 48h to 72h after transfection. This was equally true for cells
transfected with pEGFP-tNasp but also for cells transfected with the pEGFP control vector
independently of Tra2b silencing. This indicated that the sole presence of the pEGFP vector
backbone is toxic for the cells probably due to high expression levels of EGFP. Also possible is a
contamination with endotoxins from the plasmid preparation. In an attempt to reduce toxicity
the amounts of vector were reduced to 0.5 µg pEGFP per 6-well plate. This equally resulted in
a very high cell mortality rate.
As previously determined (Figure 37 C), upregulated p21 expression levels take up to
72h of Tra2b depletion to be clearly detectable. However, due to the high rates of cell death in
pEGFP-tNasp rescue experiments it was not possible to accurately determine p21 levels via
quantitative real-time PCR 72h after transfection. At this time point cells were affected to
severely by the procedure, that also normalization of transcript levels was not possible due to
highly fluctuating Gapdh expression. It is not clear whether the overexpressed tNasp protein
itself also exerts a cytotoxic effect to NSC34 cells. However, the fact that the sole pEGFP vector
even at low dosage is able to inflict great damage to the cells suggests that another expression
system for tNasp is recommendable. Employing a tag-free expression system would allow
evaluation of inert toxicity of the tNasp protein and would exclude possible interference with
tNasp functionality.
Here the cell-cycle-regulating protein p21 was shown to be upregulated on RNA and
on protein level as a response to Tra2b-depletion. This caused cell-cycle arrest and cell death
in murine neuronal stem cells (NSC34 cells). Furthermore, p21 was demonstrated to be
upregulated in brains of neuronal-specific Tra2b knock-out mice. Upregulation of p21 in
neuronal precursor cells and strongly increased apoptosis and loss of the proliferative
Figure 38 | Expression of EGFP-tNasp in NSC34 cells.
NSC34 cells were co-transfected with siRNA against Tra2b and pEGFP or pEGFP-tNasp. Proteins were isolated 48
hours after transfection. NSC34 showed solid expression of EGFP and the EGFP-tNasp fusion-protein, showing
bands at the expected molecular weights of 28 and 111 kDa, repectively. β-actin was used as a loading control.
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potential in the ventricular and subventricular zone of the developing murine brain strongly
suggest that Tra2b-depletion causes brain developmental defects by increased p21 levels in
neurogenic brain areas. By what signaling pathway it comes to upregulation of p21 expression
could not be elucidated at last. The involvement of the tNasp protein in the chain of events
cannot be excluded and will be discussed in detail (6.6). Also other factors that act besides p21
upregulation might impact cell viability in the developing murine brain. However, p21
upregulation appears to be a major contributor in the brain developmental pathology and cell
death, as to its direct involvement in cell cycle regulation (Harper et al. 1993)
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6. Discussion
Alternative splicing is a complex and extremely potent mechanism to modulate gene
function and individual splicing factors can exert an effect on a specified group of transcripts
(Nilsen and Graveley 2010; Zheng and Black 2013). Many features of the general splicing
machinery are well understood but little is known about the function and target transcripts of
non-essential splicing factors. Mice deficient for the splicing activator Tra2b are embryonically
lethal at early gestational stages (Mende et al. 2010). In this study a neuronal-specific knock-
out mouse model for Tra2b was generated. These mice are born but die shortly after delivery
and display severe developmental defects in the cortical and thalamic brain regions.
Degeneration of these regions is preceded by massive apoptotic events resulting in a loss of
proliferative potential. These data indicate that Tra2b is essential for survival and for neuronal
development. Well-known Tra2b-related splicing processes were validated in neuronal specific
Tra2b knock-out mice and new targets were identified using high throughput screening
approaches. After discussing the brain developmental defects observed in KO mice (6.1 and
6.2) it will be considered to what extent the identified aberrantly spliced exons might
contribute to cell death and misdevelopment (6.5). The applied high throughput screening
strategies will be evaluated as to their potential to identify changes of splicing patterns in vivo,
while emphasizing their individual advantages and drawbacks (6.3). Further, the mode of
action of Tra2b and its interplay with splice sites as well as their total combinatorial effect on
exon inclusion will be compared for several of its target exons (6.4). Finally, the impact of p21
upregulation and its possible foundations will be discussed (6.6).
6.1. Characterization of neuronal-specific Tra2b knock-out mice: Tra2b is
essential for brain development in mice
Neuronal-specific Tra2b knock-out mice die within the first 36 h of life. This is in clear
contrast to ubiquitously Tra2b depleted animals that die very early during embryonic
development (Mende et al. 2010). Sole depletion of Tra2b in the central nervous system
allowed birth of viable pups that were morphologically (outer appearance) indistinguishable
from controls. Initial histological analysis of the brain was carried out and revealed gross
morphological alterations in the brains of KO mice including severe ventriculomegaly of the
third and the lateral ventricles. Brain volume that was occupied by largely cortical tissue in
control animals was occupied by the ventricles in KO animals. Cortical structures and the
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typical layered patterning of the cortex were not observable in KO animals. This clearly
suggests an important role for Tra2b in neuronal development.
Furthermore, medial structures of the brain that were close to the third ventricle
appeared absent in KO mice. These regions were with high likelihood identified as anterior
parts of the thalamus. A clear histological identification of thalamic structures was difficult. In
frame of histological analyses coronal sections (frontal sectioning) were analyzed and the
alignment of sectioning levels for specimen comparison had to be set by reference points in
the brain. In most cases this allowed comparison of sections belonging to sectioning levels very
close to each other. Due to gross morphological changes in knock out brains, reference points
could not always be clearly allocated. This made it difficult to assess the depth of sectioning
from anterior to caudal and to distinguish between structures anterior of the thalamus, or the
thalamus itself. Furthermore, the developing mouse brains underlied rapid morphological
changes. Within 2 days of brain development, structures of the brain did significantly change
their appearance which taken together made the precise identification of structures difficult.
The described brain phenotype including structural aberration and full loss of defined
brain structures indicates a prominent role of Tra2b during development or maintenance of
these structures. Indeed, Tra2b appeared to be strongly expressed in those regions of CTRL
animals that are affected in KO animals. Moreover, both the cortex regions and the thalamic
regions showed strongly increased occurrence of localized apoptosis measured by Caspase3
immunostaining. Caspase3 expression was found highest in the cortical layers close to the
lateral ventricles (i.e. ventricular and subventricular zone) as well as at the thalamus. Massive
apoptosis was followed by a drastic reduction in expression of the proliferation marker Ki67.
The ventricular zone is a neurogenic area and origin of neuronal migration to form the layered
structure of the cortex (Krubitzer and Huffman 2000; Lopez-Bendito and Molnar 2003).
Consequently, cell death and the incapacity to proliferate are detrimental for normal cortex
formation.
Another approach to explain failure in cortex development or maintenance is via the
absence of thalamic input. Thalamic and cortical development depend on each other and
occur largely in parallel. Most cortical restructuring takes place in the second to third week of
gestation (13-18 dpc). Further, thalamocortical projections are necessary for normal cortical
patterning (Lopez-Bendito and Molnar 2003). Occurrence of apoptosis in thalamic regions of
KO mice parallels this developmental time window. Absence of thalamic projections targeting
defined areas of the cortex might explain aberrant cortical patterning and probably
deterioration of cortical structures. However, this study does not provide direct evidence for
the absence of thalamocortical projections. From the data obtained in this study it cannot be
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deduced which region of the brain was affected first, thalamus or cortex. Apoptosis occurred
simultaneously at around 14.5 dpc in both structures. This might probably underline the
parallel development and co-dependency of thalamus and cortex but does not necessarily
indicate causality.
On the way of indentifying the underlying mechanism for brain malformations the
question arose whether brain development itself is disturbed in KO mice – meaning structures
are not properly generated – or whether properly developed structures undergo apoptosis
causing the observed malformations. First, the gross morphological appearance of the cortex
was largely indifferent between CTRL and KO animals at 14.5 dpc and cortical layers were
found generally intact in KO animals at this early stage. This suggests that cortical development
itself is obviously not impaired before 14.5 dpc. Also the temporal occurrence of apoptosis and
loss of the proliferative potential support this idea. Onset of apoptosis was detected at 14.5
dpc continuing on until 15.5 dpc. However, the proliferative potential was not impaired at 14.5
dpc, but started to decrease at 15.5 dpc and was fully lost at 16.5 dpc. This strongly indicates
that the loss of the proliferative potential is a direct consequence of apoptosis. Thus, brain
development is not necessarily impaired per se. Instead properly generated structures die due
to apoptosis, which in turn precludes further proliferation and differentiation of neurons.
Results indicated that apoptosis is the primary cause for brain malformations, but the
question for the trigger of apoptosis remains. On the one hand side apoptosis could have been
induced by the lack of thalamocortical signaling as described previously in this chapter. On the
other hand apoptosis could be a secondary effect evoked by increased cerebroventricular
pressure. Opposed to the idea that apoptosis causes cortical decay on a cellular level and as a
consequence liquid filled ventricles occupy the vacant space, an increased pressure of
cerebrospinal fluid within the ventricles may have caused repression of cortical tissue as well.
This effect is referred to as normal pressure hydrocephalus (Adams et al. 1965). Increased
pressure of cerebrospinal fluid may be caused by impaired liquor production or resorption, as
well as duct obstruction preventing circulation and exchange of liquor between the ventricles.
Thus, pressure-related decay of cortical tissue might be an alternative explanation for
ventriculomegaly. Which molecular and cellular responses lastly mediate apoptosis and which
of the previously discussed mechanisms is the basis of such a response cannot be answered at
this point. The relevance of Tra2b-related missplicing events occurring in KO brains and their
possible effects on the molecular level will be discussed in chapter 6.5.
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Molecular biological analyses of the murine brains via quantitative real-time PCR
suggested a rather constant expression of Tra2b throughout the brain that did not show gross
alterations during embryonic development until birth. This suggests that there is no specific
time point at which Tra2b is required most and therefore ablation of Tra2b is a non-
physiological situation at any time point of development. Changes in splicing caused by its
absence should thus evoke splicing patterns that are untypical for the developing brain at any
given time point.
Even though neuronal-specific Tra2b knock-out mice always died within the first 36 h
of life, the severity of their brain phenotype was subject of variation. Ventriculomegaly and
loss of cortical patterning were always observable, but the extent of ventricular dilation
appeared less severe in some KO animals than in others. This might be due to incomplete or
strongly mosaic knock out of Tra2b. Indeed, some KO mice were demonstrated to retain
increased Tra2b expression levels. Quantification of Tra2b expression demonstrated a robust
average reduction of expression in KO animals at all investigated developmental stages, but
single KO individuals showed Tra2b expression levels that were higher.
As described previously, gradually changed Tra2b expression levels (measured on
whole brain RNA) are likely not due to real expressional modulation but rather originate from
an altered ratio and distribution of Tra2b expressing and non-expressing cells in a mosaic
brain. Tra2b knock-out was mediated by Cre-recombinase and Cre expression relied on the
activity of the rat Nestin promoter in the different cell populations of the brain (Tronche et al.
1999). However, mosaic expression patterns of Cre-recombinase were theoretically expected
to be consistent between individuals. For what reason Tra2b knock-out was differently
efficient in individual mice remains elusive. The possibility of Tra2b expression being variable
independently of Cre expression is supported by variable expression levels in control mice.
These mice do not harbor the Nestin-Cre transgene and carry either the Tra2bfl/+ or the
Tra2bfl/fl alleles. Variability of Tra2b expression in these mice suggests that Tra2b expression
levels might generally be subject of natural variability between individuals. Attempts to
correlate mild brain phenotypes with retained Tra2b expression levels largely failed as analysis
of RNA obtained from formalin-fixated and paraffin-embedded sections did not yield high
quality data. By comparing Tra2b expression data of individual mice (Figure 15), Tra2b
expression levels in KO mice were found to partially exceeded expression found in HET mice by
far. Intriguingly, despite sometimes displaying lower expression levels than KO mice, HET mice
always had normal life expectancies and never displayed any kind of brain phenotype. This
strongly argues for a mosaic effect being the underlying reason for this variability. Not total
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Tra2b amounts expressed throughout the brain, but rather the identity of cells or brain regions
that retain Tra2b expression appears important for neuronal development and survival.
A less severe cortical phenotype has recently been demonstrated in a conditional
Emx1-Cre Tra2b mouse model (Roberts et al. 2013). Emx1 is a transcription factor that is
expressed in the embryonic cortex (Simeone et al. 1992). These knock-out mice were fully
viable and did not show gross behavioral abnormalities, suggesting that cortical loss of Tra2b
can be tolerated. Still these mice showed apoptosis within the cortex and disorganization of
the cortical plate zone. The brain phenotype demonstrated for Emx1-Cre mice was clearly
milder than observed in Nestin-Cre KO animals presented in this study. Depletion of Tra2b by
Nestin-Cre in neuronal progenitor cells, obviously affects a broader range of neuronal cells,
which showed to be essential for survival and affected regions of the brain beyond the cortex.
The neuronal-specific knock-out of Tra2b in this study was achieved by using
expression of Cre-recombinase in neuronal and glial precursor cells (Tronche et al. 1999).
Expression of Cre-recombinase in these cell populations has been demonstrated to exert
genotoxic stress that manifests in hydrocephaly and cell death within the cortex and the
ependymal cell layer (Forni et al. 2006). Thus, high expression levels of Cre-recombinase have
been implicated to confuse developmental studies in mice.
In contrast to the previously mentioned study, all mice used in the present study were
bred to generate exclusively mice carrying a single Cre-transgene. Thus, expression levels of
Cre-recombinase were expected to be drastically reduced as compared to the above
mentioned study (Forni et al. 2006). Furthermore, heterozygous knock-out animals (HET) were
always included in analyses conducted in this study. HET and KO mice equally harbor a single
Cre-transgene, but HET mice never displayed impaired survival or any kind of brain phenotype.
This clearly indicates that Cre-recombinase-mediated toxicity does not contribute to the
observed developmental defects in neuronal-specific Tra2b knock-out mice in any way.
6.2. Molecular analysis of Tra2b KO mice: Identification of well-known
Tra2b-dependent splicing processes in vivo
In preparative experiments for high throughput approaches for the identification of
Tra2b splicing targets, well-known Tra2b-dependent splicing processes should be reconstituted
in vivo. In this study splicing of the Nasp T-exon, Tra2a exon 2, Mapt exon 10 and Cltb exon 5
was investigated using whole brain RNA of KO and CTRL mice. Furthermore, the self-splicing
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effect of Tra2b regulating its own exon 2 was investigated (Stoilov et al. 2004). These exons
have previously been identified as being splicied by Tra2b using in vitro experimental strategies
including CLIP and minigene experiments (Stamm et al. 1999; Kondo et al. 2004; Grellscheid et
al. 2011a). First attempts of identifying these splicing processes in vivo failed, as the detected
differences were very small and non-significant. As described in 6.1, the residual Tra2b
expression found in KO mice but also in non-KO genotypes was somewhat variable between
individuals. Therefore, KO animals with Tra2b levels clearly higher than the average expression
of that genotype were excluded from analyses. As mentioned, differential expression levels in
KO brains are likely caused by Cre-recombinase mediated mosaicism or naturally occurring
variations in Tra2b expression. When analyzing whole brain RNA (as it is the case here),
retained Tra2b expression in some areas of the brain might not only cause amelioration of the
brain phenotype but might also result in normal transcript splicing in non-affected tissues.
During analysis of the whole brain mRNA mixture, mRNA from non-KO cell populations likely
masked the splicing effect that occurred in KO cell populations. Exclusion of KO samples with
high Tra2b levels minimizes the contribution of non-KO tissue to the whole brain RNA analyzed
here. Indeed, analysis of whole brain RNA with Tra2b/Gapdh levels strictly lower than 0.4
allowed successful reconstitution of known Tra2b-related splicing events in vivo. This did not
only prove the physiological relevance of these in vitro identified splicing processes in the
developing mouse brain, but also provided proof of concept for the identification of altered
splicing patterns that are based on absence of Tra2b in an in vivo system. This paved the way
for using RNA obtained from whole brains of Tra2b knock-out mice in high throughput
screening approaches to identify transcripts or exons targeted by Tra2b.
In vivo splicing analysis demonstrated that the autoregulatory splicing feedback-loop
of Tra2b regulating inclusion of its own exon 2 is active in the developing mouse brain. This
autoregulation is likely the primary cause for the absence of any brain phenotype in HET mice
and likely also contributes to the dampening of splicing effects in HET mice that – if even
detectable – were always much weaker than in KO animals. Heterozygous knock-out of Tra2b
exerted clearly diverse regulatory effects on the amounts of functional (Δ2) and non-functional
(FL) Tra2b isoform transcripts. While non-funcional transcript levels were very robustly
downregulated, the functional transcripts only decreased by approx. 20 %. A heterozygous
deletion of Tra2b disables 1 of 2 Tra2b gene copies. Still, non-functional transcripts are
reduced by more than 50 % and functional transcripts by far less than 50 %. This suggests that
the autoregulatory feedback-loop counteracts negative effects of the missing gene copy,
resulting in almost non-reduced levels of functional transcripts. This is further supported by
indistinguishable Tra2b protein levels between CTRL and HET mice. As mRNA levels of
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functional transcripts were reduced by approx. 20 % but protein levels were not, an
independently acting translational regulatory mechanism cannot be excluded. This data fully
supports the observed absence of any developmental brain phenotype in HET mice and
demonstrates that a single Tra2b gene copy is sufficient to provide the required Tra2b protein
levels which is supported by a splicing-shift towards the functional Tra2b isoform. Even
though, in HET mice significant splicing effects were never detected as compared to CTRLs, HET
mice always showed the correct tendency and constituted the intermediate situation between
CTRL and KO mice. Tra2b is known to impact splicing of exons in a concentration-dependent
manner (Hofmann and Wirth 2002; Grellscheid et al. 2011a; Grellscheid et al. 2011b). It is likely
that slightly reduced concentrations of functional Tra2b protein may exert a splicing effect on
those transcripts that are very sensitive to changes in Tra2b concentratons but not to others.
What are the characteristics of transcripts affected by such slight reductions in concentrations
and what is the physiological relevance for that will be discussed in section 6.4.
Incomplete or mosaic knock-out of Tra2b in murine brains prevented the detection of
Tra2b-mediated splicing processes in vivo. This might correlate with milder brain phenotypes
observed in some KO animals and also explains a strong masking of Tra2b-dependent splicing
processes. Furthermore, increased Tra2b levels could also be attributable for longer survival of
new born mice, even though the variability in survival was minimal and mostly differed by
some hours only. Exclusion of brain RNAs with insufficient Tra2b knock-out allowed solid
detection of Tra2b-related splicing events. Only brains for which known-splicing events have
been reconstituted were used for high throughput screening approaches. The general success
and applicability of whole transcriptome sequencing and mouse exon arrays for whole brain
RNA obtained from in part mosaic brains will be evaluated in the subsequent section (6.3).
6.3. Identification of alternatively spliced exons on murine whole brain
RNA: The challenge of heterogeneous transcriptome compositions in
complex tissues
A primary objective of this study was the in vivo identification of Tra2b splicing targets
using high throughput screening approaches on mRNA obtained from neuronal-specific Tra2b
knock-out mice. Due to mosaic effects, morphological changes of the brain, total expression
levels of Tra2b and detectable effects on Tra2b splicing targets were variable between animals
of the same genotype. To provide a solid basis for these experiments only animals with strong
Tra2b downregulation were used for screening analyses (6.2).
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In the frame of this study whole transcriptome sequencing (5.5) and mouse exon array
analysis (5.6) were performed to identify novel Tra2b splicing targets. Both approaches yielded
very limited success in the identification of novel splicing targets. The following sections will
deal with the problems encountered during analyses and will speculate about possible
underlying reasons for the weak performance. Therefore, this section will include specific
aspects for (i) whole transcriptome sequencing, (ii) exon array analysis and (iii) aspects that
commonly caused problems for both approaches.
(i) Whole transcriptome sequencing: None of the candidate exons obtained by whole
transcriptome sequencing could be validated by subsequent PCR analysis. The primary reason
for failure in detection of candidates and detection of a magnitude of false positives is likely
technological inadequacy. Recent studies have revealed that whole transcriptome sequencing
is able to identify most of the expressed mRNA isoforms even at moderate levels of coverage
with approx. 100 x 106 reads (Toung et al. 2011). However, for a precise determination of
transcript abundances as it is needed for splicing-related analyses about 500 x 106 reads have
been found to be necessary (Toung et al. 2011). Whole transcriptome sequencing performed
in frame of this study yielded an average coverage of 53-fold assuming a 100Mb
transcriptome. Read numbers obtained were between 22.2 x 106 and 45.2 x 106 and are
therefore far below the required values needed for accurate quantification of transcripts or
exons. Due to very low coverage the representation of especially lowly abundant exons can be
dramatically disturbed. Minor changes in expression of a lowly abundant transcript can easily
be interpreted as a multi-factor up- or downregulation. This effect generates false positive
targets whose actual change in expression or splicing is physiologically fully negligible. This
effect became apparent during the validation process of candidates, in which isoform specific
PCRs were used. Frequently, the isoform lacking the respective candidate exon could not be
detected at all, even though transcriptome sequencing suggested highly significant changes in
exon abundance. Such candidate exons were considered to be false positives as either the
isoform lacking the exon of interest does not exist and was thus an artifact result, or Tra2b
depletion caused a change in exon abundance, however at a very low expressional level that a
physiological impact can virtually be excluded.
Another weakness of analysis that might have led to inaccurate detection and
generation of false positive hits is the low number of samples compared. In whole
transcriptome sequencing 3 CTRL samples were compared to 3 KO samples. A higher number
of samples could have yielded a higher significance and a more powerful detection of true
candidates; due to the high cost of whole transcriptome sequencing at the time point of
performance the screening was limited to 3 CTRL vs. 3 KO samples, however. Indeed, the low
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sample number was demonstrated to make solid calling of splice variants prone to single
sample variations. Re-sequencing of a single sample and repetition of analysis changed
candidates and statistics dramatically (5.5.3). A higher number of samples will generally be
able to compensate for single sample variations, while preserving significance. In the present
analysis localized coverage deviations within a single sample hampered the analysis in so far
that it did not only cause detection of false positive exons, but also prevented the detection of
in vivo validated and strongly regulated exons like the Nasp T-exon or Tra2a exon 2. This
suggests that besides multiple false positive candidates, a whole magnitude of real candidates
was not detected. The RPKM-based analysis, which is specialized for calculating exon
abundances, while normalizing to compensate differences in the total read number and
differential total transcript abundances, failed to overcome localized disturbances in
sequencing coverage. Whether this weakness is purely attributable to this analysis method or
equally to sequencing and read mapping algorithms cannot be determined with certainty at
this point.
(ii) Exon array analysis: Multiple candidates were identified as being differentially
spliced or differentially expressed between CTRL and KO mice. Despite only two exons were
validated to be spliced by Tra2b in this study (Sgol2 exon 4 and Tubd1 exon 4), this provides
proof of concept for the in vivo identification of splicing targets in a knock-out mouse model.
However, this also demonstrates the limitations of the system. Like whole transcriptome
sequencing also array analysis yielded multiple false positive candidates, but was able to in
part recognize bona fide Tra2b splicing targets that were previously validated in vivo. Other
well known target exons of Lpin1 (Pihlajamaki et al. 2011) or Mypt1 (Shukla and Fisher 2008)
were not detected as being differentially spliced, however. Reduced Tra2b levels have been
associated with upregulation of a lipogenic Lpin1 isoform that is involved in obesity
(Pihlajamaki et al. 2011). Splicing of Mypt1 exon 23 has been shown to be regulated by Tra2b
and to be responsible for the diversification of smooth muscles into fast and slow contractile
types (Shukla and Fisher 2008). Results for both of these transcripts have been obtained using
RNA from liver and muscle, respectively. Both Lpin1 and Mypt1 are physiologically relevant in
these tissues. Even though expression databases suggest that both are expressed in brain,
Tra2b-related splicing processes might be absent in brain and might therefore not be detected.
Despite confirmed targets were not identified as top ranking candidates and definite
false positive candidates obtained a better rank, exon array analysis produced data of higher
quality compared to whole transcriptome sequencing. The sole quantity of significant hits was
smaller as compared to whole transcriptome sequencing and filtering was applicable to reduce
candidates to reasonable amounts. This is likely based on a much smaller variability between
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samples, as data obtained from arrays did not underlie any kind of coverage fluctuations as
described before for whole transcriptome sequencing.
Even though analyses for changes in alternative splicing and changes of expression on
a transcript wide level were performed independently, many candidates were identified as
being alternatively spliced and transcriptionally regulated. Experimental proof was provided
that whole transcript levels but not splicing processes of these candidates were altered.
Astonishingly, the majority of double identified transcripts/exons were identified with
decreased whole transcript abundances. It cannot be excluded, that the failure in analysis is a
result of severe morphological changes in KO brains that via tissue loss caused exons or whole
transcripts to appear lower expressed. However, the mode of analysis was chosen to prevent
exactly this phenomenon, as exon abundances were normalized to whole transcript
abundances. Hybridization problems of individual exons can be virtually excluded as a reason,
as this would apply equally for and KO and CTRL samples. As also in whole transcriptome
sequencing, weakly expressed transcripts are prone to false positive detection, as minor
changes appear bigger than they actually are. This might in part be due to in vitro
transcription-based amplification of transcripts that was performed during exon array
preparation. All these arguments state possible explanations for aberrant splicing detection,
but an ultimate disclosure covering the broad majority of aberrantly detected candidates
cannot be provided here.
Analysis of exon array data included various filtering strategies including enrichment of
putative Tra2b binding sites. Exons that were significantly detected as being alternatively
spliced were further filtered for a high abundance of (A)GAA motifs (Clery et al. 2011). This
short sequence motif statistically occurs once in a 256 bp stretch. Even candidate exons
containing a multitude of their respective statistically expected number of GAA-motifs could
not be validated as real Tra2b splicing targets. This suggests that even very high frequencies of
putative binding sites are not necessarily indicative of Tra2b-related splicing regulation. Thus,
filtering for putative binding sites is not a reliable method to call Tra2b-dependent exons, but
can probably be used to complement other filtering approaches in parallel (as in Figure 27).
However, both of the validated exons of Sgol2 and Tubd1 comprised multiple binding sites (4
and 10, respectively). Also many other in vivo validated Tra2b-dependent exons of Mapt,
Tra2a and Nasp contain at least one putative binding site. These data indicate that the
presence of GAA-binding motifs is not an indicator for Tra2b dependency, but exons that
depend on Tra2b in most cases harbor at least a single binding site. However, there are
examples of indirect regulation by Tra2b that does not depend on any sequence motif. The
Cltb exon 5 is negatively regulated by Tra2b. Previous studies have shown that Tra2b indirectly
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regulates the Cltb exon 5 (Stamm et al. 1992; Stamm et al. 1999) and this exon does not
contain any putative binding site. The impact of the presence and the number of Tra2b binding
sites on splicing will be further discussed in section 6.4.
(iii) Common problems in whole transcriptome sequencing and exon array analysis:
The brain development of KO animals is strongly impaired and mice display severe alterations
in the brain phenotype. Large areas of the brain, like major parts of the cortex, are fully absent
in KO animals and the free brain volume is occupied by the liquid filled ventricles
(ventriculomegaly). As introduced before (6.1 and 6.2), changes of the total cellular
composition of the brain directly impact the composition of expressed transcripts, as well as
the composition of spliced isoforms. Tissue loss has biggest and most direct impact on general
transcript expression levels. Transcripts that are typically expressed in brain regions that are
affected or absent in KO brains, were likely identified as being transcriptionally downregulated
in KO mice. With very high probability those transcripts are false positive hits, as their
downregulation is solely based on tissue loss. Therefore, the severe brain phenotype including
massive tissue loss in neuronal-specific Tra2b knock-out mice virtually precludes the reliable
detection of downregulated transcripts. The decrease in transcript abundance, that is based on
tissue loss, might be very strong and is thus easily detectable in both whole transcriptome
sequencing and exon arrays. Real physiological transcriptional downregulation is likely weaker
than the previously mentioned artificial effect. Even if real downregulation events are properly
detected in high throughput screening approaches, the much stronger tissue loss-based effects
will appear to be more promising and more significant candidates, which makes real changes
even more difficult to detect. This argumentation is also applicable to splicing processes and
the quantification of single exons. Changes in splicing patterns indentified in vivo using
neuronal-specific knock-out mice could also be due to changes in cellular brain composition
and needed to be validated in artificial systems to proof the real impact of Tra2b on the
respective exon (5.7).
In contrast to that, the situation is different for transcriptionally upregulated
transcripts. If a transcript is identified as upregulated in KO brains in a high throughput
screening, there is a high probability that this constitutes a real physiological transcriptional
upregulation. Tissue loss and thus transcript loss counteracts the detection of upregulated
transcripts and upregulated candidates likely are stronger upregulated than they appear. The
cell cycle regulator p21 (Cdkn1a) was found to be upregulated in KO brains and Tra2b knock-
down experiments indicated an even stronger upregulation of p21 in cell culture than in KO
brains. This will be discussed in detail in section 6.6.
131Discussion
Even though both methods, whole transcriptome sequencing and exon arrays have
each its own technological weaknesses, the major problem precluding solid detection of
alternatively spliced exons primarily was the biological material itself. Whole brain RNA was
used as starting material for both analyses. Brains of KO mice were too severely affected and
whole brain RNAs obtained from CTRL and KO brains were like intrinsically too different to
confidently call physiological splicing changes. This study was aiming at the identification of
Tra2b splicing targets in neuronal tissue. Data obtained here suggests that a more
homogeneous system that is not severely affected by absence of Tra2b per se is needed. To
directly overcome heterogeneity-based problems that caused failure of solid quantification of
exons and transcripts in the presented experiments, laser dissection of distinct brain areas
would allow analysis of comparable brain areas of CTRL and KO mice. Indeed, expression
patterns and alternative splicing are highly variable in different brain areas and laser
microdissection in combination with quantitative PCR has been successfully used to detect
such spatial differences (Baj et al. 2013). As only low amounts of starting material are needed
for exon array analysis, RNA obtained from microdissected brain specimens would likely suffice
to conduct a high throughput experiment while maintaining CTRL and KO samples comparable.
Probably usage of whole brain RNA from 14.5 dpc could improve high throughput approaches,
as the phenotype of KO brains is still moderate, but origins and foundations leading to the
ultimate developmental defect are already manifested. Also the use of a cell culture system
could be advisable. Even though this might not fully reflect physiological processes as they
occur in vivo, a homogeneous cellular system could provide an accurate splicing comparison
using high throughput approaches. Overexpression of Tra2b in cells as it is used in minigene
approaches likely results in detection of non-physiological targets, as exons might be
responsive to unnaturally high Tra2b concentrations, which does not reflect the physiological
situation, however. Instead, Tra2b knock-down in cell culture could probably detect exons,
whose inclusion is physiologically strictly Tra2b-dependent.
6.4. The role of Tra2b in alternative splicing processes: From fine tuning
to a splicing switch
Tra2b has been demonstrated to promote as well as to repress splicing inclusion of
exons (Stamm et al. 1999; Kondo et al. 2004). Thereby its mode of action is different as it can
bind target mRNA directly via its RRM thus promoting exon inclusion (Stoilov et al. 2004), or
act indirectly via other splicing factors or interacting partners to repress exon inclusion (Stamm
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et al. 1992; Stamm et al. 1999). However, this paradigm is not fixed as the effect of Tra2b on
exon inclusion is independent of its mode of action. Inclusion of SMN2 exon7 has been shown
to be promoted by Tra2b, which was further facilitated by hnRNP-G, the SR protein SRp30c
(Hofmann and Wirth 2002) and TDP-34 (Bose et al. 2008). Furthermore, exons that were
effectively included by FL Tra2b via sequence specific binding were strongly repressed by a
Tra2b construct lacking the RRM, indicating that different isoforms of Tra2b can adversely
either promote or repress exon inclusion (Grellscheid et al. 2011a).
Besides its direct or indirect effect, the strength of impact that Tra2b can exert on
splicing of an exon may depend on its concentration or the number of Tra2b binding sites
within an exon, which allows multiple molecules to associate sequence specifically. Moreover,
the intrinsic splice site strength of an exon appears to strongly determine the maximal
modulating impact that Tra2b can exert on exon inclusion (Hertel 2008; Grellscheid et al.
2011b). The effect of splice site strengths on the power of Tra2b became apparent in minigene
splicing assays for Sgol2 exon 4 and Tubd1 exon 4. Experiments conducted in this study used
human and murine minigenes in a human cellular system (HEK293T cells). As the splice site
strengths are determined by the effectivity of the interplay of spliceosomal components with
the respective splice sites of exons, it needs to be considered that the human/primate splice
site consensi are different from rodent consensus sequences. Therefore, the strength of a
murine splice site might be different in a human cellular system. Compared to the primate
splice site consensus the 3’ and 5’ splice sites of human SGOL2 exon 4 are stronger than the
splice sites of the murine version. Accordingly, exon 4 of the human minigene was effectively
included at physiological TRA2B concentrations in HEK293T cells (Figure 33). Knock-down or
overexpression of TRA2B failed to abolish or to promote inclusion of that exon, suggesting that
the intrinsically strong splice sites are sufficient to constitutively include exon 4 of the human
SGOL2 transcript. In contrast, the somewhat weaker splice sites of the murine Sgol2 exon 4
only allowed inclusion of exon 4 in less than 50 % of transcripts at physiological TRA2B levels.
Here overexpression of TRA2B promoted exon 4 inclusion up to 90 % supporting the idea that
TRA2B has a greater impact on splicing in the context of weak splice sites (Grellscheid et al.
2011b). Both the murine and human version of TUBD1 have rather weak splice sites.
Disregarding the plethora of other splice factor binding sites present in both versions of the
TUBD1 exon 4, TRA2B exerts a positive effect on splicing inclusion at physiological levels in
HEK293T cells. This was demonstrated in TRA2B knock-down experiments in which exon 4
inclusion was slightly but significantly reduced. This suggests that TRA2B is not necessary but
at least contributes to TUBD1 exon 4 inclusion at physiological levels. Given the high number
of putative binding sites for other splice factors it appears likely that TRA2B acts in concert
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with other factors to facilitate splicing and to compensate weak splice site strengths of TUBD1
exon 4. This is further supported by the fact that TRA2B overexpression causes virtually
complete inclusion of exon 4 into the TUBD1 transcripts.
The Nasp T-exon is roughly 1 kb long and is therefore clearly longer than the average
eukaryotic exon (Luco et al. 2011). Absence of Tra2b was shown to cause strong
downregulation of T-exon inclusion (Figure 18). This suggests not only that Tra2b promotes
T-exon inclusion but also that it does so very strongly at physiologically low concentrations.
This might be explained by the more than 10 in part clustered putative Tra2b binding sites
within the T-exon. Furthermore, spliceosome assembly for the T-exon likely occurs over the
exon, as its up- and downstream introns (594 bp and 4,639 bp) are clearly too large to allow
spliceosome assembly spanning the intron (Fox-Walsh et al. 2005). For that reason efficient
splicing of the Nasp T-exon strongly relies on the splice sites and other accessory splice factors
to facilitate inclusion, as also the sole length of the T-exon makes recognition more difficult.
This is in line with the very strong impact that physiological Tra2b levels exert on T-exon
inclusion. Indeed, targeted disruption of some Tra2b binding sites within the T-exon has been
demonstrated to dramatically reduce T-exon inclusion at physiological Tra2b levels (Grellscheid
et al. 2011a). This has been rescued by increased Tra2b concentration which likely worked via
remaining Tra2b binding sites in the T-exon.
Taken together these data and data obtained in frame of this study suggest that the
impact of Tra2b on splicing can be modulated by many factors: The splice site strengths and
the lengths of the respective exon and the flanking introns, the concentration (i.e. expression)
of Tra2b and the number and probably location of Tra2b binding sites. Therefore, the effects
that Tra2b exerts on different target exons are very versatile.
The effect of strong versus weak splice sites on the impact of Tra2b-mediated splicing
enhancement has been impressively demonstrated for the HIPK3 T-exon (Grellscheid et al.
2011b). Cooperation of multiple Tra2b binding sites has been shown to be able to assure solid
exon inclusion and to overcome an intrinsically weak exon definition based on weak splice
sites. Exons of this kind have been proposed to require Tra2b and multiple binding sites for
effective inclusion. Binding sites have been demonstrated to become partly redundant with
increased splice site strengths. Strong splice sites accordingly have been shown to reduce the
positive total effect that Tra2b could exert on exon inclusion (Grellscheid et al. 2011b).
These data obtained for the HIPK3 T-exon (Grellscheid et al. 2011b) and by in vivo
splicing analyses of Mapt exon 10, Nasp T-exon and Tra2a exon 2 in this study, demonstrate
the two adverse extremes of Tra2b function in terms of positive splicing regulation: Fine tuning
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of exon inclusion as forMapt exon 10 and adversely, function as a splicing-switch by drastically
changing exon inclusion rates as shown for the Nasp T-exon and Tra2a exon 2. Especially the
latter appear to be of great physiological relevance as knock-out of Tra2b compared to
physiological levels caused tremendous loss of exon usage. The testis-specific T-exon of Nasp
constitutes a robust example for tissue specific Tra2b-dependent splicing, as high
concentrations of Tra2b – as they are present in testis (Grellscheid et al. 2011a) – are needed
to facilitate effective inclusion. Possible physiological roles of Nasp splicing will be further
discussed in 6.5. Other well-known examples for splicing-switch mechanisms are the splicing of
MYPT1 exon 23 (Shukla and Fisher 2008) and sex determination in D. melanogaster which is
mediated by Transformer-2-dependent splicing of the doublesex gene (Belote and Baker 1982).
In both cases the concentration of Tra2b is the critical determining factor for exon inclusion or
exon skipping. In D. melanogaster Transformer-2 is much stronger expressed in females than in
males, which allows effective inclusion of doublesex exon 4 only in females but not in males
(Belote and Baker 1982; Butler et al. 1986). In the MYPT1 transcript inclusion of exon 23
mediates diversification of fast contractile smooth muscles. TRA2B concentrations have been
reported to be 10-fold lower in smooth muscles that are committed to a slow contractile
phenotype (Shukla and Fisher 2008). Thus, differential expression of Tra2b may contribute
significantly to diversity between different tissues (or sexes) by switch-like regulation of
splicing processes.
As demonstrated by in vivo splicing analyses Tra2b depletion had a rather weak effect
on Mapt exon 10 inclusion (Figure 17). Even in absence of Tra2b, Mapt exon 10 was less but
still effectively included, suggesting that it does not fully depend on Tra2b. This is in line with
multiple splicing enhancing/regulating elements in Mapt exon 10 that have been functionally
validated due to their association with exon 10 missplicing in neuronal disease (reviewed by
(Liu and Gong 2008)). This delicately regulated splicing of Mapt exon 10 appears to reflect the
physiological requirements as exon 10 inclusion needs to be precisely balanced to assure
correct microtubule organization and neuronal functioning (Goedert and Jakes 1990; Wang et
al. 2005; Glatz et al. 2006; Wang and Liu 2008; Zhou et al. 2008). Taken together the tight
regulation of Mapt exon 10 and the moderate impact of Tra2b on its inclusion suggests a role
in fine tuning of that exon. Moreover, this argumentation demonstrates that in vivo splicing
analysis in a KO system as it was conducted in this study, might probably allow making direct
conclusions about the physiological importance of Tra2b for a specific exon. Possibly the
extent of a splicing-shift caused by Tra2b ablation in vivo might allow to deduce the
physiological impact of Tra2b for the respective splicing process directly. This way of analysis is
not possible in Tra2b overexpression approaches. These experiments allow detection of a
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general responsiveness of an exon to extreme splice factor concentrations. Such are not
physiological, however, and a direct conclusion for a real function in splicing should not be
deduced from overexpression experiments alone. This underlines the importance of in vivo
splicing analyses to determine the real physiological extent of splice-modulating power of a
splicing factor.
6.5. Implications of aberrantly spliced transcripts in murine brain
development
Splicing targets of Tra2b have previously been identified primarily by in vitro
approaches like minigenes or crosslinking-immunoprecipitation. Such approaches detect even
weak and transient interactions of splicing factors with transcripts and often evaluate the
impact of a splicing factor on an exon under non-physiological conditions including artificial
exon constructs and overly high splice factor concentrations (i.e. overexpression). In this study
several previously detected Tra2b-related splicing events were identified in the developing
mouse brain under physiological conditions. Validation of splicing events in vivo demonstrates
that Tra2b facilitates splicing under naturally occurring conditions, suggesting that the
validated splicing events are of biological relevance and likely functionally implicated in
neuronal development. Targets that were in vivo validated in frame of this study include
Clathrin light chain b (Cltb), Microtubule associated protein tau (Mapt), the Tra2b paralog
Tra2a and the Nuclear autoantigenic sperm protein (Nasp). Furthermore, Shugoshin-like 2
(Sgol2) and Tubulin delta 1 (Tubd1) were identified as novel in vivo targets of Tra2b. Whether
and to what extent missplicing of these transcripts contributes to aberrant brain development
in neuronal-specific KO mice cannot be defined with certainty. However, there are strong
implications as some targets are closely related to neuronal function and disease. In the
following, possible effects of aberrant splicing on murine brain development, but also general
implications will be discussed with regard to individual alternatively spliced Tra2b in vivo
targets. The possible physiological impact of Nasp missplicing will be discussed in a dedicated
chapter (6.6).
Shugoshin-2, exon 4
By filtering and enrichment of exons containing Tra2b binding sites Shogoshin-2 (Sgol2) exon 4
was identified as a novel Tra2b splicing target and was furthermore confirmed to be
responsive to increased TRA2B concentrations in minigene experiments (Figure 31, Figure 33).
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Shugoshin-2 has beed demonstrated to protect the integrity of the cohesin-complexes which
regulate sister chromatid cohesion during meiosis I (Llano et al. 2008; Clift and Marston 2011).
In contrast to mitosis, in which sister chromatids are separated to achieve equal distribution to
daughter cells, sister chromatids remain connected during anaphase of meiosis I and the
homologue chromatid pairs are separated instead to form haploid daughter cells. Sister
chromatids separate during meiosis II (Campbell and Reece 2002). Absence of Shugoshin-2 in
mice has been shown to cause premature release of meiosis-specific cohesin complexes from
anaphase I centromeres, which has been demonstrated to result in complete loss of centromer
cohesion during metaphase II. This in turn has been described to be causative for generation of
aneuploid gametes, which caused infertility in male and female mice (Llano et al. 2008). The
same workgroup has demonstrated that Sgol2 deficiency has no impact on mitosis, as adult
tissues and cultured fibroblasts were not impaired over many passages. This is in contrast to
Shugoshin (SGO1), which has very recently been demonstrated to regulate centromeric
cohesion not only in meiosis but also during mitosis (Yin et al. 2013). Database entries for
SGOL2 as expected suggest highest expression in reproductive tissue (primarily testis and
ovary) but also in brain, muscle and internal organs. Still, very little is known regarding somatic
functions of SGOL2. However, the facts of SGOL2 being expressed in non-reproductive tissue
and the involvement of its homolog SGO1 in mitosis preserves the possibility of SGOL2 being
involved in the regulation of mitotic chromatid cohesion as well. Disturbed chromosome
distribution to daughter cells during mitosis could surely abolish cell proliferation and in turn
cause brain developmental defects observed in neuronal-specific Tra2b knock-out mice.
Ablation of Tra2b was demonstrated to result in reduced inclusion of exon 4 of the murine
Sgol2 transcript in vivo. Exon 4 has a length of 78 bp and its splicing-related skipping removes
26 amino acids from the protein product but does not perturb the coding frame of the
transcript. As no functional domains have yet been identified for SGOL2, the molecular
consequences of exon 4 loss cannot be assessed. Despite loss of the molecular function of
Sgol2 in mitotic tissue might be sufficient to cause cell death, missplicing of Sgol2 exon 4 is
likely not contributing to aberrant brain development in neuronal-specific knock-out mice.
Evidence has been provided that Sgol2 is not involved in the regulation of mitotic chromatid
cohesion (Llano et al. 2008) and absence of the exon 4 coding information cannot be further
assessed with regard to protein function and stability. Most importantly, changes in exon 4
splicing caused by Tra2b-depletion were minor in vivo. Even though exon 4 was significantly
less included in Sgol2 transcripts, the full-length isoform was still the prominent transcript –
regardless of the presence of Tra2b.
137Discussion
Given the involvement of SGOL2 in gametogenesis and the elevated expression of
TRA2B in testis, especially during and after meiosis in spermatocytes and spermatids
(Grellscheid et al. 2011a), SGOL2 could be a functional TRA2B target during spermatogenesis.
Intriguingly, with Sgol2 and Tubd1 (subsequent paragraph) two strongly testis-related splicing
targets were identified. Taken together, the strong expression of Tra2b in testis, splicing of
tNasp in testis (Grellscheid et al. 2011a), and the identification of the two novel testis-related
splicing targets Sgol2 and Tubd1 strongly suggests a central role for Tra2b in testis and likely
during spermatogenesis. Heterozygous ablation of Tra2b in ubiquitous knock-out mice has not
been reported to exert any effect on fertility (Mende et al. 2010). However, the compensatory
effect from the auto-regulatory splicing-feedback loop, likely prevents any phenotype in
ubiquitous heterozygous KO mice. The impact of Tra2b-related missplicing of Sgol2 exon 4 and
Tubd1 exon 4 will be further investigated in a collaborative approach in the laboratories of
David J. Elliott using testis-specific Tra2b knock-out mice. This might allow optimal assessment
of the impact of Tra2b depletion on Sgol2 and Tubd1 splicing in the physiologically relevant
tissue.
Tubulin delta chain, exon 4
Tubd1 exon 4 was identified as a Tra2b splicing target in vivo and was validated in minigene
experiments (Figure 31, Figure 33). Delta tubulin has been reported to be highly expressed in
testis and to be associated with the manchette, which is a specialized microtubule system that
is involved in the reshaping of the sperm head during spermatogenesis (Smrzka et al. 2000).
Nuclear elongation is a hallmark of spermatid reshaping and Tubd1 has been suggested to
participate in the formation of the manchette, more specifically of the perinuclear ring that is
generated during round-to-elongating transition (Kato et al. 2004). The somatic function of
delta tubulin is poorly understood: In mammals it has been found in the cytoplasmic and
nuclear fractions of cells, but has not been shown to co-localize with microtubules (Smrzka et
al. 2000). The same workgroup has demonstrated co-immunoprecipitation of delta and
gamma tubulin and suggested a distinct role for mammalian delta tubulin that is different from
other known tubulins. While strongly expressed in testis, expression levels in brain are low.
Thus, the physiological relevance to brain development cannot be fully clarified. Skipping of
exon 4 from the Tubd1 transcript causes a frameshift resulting in numerous premature
termination codons. Results obtained in this study indicate that skipping of exon 4 results in
nonsense-mediated decay (Figure 31), thus likely resulting in a decrease of the Tubd1 protein
concentration. As similarly mentioned for Sgol2, the physiological effects of Tubd1 missplicing
and consequently downregulation could optimally be investigated in testis-specific Tra2b
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knock-out mice. Functionally, Tra2b-mediated splicing of Tubd1 exon 4 might constitute a
mechanism to regulate Tubd1 expression on a post-transcriptional level to restrict its
expression to specific stages of spermatid development. During spermatogenesis Tubd1 has
been demonstrated to be part of the perinuclear ring which forms during the transition from
round to elongating spermatids (Kato et al. 2004). This transition is preceded and partly
paralleled by massive Tra2b expression during spermatocyte and round spermatid stages
(Grellscheid et al. 2011a). These events may probably be temporally well coordinated.
Speculatively, elevated Tra2b levels in round spermatids might increase Tubd1 expression via
exon 4 inclusion to facilitate transition into spermatid elongation.
Clathrin light chain B, exon 5
Clathrins are functionally versatile proteins mainly involved in vesicle coating and regulation of
endocytosis (reviewed in (Brodsky 2012)). Splicing of exon 5 (also exon EN) of Clathrin light
chain b (Cltb) has been shown to be indirectly regulated by Tra2b in a negative fashion in vitro
(Stamm et al. 1999). In this study the Tra2b-dependent regulation of Cltb exon 5 was detected
in vivo (Figure 17), suggesting that this repressive mode of splicing modulation by Tra2b is
physiologically relevant in the murine brain. The neuronal Cltb isoform II (exon 5 included)
comprises regulatory features for the C-terminal calmodulin binding domain. This isoform has
been demonstrated to be sensitive to calcium and it has been proposed that skipping of Cltb
exon 5 (isoform III) might keep vesicles in a calcium-insensitive state in non-neuronal tissue
(Stamm et al. 1992; Pley et al. 1995). In neurons this might represent a calcium dependent
regulatory feature for vesicle release and recycling (Wu et al. 2009; Haucke et al. 2011; Saheki
and De Camilli 2012). Altered splicing of Cltb exon 5 might therefore perturb the
responsiveness of synaptic vesicles to calcium and cause impact synapse formation and
function.
Microtubule associated protein tau, exon 10.
Microtubules determine and regulate cell morphology and help organizing intracellular
components. The microtubule associated protein Tau (Mapt) belongs to the family of
microtubule associated proteins (MAP), which can regulate the microtubule polymerization
state and may facilitate interactions to various components of the cytoskeleton (Ramirez et al.
1999). Tau has been described to regulate microtubule stability and assembly and to exert
direct impact on neuronal morphology (reviewed in (Wang and Liu 2008)). It is enriched in
axons of mature as well as developing neurons (Kempf et al. 1996). Hyperphosphorylated Tau
has been reported to be the major constituent of neurofibrillary tangles and has been
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associated to several diseases that are commonly termed tauopathies (Andreadis 2005). These
include e.g. progressive supranuclear palsy, corticobasal degeneration, Pick’s disease and
FTDP-17 (Buee et al. 2000; Ingram and Spillantini 2002).
There are numerous isoforms being generated from the MAPT gene, as 8 out of 16
exons are alternatively spliced in humans (Andreadis 2005). Especially missplicing of exon 10
which encodes 1 out of 4 microtubule binding domains, thereby controlling microtubule
affinity, is involved in numerous neurological disorders and has been studied extensively (Jiang
et al. 2003; Kondo et al. 2004; Shi et al. 2008; Zhou et al. 2008). Under normal conditions the
ratio between the 3R (exon 10 skipped) and the 4R isoform (exon 10 included) is tightly
regulated by TRA2B-dependent splicing processes in humans and both isoforms coexist at
similar levels. This defined ratio is a prerequisite for normal microtubule function and stability
and has been shown to be shifted by increased exon 10 usage in postmortem Alzheimer’s
disease brains (Glatz et al. 2006). Nevertheless, also a decrease of exon 10 usage has equally
been shown to cause neurodegeneration (Andreadis 2005). In this study, ablation of Tra2b in
KO mice was shown to reduce exon 10 usage causing changes of the 3R:4R ratio in the
developing mouse brain. Notably, exon 10 splicing of the murine Mapt gene is different from
humans. While humans preserve a tightly regulated balance between 3R and 4R protein
species during adulthood (Goedert and Jakes 1990; Gao et al. 2000), adult rodents use exon 10
constitutively and thus produce exclusively the 4R isoform. Co-expression of both isoforms in
mouse occurs only during embryonic development and expression of the 3R isoform has been
reported to decline at postnatal day 8 (Kosik et al. 1989). Despite expressing solely 4R Tau in
adulthood, aged rodents have been reported to fail developing neurofibrillary tangles (NFT)
and induction of NFT in transgenic animals has appeared equally difficult (Gotz 2001;
Andreadis 2005). Even though adult rodents are obviously and in contrast to humans immune
to NFT formation based on increased 4R Tau levels, the tight regulation of 3R to 4R ratios
during development suggests distinct functions of both isoforms in the developing brain.
Shifted compositions of 3R and 4R Tau species during development can add unique regulatory
cues to the microtubule network that might be necessary for axonal outgrowth and guidance –
processes that are of central importance during brain development. Still, distinct functions of
3R and 4R Tau isoforms beyond microtubule regulation cannot be excluded.
Ablation of Tra2b during murine brain development was shown to directly impact the
isoform distribution in KO brains. Due to the fact that Tau isoforms are equally balanced in the
developing rodent as compared to humans, it appears likely that a disturbance of this splicing
regulation might similarly elicit neurodegenerative processes in the mouse and finally
contribute to the observed brain phenotype.
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Even though single missplicing events discussed here provide good indication for a
causative relationship to failure of neuronal development and neurodegeneration, the whole
phenotype is more likely to be a combinatorial consequence of multiple factors being
deregulated. Furthermore, the inability of high throughput screening approaches to detect
Tra2b splicing targets is not indicative of the lack of such targets. With a very high probability
many targets of Tra2b are hitherto not identified and each single one of them might contribute
to the global brain phenotype of neuronal-specific Tra2b knock-out mice.
6.6. Tra2b depletion transcriptionally activates p21 and causes apoptosis
in neurogenic brain areas
Mouse exon array analysis identified a 1.5-fold transcriptional upregulation of the cell
cycle regulator p21 (Cdkn1a, cyclin dependent kinase inhibitor 1a) in brains of neuronal-
specific Tra2b knock-out mice compared to controls. P21 is a well known inhibitor of the cell
cycle that works via inhibition of the cyclin-dependent kinases CDK2 and CDK4, which leads to
G1-phase cell cycle arrest (Harper et al. 1993). Inhibition of CDKs prevents phosphorylation of
retinoblastoma (Rb) and thus prevents dissociation of the histone deacetylase-Rb repressor
complex and activation of transcription factors (e.g. E2Fs). This causes repression of S-phase
genes and the cell enters G1-phase arrest (Nevins 1992; Harper et al. 1993). P21 upregulation
that was detected on the array was confirmed by comparing cohorts of CTRL, HET and KO mice
via semi-quantitative RT-PCR. Quantification indicated only a moderate (but significant)
upregulation of Cdkn1a transcripts in whole brain RNA. Coming back to an earlier assessment,
the measured upregulation of transcripts may deviate negatively from the real upregulation,
as tissue loss in KO brains counteracts the detection of transcriptionally upregulated genes.
Indeed, it can be speculated that p21 upregulation was restricted to affected brain areas that
were demonstrated to undergo apoptosis and subsequentially lose their proliferative
potential. These cell populations contribute a relatively small fraction to the whole brain RNA
used for quantification experiments. Thus, p21 was supposedly massively upregulated in the
affected brain areas, but not upregulated in unaffected regions. To generate evidence for this
hypothesis attempts were made to immunohistochemically detect p21 on paraffin-embedded
brain sections. Detection on brain sections was highly unspecific, however, which precluded a
direct localization of p21 expression in the developing murine brain. In line with this
hypothesis and with aberrant brain development in neuronal-specific Tra2b KO mice, p21 has
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been shown to restrict neuronal proliferation in the subgranular zone of the dentate gyrus of
the hippocampus (Pechnick et al. 2008) giving an example of how p21 expression can impact
CNS development.
To validate in vivo findings obtained in this study and to assess the extent of p21
upregulation in a homogeneous cellular system, Tra2b knock-down experiments were
performed in the neuronal precursor cell line NSC34. Transfection of cells with siRNAs specific
to Tra2b caused tNasp depletion due to altered splicing of the Nasp transcript which
functionally indicated the loss of Tra2b. In contrast to the rather weak upregulation of p21
observed while using whole brain RNA, material from NSC34 cells showed a massive and highly
significant upregulation of p21 on transcript and on protein level (Figure 36, Figure 37).
Strikingly, the majority of Tra2b-depleted NSC34 cells had died 96 h after Tra2b depletion.
Tra2b depletion was already detectable after 24 h, but strongly increased p21 levels were not
detectable before 72 h of treatment had passed. This suggests that upregulation of p21 is
closely related to cell death in NSC34 cells, which very likely reconstitutes the mechanisms
causing apoptosis in brains of neuronal-specific knock-out mice. Moreover, susceptibility to
Tra2b-depletion which results in cell death as a late consequence does not appear to be a
general feature. Murine fibroblasts were depleted of Tra2b but were growing at high
proliferation rates over many passages (also shown by (Mende et al. 2010)). This indicates that
some cell types like fibroblasts probably tolerate absence of Tra2b, while others like neuronal-
like cells do not. These findings strongly suggest that p21 upregulation that is caused by Tra2b-
depletion promotes apoptosis and loss of the proliferative potential and might strongly be
accounting for malformations of the brain observed in neuronal-specific Tra2b knock-out mice.
In search of a possible link between depletion of Tra2b and the transcriptional increase
of p21, the splicing of tNasp achieved special attention. The nuclear autoantigenic sperm
protein (Nasp) is a histone chaperone that is expressed as two distinct isoforms: The sNasp
(somatic) isoform and the tNasp (testis or embryonic) isoform that was demonstrated to be
expressed in embryonic brain and has previously been described to be strongly expressed in
testis (Grellscheid et al. 2011a). Splicing regulation of the tNasp-specific cassette-exon is
facilitated by numerous Tra2b binding sites which are evolutionarily highly conserved. The
tNasp protein itself has previously been demonstrated to affect progression of the cell cycle, as
its absence has been shown to cause failure in passing the G1/S-phase border (Richardson et al.
2006). Furthermore, direct ablation of tNasp via siRNAs has been demonstrated to cause
apoptosis of prostate cancer cells via an upregulation of p21 (Alekseev et al. 2011). As Tra2b-
depletion as a primary effect causes splicing-related downregulation of tNasp in vivo and in
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NSC34 cells, the question arises whether p21 upregulation is directly based on the loss of
tNasp.
Mice ubiquitously depleted of Tra2b die at early stages of gestation (Mende et al.
2010), which precludes detailed analyses of a systemic upregulation of p21 during
embryogenesis. A strong reduction in proliferative potential could well explain developmental
arrest. Interestingly, mice ubiquitously depleted of Nasp survived until the blastocyst stage of
development (approx. 3.5 dpc) (Richardson et al. 2006). The same workgroup proposed that
survival until this stage was based on maternal tNasp protein present in the oocyte. Also
depletion of tNasp in cells has been demonstrated to cause cell cycle arrest with some delay.
Slow degradation of previously produced tNasp protein could well explain this delay and is in
line with the delayed cell death observed in NSC34 cells as well.
tNasp has a well-established role as a histone chaperone and transporter. It has been
demonstrated that tNasp directly binds to linker histones H1 and transports them into the
nucleus in an energy and NLS-dependent fashion (Alekseev et al. 2005). Linker histones
regulate nucleosome spacing and chromatin remodeling and thus have impact on gene
transcription (Cheung et al. 2002; Horn et al. 2002; Fan et al. 2003). Within the nucleus, linker
histones are constantly exchanged (Lever et al. 2000) and histone H1 molecules not bound to
DNA have been suggested to be bound to Nasp (Alekseev et al. 2003; Alekseev et al. 2005).
Thereby, Nasp has been demonstrated to be non-selective for any Histone H1 subtype
(Richardson et al. 2000). These results imply Nasp in having a role in the regulation of linker
histone homeostasis. Linking this to the putative role of tNasp in the transcriptional
upregulation of p21 it appears intriguing that sole ablation of Histone H1 (independently of
Nasp) causes cell cycle arrest and altered expression of cell cycle-related genes including p21
(Sancho et al. 2008). Based on this the following mechanistic model is proposed: Tra2b-
dependent missplicing of Nasp results in deficient histone import to the nucleus and causes
failure to pass the G1/S-phase checkpoint via p21-mediated cell cycle inhibition.
To validate this hypothesis, attempts were made to rescue p21 upregulation and cell
death in NSC34 cells by overexpressing tNasp from a vector. First experiments showed high
cellular toxicity of tNasp overexpression in NSC34 cells and clear data could not be obtained.
Similar to tNasp depletion, also tNasp overexpression has been demonstrated to affect the
progression of the cell cycle (Alekseev et al. 2003), but dosage compensation of the expression
vector did not reduce toxicity. Very likely, cellular toxicity is mediated by the pEGFP-C2 vector
backbone itself, as transfection of an empty vector at equal amounts also caused the cells to
die within 2 days after transfection. Thus, usage of another expression system is advisable.
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6.7. Concluding remarks: Implications for treatment strategies involving
histone deacetylase inhibitors
The present study was aiming at the identification of Tra2b splicing targets in vivo
using neuronal-specific Tra2b knock-out mice. Identification of transcripts processed by Tra2b
was in so far important as Tra2b is transcriptionally upregulated as a response to treatment
with valproic acid and other HDAC inhibitors (Brichta et al. 2003; Riessland et al. 2006). HDAC
inhibitor treatment has been demonstrated to be a promising approach as a therapy for SMA
(1.6.1). However, HDAC inhibitors and especially valproic acid are also used or clinically tested
for the treatment of epilepsy (Davis et al. 1994), bipolar disorder (Cipriani et al. 2013) and for
the prophylaxis of episodic migraine (Linde et al. 2013). Furthermore, VPA has been attributed
to have anti-cancer properties, as it abolished growth of HeLa cervical cancer cells and induced
apoptosis in thyroid carcinoma cells (Cha et al. 2013; Han et al. 2013). Given the broad use of
VPA in various conditions and its upregulating effect on the expression of Tra2b (Brichta et al.
2003), the identification of Tra2b-dependent splicing processes is of very high relevance.
Splicing of exons that are regulated by Tra2b is likely to be altered by increased Tra2b levels
and thus HDAC inhibitor - and especially VPA treatment - could cause splicing-related side
effects.
VPA treatment increases the expression of Tra2b. In this study attempts were made to
identify Tra2b targets in knock-out mice. Splicing related effects caused by Tra2b upregulation
and knock-out are supposedly different, depending on the type of exon (6.4). Ablation of Tra2b
exerts the biggest effects on exon inclusion, if the exon is generally weakly defined and its
inclusion strongly relies on Tra2b. Overexpression of Tra2b has a different effect and exons
that under physiological conditions are not or only weakly affected by Tra2b, might be
promoted at strongly increased Tra2b concentrations. Notably, expressional increase of Tra2b
induced by VPA is not equal to an overexpression but rather remains within a range similar to
physiological levels. Such - compared to overexpression experiments - moderate increase of
Tra2b expression is very likely to exert impact on the fine tuning of exons. Affected exons are
probably characterized by generally weak splice sites and their inclusion to a great extent relies
on splice factors other than the spliceosome. This makes putatively affected exons responsive
to even moderately increased Tra2b concentrations. That effect of course applies for the
weakly defined SMN2 exon 7, but might also apply for Mapt exon 10. The Mapt exon 10
constitutes a very good example representing a tighly regulated and fine-tuned exon. In vivo
depletion of Tra2b caused a moderate but significant decrease of exon 10 inclusion (Figure 17).
Moreover, (physiologically) increased levels of Tra2b have been associated to enhanced exon
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10 inclusion levels and to imbalances in the 3R:4R isoform ratio of Tau in post mortem
Alzheimer’s disease brains (Glatz et al. 2006). Slight disturbances in the ratio of Tau isoforms
can disturb neuronal function, which makes Tau a critical candidate as a putative off target in
VPA treatment strategies. For that reason, investigations on Mapt splicing during VPA
treatment should be conducted to assess the direct impact of VPA treatment on the Tau
isoform ratios.
This study was not able to largely expand the list of known Tra2b-depending splicing
targets. This was mainly due to failure of high throughput screening approaches based on the
strong heterogeneity between CTRL and KO brains used for comparison. Still, the identification
of Sgol2 and Tubd1 as novel targets of Tra2b and the in vivo identification of bona fide
Tra2b-related splicing processes, yielded new insights into the different modi of alternative
splicing control mediated by Tra2b (6.4). Even though differentially strong impact on splicing of
various exons can probably be explained by the number of Tra2b binding sites and the
predicted splice site strength, this data and the current understanding of the interplay within
the whole splicing machinery is insufficient to predict the impact of Tra2b on exon splicing
without experimental testing. Therefore, further experimental studies are necessary to identify
targets affected by HDAC inhibitor treatment. This study underlined that a subset of splicing
targets is responsive to minor changes of Tra2b concentrations and some exons underlie a
fine-tuned regulation of inclusion that is a prerequisite for normal physiological function. Also
Tra2b was demonstrated to drive tissue-specific splicing processes that may convey tissue-
specific functions to gene products. Thus, HDAC inhibitor-induced expressional changes of
Tra2b definitively have the power to alter splicing processes that may cause aberrant function
in multiple systems.
Besides Tra2b-mediated splicing aberrations, HDAC inhibitors are very broadly acting
compounds that affect transcription of genes very unspecifically and alter the expression of a
multitude of genes simultaneously. Even though this work focused on splicing-related
aberrations, also deregulation of transcription is a source for side effects in HDAC inhibitor
treatment as well and needs to be considered. A very common side effect of VPA treatment in
various conditions is a massive gain of weight and the underlying functional mechanism is
subject of controversial discussion (Verrotti et al. 2011). Typical features of long-term valproic
acid treatment include metabolic disturbances like hyperinsulinemia and insulin resistance and
VPA-related weight gain is associated with long-term vascular complications (Belcastro et al.
2013). Recently, metabolites of VPA have been identified to have an activating effect on the
AMP-activated protein kinase, which is a key regulator of cellular metabolism (Avery and
Bumpus 2013). Involvement of Tra2b in obesity and lipogenesis has been reported via splicing
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of exon 6 of the Lpin1 gene (Pihlajamaki et al. 2011). Inclusion of exon 6 has been
demonstrated to promote expression of the lipogenic isoform of Lpin1 and Tra2b has been
proposed to inhibit exon 6 inclusion via competition with U1 snRNA. Increased levels of Tra2b
have been shown to inhibit production of the lipogenic isoform. This mechanism of regulation
is converse to weight gain during VPA treatment, which with virtual certainty excludes Tra2b
to be involved in VPA-mediated weight gain via splicing of Lpin1. Of note, Lpin1 exon 6 was not
detected as an alternatively regulated candidate exon on mouse exon arrays, despite
expression databases suggest Lpin1 expression in the embryonic and adult brain.
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7. Summary
TRA2B is a serine-arginine-rich splicing factor that contributes to the alternative
splicing of exons and depletion of Tra2b in the mouse causes early embryonic lethality. It
modulates splice site selection in a concentration dependent fashion and associates to target
exons either directly via GAA binding motifs or indirectly via interactions with other splice
factors. TRA2B is highest expressed in neuronal tissue and testis and its expression and
activation are controlled via an autoregulatory self-splicing mechanism and by
phosphorylation. Depending on interactors and on the position of binding, TRA2B can promote
either inclusion or skipping of exons. TRA2B has been associated with splicing processes
involved in development, vascularization, spermatogenesis and neuronal function and
deregulation of splicing processes has been linked to conditions like Alzheimer’s disease,
dementia and Parkinson’s disease. Importantly, TRA2B is involved in the splicing of the SMN
transcript and has been demonstrated to promote inclusion of exon 7. The functional loss of
the SMN1 gene causes spinal muscular atrophy, whereas the copy number of SMN2, which is
alternatively spliced to mainly block exon 7 inclusion, is the major determinant of the disease
severity. Correction of the SMN2 splicing pattern to increase the number of functional full-
length transcripts is a promising avenue for SMA therapy. The use of HDAC inhibitors like VPA
has been demonstrated to correct the SMN2 splicing pattern to a great extent by
transcriptional upregulation of TRA2B. Despite promising trial of VPA in SMA therapy and
successful application in other conditions like epilepsy and bipolar disorder, it can be assumed
that the splicing of other transcripts targeted by TRA2B besides SMN2 will be affected by its
upregulation.
In the present work a neuronal-specific Tra2b knock-out mouse was generated to
identify transcripts targeted by Tra2b in the central nervous system. Mice homozygously
depleted of Tra2b in the central nervous system died shortly after birth and presented severe
abnormalities in cortical development. These included a loss of cortical patterning, a reduction
of the total cortical width and ventriculomegaly. By immunohistochemical analyses of brain
sections at developmental stages reaching from 14.5 dpc to birth, massive apoptosis was
detected in the ventricular and subventricular layers of the lateral ventricles and in the
thalamic region. Apoptosis at 14.5 dpc was followed by a loss of the proliferative potential in a
timely fashion, which caused a progressive loss of cortical material and ventricular dilation that
reached its end stage at 16-17 dpc. Based on a mosaic knock-out of Tra2b in the murine brain,
mRNA and protein levels of Tra2b were drastically reduced, but not fully absent as
demonstrated by quantitative PCR and semi-quantitative Western Blot. Heterozygous knock-
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out animals were fully viable, showed no apoptosis, normal brain development and Tra2b
protein levels comparable to control mice. Analysis of Tra2b isoforms revealed that the
autoregulatory splicing feedback-loop of Tra2b is functional in vivo in the mouse brain and
compensates for the loss of a single gene copy by upregulation of functional Tra2b transcripts
due to skipping of exon 2.
By the use of quantitative PCR, previously and in minigene approaches identified
Tra2b-dependent splicing processes of Mapt, Cltb, Tra2a and Nasp were indentified in vivo
providing proof of concept for the identification of splicing processes in the Tra2b-deficient
murine brain. For the in vivo identification of novel Tra2b target exons, whole transcriptome
sequencing and mouse exon array analysis were performed using whole brain RNA from
neuronal-specific knock-out mice. Based on dramatic differences between control and knock-
out brains and drastically altered cellular compositions, the reliable identification of targeted
exons proved to be difficult. Exons of the Shugoshin-like 2 and Tubulin delta chain were
identified via exon array analysis to be promoted by Tra2b in vivo. These splicing processes
were confirmed by quantitative PCR and both identified exons were shown to be responsive to
increased Tra2b concentrations in a minigene splicing assay. Some of the in vivo identified
Tra2b-dependent splicing processes have possible implications in neuronal development and
function, and might therefore contribute to the observed aberrations in brain development.
Moreover, the cell cycle regulating gene Cdkn1a (encoding p21) was found
upregulated in brains of neuronal-specific knock-out mice using exon arrays, and p21
upregulation was validated by quantitative PCR. P21 is a well-known inhibitor of cell cycle
progression that causes cells to enter cell cycle arrest at the G1-S-phase transition. RNAi-
mediated depletion of Tra2b in NSC34 neuronal precursor cells caused a drastic increase of
p21 expression on RNA and on protein level. Strikingly, NSC34 cells died shortly after p21
expression had increased, indicating an apoptotic effect. This suggests that an increased p21
expression is likely the reason for apoptosis and the loss of the proliferative potential in
neurogenic areas of the developing Tra2b-depleted brains. Previous studies have linked
deficiency of the histone chaperone Nasp to upregulation of p21 and to apoptosis. Further
investigations need to clarify, whether Tra2b-related missplicing of Nasp (tNasp depletion) is
the underlying reason for p21 upregulation and apoptosis.
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8. Zusammenfassung
TRA2B ist ein SR-related Spleißfaktor, der das alternative Spleißen von Exonen reguliert
und die Abwesenheit von TRA2B führt zu früher embryonaler Lethalität in Mäusen. TRA2B
moduliert die Auswahl von Spleißstellen in Abhängigkeit von seiner Konzentration. Dabei
assoziiert TRA2B entweder direkt über GAA Bindestellen mit seinem Zielexon oder es bindet
indirekt durch Interaktion mit anderen Speißfaktoren. TRA2B wird am stärksten in neuronalem
Gewebe und in Testis exprimiert, während die Expression selbst sowie der Aktivierungszustand
über einen sich selbst regulierenden auto-Speißmechanismus und durch Phosphorylierung
gesteuert werden. In Abhängigkeit von seinen Interaktionspartnern und der Bindestelle
innerhalb eines Transkripts kann TRA2B entweder den Ein- oder Auschluss eines Exons
fördern. TRA2B wurde in vorhergegangenen Studien mit Spleißprozessen in Verbindung
gebracht, welche für die Entwicklung, Vaskularisierung, Spermatogenese und neuronale
Funktion von Bedeutung sind. Störungen in TRA2B-abhängigen Spleißprozessen wurden in
Krankheiten wie Alzheimer, Demenz und Parkinson nachgewiesen. Von hoher Bedeutung ist
der Einfluss von TRA2B auf das Spleißen von SMN Exon 7. Der funktionelle Verlust des SMN1
Gens verursacht spinale Muskelatrophie, wobei die Kopienanzahl des nahezu identischen
SMN2 Gens den Schweregrad der Erkrankung bestimmt. Durch alternatives Spleißen kommt es
zum Ausschluss von Exon 7 des SMN2 Gens in 90 % aller Transkripte. Die Wiederherstellung
des SMN2 Spleißmusters und die damit verbundene Vervielfachung von SMN2
Volllängentranskripten bietet deshalb einen vielversprechenden Therapieansatz für die SMA.
Vorhergegangene Studien haben gezeigt, dass HDAC Inhibitoren wie VPA das SMN2
Spleißmuster über eine transkriptionelle Heraufregulation von TRA2B zu revertieren
vermögen. VPA wurde in klinischen Studien für eine mögliche SMA Therapie getestet und VPA
wird erfolgreich bei Epilepsie und bipolaren Störungen eingesetzt. Es kann jedoch davon
ausgegangen werden, dass die transkriptionelle Verstärkung der TRA2B Expression neben
SMN2 das Spleißen von anderen Transkripten beeinflusst.
Im Rahmen dieser Studie wurden neuronal-spezifische Tra2b Knock-out Mäuse
generiert, um von Tra2b regulierte Transkripte im zentralen Nervensystem zu identifizieren.
Mäuse mit homozygoter Tra2b Deletion im zentralen Nervensystem starben kurz nach der
Geburt und zeigten schwerwiegende Fehlbildungen des Gehirns. Diese äußerten sich
insbesondere durch den Verlust der Organisation der cortikalen Laminierung, einer
Reduzierung der cortikalen Dicke und Ventrikulomegalie. Durch immunhistochemische
Analysen von Dünnschnitten des Gehirns beginnend bei 14.5 dpc bis zur Geburt, konnte in den
ventrikulären und subventrikulären Schichten der lateralen Ventrikel sowie in der
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Thalamusregion Apoptose nachgewiesen werden. Apoptose wurde erstmals bei 14.5 dpc
beobachtet und wurde gefolgt von ausbleibender Proliferation, was einen fortschreitenden
Verlust von cortikalem Material und die Erweiterung der lateralen und des dritten Ventrikels
zur Folge hatte. Diese erreichten bei 16-17 dpc ihr Endstadium. Basierend auf einem
mosaischen Knock-out von Tra2b im murinen Gehirn, waren mRNA- und Proteinspiegel von
Tra2b zwar drastisch reduziert, aber noch immer nachweisbar. Heterozygot deletierte Mäuse
waren uneingeschränkt lebensfähig und zeigten eine normale Gehirnentwicklung, die von
Kontrolltieren nicht unterscheidbar war. Durch qPCR Analyse der Tra2b isoformen konnte der
zuvor beschriebene Selbstspleißmechanismus von Tra2b funktionell in vivo nachgewiesen
werden. Durch einen verstärkten Ausschluss von Tra2b Exon 2 wurde der Verlust einer Tra2b
Genkopie nahezu vollständig kompensiert.
Durch isoformspezifische qPCRs konnten zuvor identifizierte Tra2b-abhängige
Spleißprozesse von Mapt, Cltb, Tra2a und Nasp in vivo nachgewiesen werden. So konnte im
Allgemeinen die Möglichkeit zur Identifizierung von Tra2b-abhängigen Spleißprozessen in
konditionalen Knock-out Mäusen bewiesen werden. Zur Identifizierung unbekannter Tra2b-
abhängiger Spleißprozesse wurden whole transcriptome sequencing und Exon Array Analysen
mit Gehirn-RNA durchgeführt. Aufgrund der dramatischen Störungen während der
Gehirnentwicklung, war die zelluläre Komposition der Gehirne insoweit verändert, sodass eine
zuverlässige Identifizierung alternativ gespleißter Exone sich als schwierig erwies. Dennoch
konnten Exone der Gene Shugoshin-like 2 und Tubulin delta chain in vivo identifiziert werden.
Die entsprechenden Spleißprozesse wurden durch qPCR Analysen bestätigt und
Minigenkonstrukte beider Exone zeigten gesteigerte Einschlussraten bei erhöhten Tra2b
Konzentrationen. Einige der in vivo identifizierten Tra2b-abhängigen Spleißvorgänge sind in
Prozessen der neuronalen Entwicklung involviert und könnten entscheidend zu den
beobachteten Fehlbildungen des Gehirns beigetragen haben.
Des Weiteren wurde durch Exon Array Analysen eine Heraufregulation des
Zellzyklusregulators Cdkn1a (p21) in Tra2b Knock-out Gehirnen nachgewiesen und durch qPCR
validiert. P21 ist ein etablierter Zellzyklusinhibitor, der eine Unterbrechung des Zellzyklus im
Übergang von der G1- zur S-Phase auslösen kann. RNAi-vermittelte Herunterregulation von
Tra2b in NSC34 neuronalen Vorläuferzellen verursachte eine drastische Erhöhung der p21
Expression auf mRNA und auf Proteinebene. Verblüffenderweise starben die meisten NSC34
Zellen kurz nach der Heraufregulation von p21, was auf einen apoptotischen Effekt schließen
lässt. Das legt die Vermutung nahe, dass Apoptose und der Verlust proliferativer Aktivität, wie
es in neuronal-spezifischen Knock-out Mäusen auftritt, in der in vivo erhöhten p21 Expression
begründet ist. In vorhergegangenen Studien war die Defizienz des Histonchaperons Nasp mit
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der Heraufregulation von p21 und Apoptose in Verbindung gebracht worden. Es sollte daher in
zukünftigen Studien geklärt werden, ob Tra2b-vermitteltes Fehlspleißen von Nasp
(Verminderung von tNasp) die Ursache für eine Erhöhung der p21 Expression ist.
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Appendix XIII
Appendix
I. Top 100 ranking candidates obtained by whole transcriptome
sequencing
Candidate hits of the initial whole transcriptome sequencing analysis were sorted by
significance level. The 100 top ranking candidates are listed below. The chromosomal
coordinates of each exon is given by CHR, EX_START and EX_END. Length gives the exon length
in bp.
GENE CHR EX_START EX_END length bp x-fold change p-val
Appbp2 chr11 85027738 85027861 123 -3.24 2.5131E-05
Renbp chrX 71174455 71174679 224 -4.11 3.9022E-05
Htt chr5 35242421 35242576 155 1.52 5.5188E-05
Elavl2 chr4 90978264 90978354 90 17.30 6.4309E-05
Rpl34 chr3 130431250 130431769 519 -1.71 6.6274E-05
AI413582 chr17 27700718 27700961 243 1.25 1.0320E-04
Tm7sf2 chr19 6063324 6063446 122 1.28 1.2083E-04
Nasp chr4 116286935 116287015 80 5.20 1.3034E-04
Zfp507 chr7 36572737 36572851 114 1.47 1.9921E-04
Bahcc1 chr11 120094261 120094421 160 -2.44 2.0975E-04
Slc43a2 chr11 75385817 75385914 97 1.80 2.4567E-04
Tanc2 chr11 105718711 105718942 231 -1.22 2.5942E-04
Zhx1 chr15 57878558 57880340 1782 -1.27 2.8100E-04
Gm6644 chr1 55500577 55500886 309 1.33 2.7701E-04
Gm6644 chr1 55501376 55501908 532 -1.22 2.7707E-04
Galk2 chr2 125713579 125713723 144 -1.67 2.8350E-04
Lin37 chr7 31342284 31342313 29 -3.17 2.8438E-04
Dlgap4 chr2 156526358 156527410 1052 1.19 2.9671E-04
Fbxl6 chr15 76367719 76367850 131 -1.25 3.1398E-04
Galk2 chr2 125713600 125713723 123 -1.75 3.6431E-04
Spnb4 chr7 28157116 28157394 278 1.46 3.7232E-04
Tank chr2 61431134 61431265 131 2.01 4.7103E-04
Tank chr2 61431154 61431265 111 2.01 4.7037E-04
AI413582 chr17 27700716 27700961 245 1.25 4.8913E-04
Lrba chr3 86519435 86519602 167 1.63 4.9624E-04
Ypel1 chr16 17082650 17082787 137 3.86 5.0883E-04
Map4k1 chr7 29767073 29767283 210 -2.24 5.5680E-04
Eya2 chr2 165596534 165596762 228 -1.44 6.3657E-04
Adcy2 chr13 68796255 68796339 84 2.32 6.3663E-04
Robo3 chr9 37224282 37225087 805 -1.41 6.5205E-04
Pias3 chr3 96503916 96504000 84 -1.55 6.8355E-04
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GENE CHR EX_START EX_END length bp x-fold change p-val
Aox4 chr1 58314059 58314154 95 1.62 6.8791E-04
Dlgap4 chr2 156526342 156527410 1068 1.19 6.8325E-04
Dlg1 chr16 31871761 31871934 173 -1.91 7.1727E-04
Dlg1 chr16 31871761 31871932 171 -1.91 7.1718E-04
2700029M09Rik chr8 63378881 63379031 150 -2.71 7.5417E-04
1700021K19Rik chr16 32844633 32844792 159 1.49 7.7601E-04
Slc2a3 chr6 122686597 122686759 162 1.31 8.0889E-04
Mtx1 chr3 89017735 89017784 49 3.37 8.3369E-04
Sbf2 chr7 117519086 117519342 256 -1.43 8.3037E-04
1700026L06Rik chr2 28549144 28549346 202 2.19 8.3661E-04
Rasgrp3 chr17 75899399 75899572 173 1.86 8.5611E-04
Scfd2 chr5 74854330 74854667 337 3.52 8.9710E-04
Rims1 chr1 22475030 22475160 130 -1.94 9.0557E-04
Syvn1 chr19 6047085 6047128 43 -3.65 9.2388E-04
Araf chrX 20429056 20429154 98 1.46 9.3155E-04
Gzf1 chr2 148510348 148510704 356 -1.24 9.4564E-04
Tnrc6c chr11 117608491 117608610 119 1.42 9.4755E-04
Surf1 chr2 26770378 26770415 37 -7.11 9.8963E-04
Ap1g2 chr14 55717415 55717998 583 -1.83 9.9639E-04
Myo10 chr15 25643626 25643971 345 2.28 1.0292E-03
Plod1 chr4 147292889 147293002 113 1.30 1.0395E-03
Agxt2l2 chr11 51398259 51398381 122 4.06 1.0618E-03
Irf1 chr11 53587564 53587696 132 2.85 1.0620E-03
Adcy6 chr15 98425344 98425473 129 1.26 1.0577E-03
Tm2d1 chr4 98041611 98041704 93 5.76 1.0674E-03
Wbp1 chr6 83069862 83070038 176 1.25 1.1906E-03
Kdm4c chr4 73944345 73944538 193 1.52 1.2451E-03
Wdfy1 chr1 79730428 79730448 20 1.86 1.2606E-03
Nadsyn1 chr7 150985696 150985827 131 1.63 1.2704E-03
Nrxn3 chr12 90088723 90089293 570 -1.63 1.2916E-03
Ftl1 chr7 52713335 52713653 318 1.24 1.3283E-03
Zfp511 chr7 147225225 147225344 119 -1.76 1.3308E-03
Snrpd2 chr7 19737825 19738084 259 -1.50 1.3403E-03
Eml4 chr17 83872990 83873088 98 1.97 1.3514E-03
Pnmal1 chr7 17547369 17547668 299 1.33 1.3520E-03
Supt6h chr11 78059050 78059489 439 -1.65 1.3841E-03
BC024978 chr7 27987646 27987716 70 3.69 1.4037E-03
Shisa5 chr9 108957377 108957521 144 -1.69 1.5042E-03
Ppp1r10 chr17 36063439 36063518 79 1.88 1.5377E-03
Trim66 chr7 116604007 116604528 521 -1.82 1.5999E-03
Prosapip1 chr2 130462679 130463155 476 -1.52 1.6142E-03
Acin1 chr14 55263521 55263628 107 -2.01 1.6334E-03
Tgfbr1 chr4 47396621 47396866 245 1.72 1.6417E-03
Dlg1 chr16 31871761 31872347 586 -1.87 1.6731E-03
Pold1 chr7 51788574 51788671 97 -2.70 1.6840E-03
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Akap9 chr5 4034748 4034867 119 1.82 1.7357E-03
Xpo6 chr7 133267886 133268045 159 1.31 1.7453E-03
Gm15952 chr3 35831967 35832089 122 2.70 1.7552E-03
Utp15 chr13 99032830 99032947 117 1.88 1.7505E-03
Pcbd2 chr13 55876728 55876808 80 1.87 1.7610E-03
Usp19 chr9 108401625 108401841 216 -1.25 1.7871E-03
Cnot6l chr5 96509091 96509154 63 2.94 1.7875E-03
Kpna2 chr11 106852383 106852646 263 1.94 1.8029E-03
Tubgcp3 chr8 12630410 12632373 1963 -1.44 1.8288E-03
Pank2 chr2 131122009 131122044 35 2.59 1.8084E-03
Ncoa1 chr12 4270747 4270848 101 2.13 1.8306E-03
Nr6a1 chr2 38596063 38596127 64 -4.63 1.8323E-03
Parp8 chr13 117715324 117715394 70 -3.51 1.8357E-03
Pappa chr4 64954353 64954466 113 3.20 1.8991E-03
Fnip2 chr3 79310129 79310200 71 1.70 1.9032E-03
Srgap3 chr6 112704565 112704667 102 -1.53 1.8775E-03
Rnd2 chr11 101329489 101329753 264 -2.78 1.9459E-03
Col6a1 chr10 76184148 76184276 128 -1.32 1.9570E-03
Cd2bp2 chr7 134337172 134337444 272 -1.47 1.9626E-03
Ppt2 chr17 34764111 34764470 359 -1.78 2.0033E-03
Phyh chr2 4851759 4851940 181 1.31 1.9936E-03
Kcnab2 chr4 151851510 151851653 143 -3.18 2.0201E-03
Fam19a5 chr15 87511910 87512059 149 -1.15 2.0401E-03
Rictor chr15 6745896 6746034 138 -2.09 2.0469E-03
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II. Differentially expressed transcripts identified on mouse exon arrays
Of all identified differentially expressed transcripts only those with relative changes in
expression larger than +1.5-fold or smaller than -1.5-fold and p-values smaller than 0.05 were
considered and are listed below. Transcript ID refers to the transcript cluster ID of the NetAffx
database for mouse WT 1.0 ST arrays.
Gene symbol Transcript ID Refseq x-fold change p-value
Defb11 6980933 NM_139221 2.0658 0.048522
Gstp2 6765276 NM_181796 1.8474 0.032396
Ccng1 6787474 NM_009831 1.8472 0.000038
Lilrb4 6767782 NM_013532 1.8272 0.025706
Lmbr1 6936930 NM_020295 1.8137 0.000605
Nfyc 6793170 NM_008692 1.7295 0.029643
Vsnl1 6798951 NM_012038 1.7261 0.028591
Sprr2e 6899429 NM_011471 1.7181 0.020085
Eda2r 7018366 NM_001161432 1.6672 0.000681
Olfr61 6965107 NM_146964 1.6627 0.018089
Sepp1 6828326 NM_009155 1.6604 0.024251
Krtap4-7 6791359 NM_029613 1.6428 0.046919
C3ar1 6957059 NM_009779 1.6267 0.001238
Mab21l2 6906620 NM_011839 1.5870 0.030646
Serpine2 6760009 NM_009255 1.5699 0.004763
D930031A20Rik 6964233 AK086471 1.5693 0.004062
Gpr50 7011861 NM_010340 1.5544 0.014725
Cdkn1a 6849595 NM_007669 1.5447 0.000405
Hmox1 6977260 NM_010442 1.5303 0.001385
Gpnmb 6946055 NM_053110 1.5184 0.011782
Fam96b 6984930 NM_026753 1.5115 0.012756
B230220N19Rik 7007728 AK045674 1.5112 0.026976
Glra1 6788423 NM_020492 1.5043 0.034485
Ctsc 6962376 NM_009982 1.5008 0.007041
Speer4f 6928962 NM_027609 -1.5027 0.037082
Dpy19l1 6994030 NM_172920 -1.5037 0.000029
Mpped1 6832276 NM_172610 -1.5039 0.004595
Sfrp1 6974663 NM_013834 -1.5084 0.022188
Nfix 6983873 NM_001081981 -1.5138 0.014852
Trim59 6905821 NM_025863 -1.5149 0.036341
Casc5 6880492 NM_029617 -1.5182 0.002964
H1f0 6831858 NM_008197 -1.5194 0.010765
Atad2 6835934 NM_027435 -1.5204 0.008777
E130114P18Rik 6923584 NR_015513 -1.5206 0.003672
Cdon 6988112 NM_021339 -1.5206 0.011740
Tmpo 6775984 NM_001080129 -1.5215 0.003863
Abcd2 6837935 NM_011994 -1.5223 0.000455
Igfbpl1 6921331 NM_018741 -1.5234 0.000428
Tcf4 6861850 NM_013685 -1.5247 0.002076
Zeb2 6886356 NM_015753 -1.5326 0.001918
Olfr510 6963311 NM_146311 -1.5354 0.033983
Sox2ot 6896671 NR_015580 -1.5355 0.001574
Cdkn2c 6924466 NM_007671 -1.5362 0.001138
Spc25 6887520 NM_025565 -1.5368 0.005265
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Gene symbol Transcript ID Refseq x-fold change p-value
Zbtb20 6841019 NM_019778 -1.5642 0.011133
Hist1h1c 6805381 NM_015786 -1.5670 0.009790
Fezf2 6822729 NM_080433 -1.5751 0.007063
Bub1 6890715 NM_001113179 -1.5766 0.005811
Kif15 6993098 NM_010620 -1.5882 0.000537
D030056L22Rik 6868519 BC020125 -1.5906 0.008919
Pax6 6879741 NM_013627 -1.5982 0.000013
Smc4 6898241 NM_133786 -1.6021 0.013139
Nusap1 6880529 NM_133851 -1.6152 0.005198
Hist1h2ba 6811715 NM_175663 -1.6162 0.034395
Kif11 6869503 NM_010615 -1.6222 0.007155
Usp1 6915734 NM_146144 -1.6303 0.020022
Rlbp1 6968704 NM_020599 -1.6363 0.000674
Mir9-2 6808621 NR_029545 -1.6379 0.000071
Neurod1 6888114 NM_010894 -1.6418 0.000130
C79407 6801335 NM_172578 -1.6463 0.001367
Nfib 6922846 NM_001113209 -1.6486 0.007677
Cdk6 6928457 NM_009873 -1.6576 0.001684
Olfr1325 7012030 NM_146398 -1.6761 0.023110
Epha3 6846670 NM_010140 -1.6916 0.001027
Nr2e1 6773556 NM_152229 -1.7001 0.000058
G2e3 6795024 NM_001167963 -1.7030 0.000861
Usp-ps 6969968 NR_033576 -1.7222 0.009437
Tiam2 6848368 NM_011878 -1.7223 0.011583
Cdca7 6878053 NM_025866 -1.7261 0.001688
Ect2 6903753 NM_007900 -1.7433 0.000693
Tra2b 6844553 NM_009186 -1.7445 0.010315
Zfp238 6755494 NM_001012330 -1.7494 0.002712
Satb2 6758862 NM_139146 -1.7605 0.007654
Olfr433 6755294 NM_146717 -1.7657 0.017448
Ccnd2 6957263 NM_009829 -1.7997 0.000541
Top2a 6791298 NM_011623 -1.8076 0.009440
Eomes 6992849 NM_010136 -1.8263 0.000286
Foxg1 6794939 NM_001160112 -1.8445 0.000809
Hist1h1b 6811530 NM_020034 -1.8480 0.006732
Dlx1 6878021 NM_010053 -1.8513 0.000522
2810417H13Rik 6989974 NM_026515 -1.8574 0.018898
Nfib 6922857 NM_001113209 -1.8625 0.001273
Arhgap11a 6889894 NM_181416 -2.0788 0.000112
Neurod6 6953866 NM_009717 -2.0829 0.010316
2610017I09Rik 6758223 NR_027826 -2.1843 0.000693
Hist1h2bb 6805380 NM_175664 -2.5570 0.020253
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III. Differentially spliced exons identified on exon arrays
Of all identified exons only those with relative changes in inclusion larger than +1.5-
fold or smaller than -1.5-fold and p-values smaller than 0.05 were considered. Filtering
strategies explained in chapter 5.6.2 and in Figure 27 were applied. Exons fulfilling the filtering
conditions are listed below. Probeset ID refers to identification number of a group of probes
representing an exon as it is listed in the NetAffx database for mouse WT 1.0 ST arrays.
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
SLU7 4714947 114 13.47 -1.9191 0.02477
KIF20B 4410288 156 13.13 -1.5488 0.00222
KIF2C 4603783 101 12.67 -1.8807 0.01001
MTHFD1L 4548959 42 12.19 1.5596 0.01384
SORBS3 4394107 87 11.77 1.6978 0.02896
PSMC3IP 4585989 146 10.52 -1.7234 0.00084
CENPK 4424232 151 10.17 -1.7252 0.00686
NRG1 4394148 51 10.04 -1.7979 0.00613
CCNB2 4583775 129 9.92 -1.6695 0.01335
ANKRD27 4374584 155 9.91 -1.5020 0.01201
TRANK1 4556735 104 9.85 1.5552 0.00786
SGOL2 4596578 78 9.85 -2.6673 0.04683
MLF1IP 4579279 79 9.72 -2.0832 0.01112
CENPE 4448452 159 9.66 -2.0459 0.04910
SLC26A4 4513897 55 9.31 -1.5611 0.02733
XPC 4540836 85 9.04 1.8936 0.02175
INTS6 4661791 143 8.95 -1.5575 0.02020
OFD1 4518495 174 8.83 -1.5665 0.00514
MEIS2 4356182 59 8.68 -1.5856 0.00315
SIAH1B 4542386 61 8.39 -1.6958 0.04213
OFD1 4349753 153 8.37 -1.6282 0.00951
CCDC73 4461583 184 8.35 -1.5059 0.03378
SGOL2 4709146 154 8.31 -1.7447 0.00706
DLX5 4410923 185 8.30 -1.7827 0.01353
KLHDC4 4507108 188 8.17 -1.9123 0.01836
MKI67 4310542 417 7.98 -1.5090 0.04443
PRR11 4320972 99 7.76 -1.5154 0.00922
CDCA5 4546320 66 7.76 -1.8696 0.01511
BRCA1 4554019 99 7.76 -1.8131 0.02303
HEG1 4578225 104 7.38 -2.1142 0.01104
ENOX2 4530030 108 7.11 -1.7849 0.00098
ARHGAP26 4327278 72 7.11 1.7719 0.01261
PTPN14 4746205 219 7.01 1.5709 0.03546
FAM107B 4727147 184 6.96 -1.6696 0.00154
SNX10 4597042 221 6.95 -1.7356 0.00079
MLH1 4544833 113 6.80 -1.5836 0.01376
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SYTL4 4694836 76 6.74 2.3830 0.02549
GTF2F1 4486003 154 6.65 -1.7839 0.00200
SYNE2 4611825 156 6.56 -1.5839 0.02015
GRAMD1C 4489059 118 6.51 -2.0551 0.03330
D930015E06RIK 4532105 79 6.48 -1.7058 0.00727
APBA1 4609243 40 6.40 1.7743 0.01322
TTK 4707365 81 6.32 -2.0089 0.00007
CACNA2D3 4313575 81 6.32 1.5554 0.00522
ZBTB40 4670785 163 6.28 -1.6228 0.02769
OVCH2 4329814 204 6.27 -1.5507 0.03872
RFTN1 4652925 82 6.24 -2.0106 0.01390
KIF18A 4462409 412 6.21 -1.7284 0.03035
ELMO3 4712245 83 6.17 1.6138 0.04499
ASPM 4513114 167 6.13 -1.8145 0.00335
GRIK1 4641203 251 6.12 1.6661 0.01374
SPTY2D1 4327656 169 6.06 -1.5769 0.04401
ASPM 4726405 170 6.02 -1.8942 0.02406
RNASEH2B 4635673 43 5.95 -1.6809 0.00022
SYNE2 4360206 129 5.95 -1.7968 0.00087
TAF5 4530560 130 5.91 -1.7218 0.01403
GCA 4430879 44 5.82 -2.5955 0.00346
4930447C04RIK 4442257 176 5.82 1.6903 0.02751
LGSN 4338761 133 5.77 -1.5240 0.04271
KDM5A 4721789 182 5.63 -1.5596 0.00644
GPR64 4738054 46 5.57 1.6862 0.03385
PLA2R1 4349740 416 5.54 -1.6316 0.02991
SSH3 4647689 47 5.45 1.6535 0.00593
PLCH1 4393121 95 5.39 -1.5513 0.01493
HNF4A 4534336 95 5.39 1.6081 0.03012
SUV420H1 4495303 239 5.36 -1.5129 0.00050
NIN 4425864 191 5.36 -1.5214 0.04612
CNTNAP2 4361055 144 5.33 1.5486 0.00680
ECE1 4628587 96 5.33 2.7274 0.01753
ARHGAP19 4562132 192 5.33 -1.5435 0.03178
ZFP105 4626084 289 5.31 -1.5801 0.00169
EZR 4627884 97 5.28 -1.9445 0.00498
CEP55 4334451 195 5.25 -1.8542 0.01566
TFDP2 4509008 147 5.22 -1.7324 0.00205
RPRD1A 4466185 98 5.22 -2.1037 0.03573
ECE2 4421701 99 5.17 1.6365 0.00414
CDH17 4555128 99 5.17 1.5607 0.01284
ATP8B3 4579465 100 5.12 1.6908 0.00031
SF3B2 4555575 100 5.12 -1.5298 0.01763
HOXC8 4691504 1705 5.10 1.6038 0.04103
BCAP29 4720125 101 5.07 -1.5115 0.02851
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FOXM1 4305232 152 5.05 -2.2088 0.00038
POLR2A 4458434 204 5.02 -1.5385 0.00020
RAPGEF4 4677994 51 5.02 2.1572 0.00355
SYNE1 4529049 153 5.02 1.6361 0.00800
SIDT1 4555772 102 5.02 1.5260 0.03208
ALLC 4462024 51 5.02 1.5400 0.04320
PRPF38B 4623817 2096 5.01 -1.5071 0.00399
GNAO1 4489479 154 4.99 -1.6702 0.00030
CPA3 4448551 103 4.97 -1.5479 0.02166
CCNA2 4670846 208 4.92 -1.7401 0.01545
ST18 4501014 104 4.92 -2.1608 0.01835
VEPH1 4493598 210 4.88 -2.1549 0.00510
DGKK 4405005 105 4.88 3.0980 0.04066
ALDOB 4374933 894 4.87 1.8427 0.01753
KIF18A 4403782 370 4.84 -1.6174 0.00304
KIF18A 4706655 370 4.84 -1.8986 0.02277
RCOR2 4517066 53 4.83 -2.6669 0.00325
DMC1 4547125 53 4.83 1.5978 0.01469
OFD1 4327484 107 4.79 -1.6517 0.00438
PLXNA2 4628626 269 4.76 -1.6269 0.00386
KCNIP4 4650677 108 4.74 1.5880 0.04691
PCLO 4319628 109 4.70 1.7506 0.01280
MBIP 4664789 219 4.68 -1.5382 0.03569
NES 4343695 5031 4.58 -1.7326 0.02448
NES 4434708 5031 4.58 -1.7789 0.04031
HCLS1 4603834 56 4.57 1.6110 0.00187
NTNG2 4678504 448 4.57 -1.5195 0.02573
MBOAT1 4523473 56 4.57 -1.6739 0.04129
RSBN1 4612612 674 4.56 -1.5093 0.02094
TPX2 4389535 169 4.54 -1.5292 0.00635
NUP107 4661967 113 4.53 -1.5011 0.01902
SPATA19 4390533 57 4.49 -1.5098 0.01334
NPR1 4573063 114 4.49 1.6498 0.03552
EFNB2 4406005 114 4.49 -1.5061 0.04358
1700025F22RIK 4728486 114 4.49 -1.6757 0.04824
TMEM176B 4395179 57 4.49 1.5149 0.04914
ASF1A 4345722 116 4.41 -1.6885 0.00595
TTC7 4445556 118 4.34 1.7040 0.01565
ARHGAP9 4457012 59 4.34 -1.5093 0.02528
MAP3K5 4572388 178 4.31 1.9921 0.04547
CENPJ 4563789 243 4.21 -1.8277 0.02338
CKAP2L 4655699 61 4.20 -1.9860 0.00757
LARS 4705431 369 4.16 -1.5188 0.00615
ANP32E 4479636 123 4.16 -1.6111 0.00770
SH3TC1 4498854 123 4.16 1.5202 0.02225
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MID1 4452815 308 4.16 -2.1009 0.04247
TGM3 4653958 246 4.16 1.5098 0.04855
FRMD4A 4437044 248 4.13 -1.6302 0.00541
PLA2G7 4404775 124 4.13 1.6547 0.01115
AOX4 4498242 62 4.13 -1.9342 0.01310
CPNE8 4467664 62 4.13 1.5033 0.01780
DDX21 4350871 186 4.13 -1.5083 0.03626
EPHA4 4665920 125 4.10 -1.6541 0.00200
CP 4745390 376 4.09 1.9315 0.04285
SAP30 4647459 126 4.06 -1.5454 0.00052
PRKG1 4517208 63 4.06 1.5457 0.01848
DUB2A 4430289 1959 4.05 -1.7222 0.00944
DTNA 4512612 127 4.03 1.8568 0.01410
TRHDE 4403978 127 4.03 1.5086 0.01631
D2ERTD750E 4616609 127 4.03 -1.8003 0.01678
TNFRSF22 4437715 129 3.97 1.7165 0.01008
ZFP445 4554588 2075 3.95 -1.5427 0.01132
LRRIQ3 4734429 324 3.95 1.6544 0.02787
INPP4B 4592600 65 3.94 1.7812 0.00958
EPHA7 4519544 65 3.94 -3.0103 0.01593
SLC27A2 4491865 131 3.91 1.6788 0.01049
AIFM1 4696782 131 3.91 -1.6289 0.01333
ANO7 4550734 131 3.91 1.5821 0.04959
ZFYVE26 4575982 137 3.74 -1.5468 0.00893
GRM8 4744663 137 3.74 1.6249 0.02911
ZSCAN2 4339247 1581 3.72 -1.6928 0.02355
DDX27 4743790 277 3.70 1.5777 0.01701
RAD17 4393293 70 3.66 -1.6108 0.00622
BC088983 4696394 211 3.64 -1.5485 0.03231
D930015E06RIK 4371766 142 3.61 -1.6043 0.00239
STK30 4377299 71 3.61 -1.9443 0.03151
MCF2 4492513 143 3.58 -1.7141 0.00434
MYBL1 4392383 72 3.56 -1.5096 0.00721
APLF 4443727 72 3.56 -1.5235 0.01628
C3 4738818 72 3.56 1.5342 0.02861
TUBD1 4335622 217 3.54 -1.6770 0.00326
POLE 4598107 145 3.53 -1.5859 0.00031
NASP 4616314 652 3.53 -1.7145 0.02272
SPATA20 4662583 363 3.53 -1.5004 0.03368
DSN1 4321696 73 3.51 -1.6469 0.02201
ORC5 4657817 221 3.48 -1.7598 0.00165
ADAMTS12 4477489 368 3.48 1.5242 0.03622
PLA2G7 4346269 149 3.44 1.6709 0.00637
LIMA1 4368416 149 3.44 -1.5060 0.01213
9130014G24RIK 4392481 823 3.42 -1.6688 0.02775
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IFITM3 4471047 374 3.42 1.6120 0.03210
CSTF3 4419823 75 3.41 -1.6309 0.00785
MTHFD1 4582739 75 3.41 -1.6544 0.02141
LRRC1 4596354 75 3.41 -1.6541 0.02152
RASGEF1B 4433006 152 3.37 -1.8033 0.04420
EME1 4653832 610 3.36 -1.6390 0.01435
SPAG5 4363783 1457 3.34 -1.5176 0.00669
RHPN2 4477249 77 3.32 1.5636 0.01444
CNST 4422191 629 3.26 3.1702 0.01696
SPOCK3 4515551 1892 3.25 1.7465 0.01574
SLC4A10 4657136 158 3.24 1.8556 0.01678
KDM2B 4328332 79 3.24 -1.5005 0.03221
H47 4448059 79 3.24 -1.5361 0.03398
ENAH 4681038 79 3.24 -1.5019 0.03725
TAF7L 4620888 79 3.24 2.9805 0.04087
PRSS16 4556206 635 3.23 1.5390 0.00734
SACS 4560545 480 3.20 1.6823 0.01206
HTR3A 4399364 161 3.18 -1.5998 0.02738
BC003331 4416326 647 3.17 -1.6843 0.03530
RAD9B 4377905 242 3.17 -1.5470 0.04848
TRA2A 4500206 811 3.16 1.5258 0.00208
SLCO1A5 4455480 655 3.13 -1.5728 0.00898
ST18 4492882 246 3.12 -1.6802 0.00237
PKHD1L1 4506571 166 3.08 -1.5203 0.00193
MPDZ 4511539 166 3.08 -1.5949 0.01005
PHF20L1 4706505 250 3.07 -1.6025 0.00013
4483198 250 3.07 1.7295 0.02964
PHF20L1 4677219 250 3.07 -1.6314 0.03172
LCP2 4475995 84 3.05 1.5375 0.00598
ACE 4629811 168 3.05 1.5395 0.03204
4930504O13RIK 4516818 253 3.04 1.6303 0.03007
LHX3 4607122 169 3.03 1.7543 0.03022
MYOCD 4466868 2456 3.02 1.9269 0.03129
F730047E07RIK 4740068 170 3.01 -1.7486 0.00042
HTR3A 4595344 170 3.01 -1.6996 0.00124
SEMA5B 4544194 428 2.99 -1.7438 0.01615
PKHD1L1 4436724 172 2.98 -1.8760 0.00066
CBFA2T2 4370307 86 2.98 -1.5000 0.00329
THNSL2 4488806 172 2.98 1.5663 0.00453
PRKD3 4344822 86 2.98 -2.8835 0.01817
LRP1B 4393083 172 2.98 1.5616 0.02738
PAM 4549185 86 2.98 -1.5351 0.04407
NUT 4406073 2232 2.98 1.6016 0.04663
PABPC2 4515030 2586 2.97 1.7722 0.01478
GAS6 4650063 173 2.96 1.6455 0.00096
Appendix XXIII
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
IQUB 4375567 173 2.96 1.9279 0.01136
POLE2 4625040 173 2.96 -1.6420 0.04054
LRP1B 4697372 2254 2.95 1.7630 0.04585
MANBA 4544437 87 2.94 1.8919 0.02124
HGF 4727408 175 2.93 -1.5910 0.04558
SPAG5 4490876 527 2.91 -1.7068 0.00012
VRK1 4651024 88 2.91 -1.9744 0.00096
ASPM 4629397 1408 2.91 -1.5253 0.01388
SLA 4388873 1937 2.91 -1.6603 0.03951
ASPM 4733897 1408 2.91 -1.5789 0.04961
EDN3 4465373 177 2.89 1.5972 0.00593
EZH2 4681112 354 2.89 -1.6003 0.01694
SLC7A3 4507707 178 2.88 1.9742 0.00225
AURKA 4612817 623 2.88 -1.5211 0.01405
CDK5RAP2 4705444 179 2.86 -1.7833 0.04189
RCBTB2 4429704 897 2.85 -1.5164 0.00013
SOX6 4595680 90 2.84 -2.2940 0.00049
HACE1 4562739 90 2.84 -1.5657 0.00115
MSH6 4329278 90 2.84 -1.6149 0.00803
KIF20A 4412443 90 2.84 -2.2795 0.01341
RACGAP1 4337642 90 2.84 -1.5121 0.02875
DHFR 4532630 4329 2.84 -1.6291 0.03442
ANGEL2 4487000 992 2.84 -1.5319 0.03675
4930583H14RIK 4349596 909 2.82 1.5726 0.00360
USP3 4688768 455 2.81 -1.5697 0.00535
MAP4K1 4584957 91 2.81 1.5749 0.01142
USP3 4689496 455 2.81 -1.7695 0.01173
PCNX 4570893 91 2.81 -1.9095 0.02433
ATP8A1 4565843 183 2.80 2.0702 0.04385
GPR158 4313474 4312 2.79 1.5638 0.00874
PTPRN 4744856 275 2.79 1.5346 0.01022
BRCC3 4538606 3318 2.78 -1.7085 0.00528
MBL2 4520356 184 2.78 -2.1122 0.00931
SRSF15 4382671 1288 2.78 -1.5258 0.01029
POLE 4488858 277 2.77 -1.7014 0.00163
PIH1D2 4617724 278 2.76 1.7806 0.02267
LIMA1 4531012 2596 2.76 -1.5865 0.02588
POLA1 4306555 93 2.75 -1.5848 0.02509
4373942 3456 2.74 1.6091 0.00478
NDP 4581991 374 2.74 -2.0329 0.01218
FBXO38 4663537 94 2.72 -1.5067 0.00691
PKD1L2 4365239 94 2.72 -1.5440 0.01219
BOC 4735672 755 2.71 -1.5133 0.01100
ADK 4466769 755 2.71 -1.5576 0.04199
PRKX 4329571 96 2.67 -1.5539 0.00619
XXIV Appendix
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
LCP1 4595737 96 2.67 1.5881 0.01335
DOK2 4503584 288 2.67 1.5278 0.02367
ELF2 4659413 96 2.67 -1.6847 0.02379
MCM2 4560441 192 2.67 -1.5402 0.04644
MS4A6D 4464067 578 2.66 1.5040 0.04085
EIF2AK4 4388293 386 2.65 -1.5193 0.00818
CTSG 4605174 193 2.65 2.0718 0.00880
KIF20A 4487970 965 2.65 -1.8862 0.03413
SYT9 4327356 2137 2.64 1.7922 0.01575
ADAM22 4442753 195 2.63 1.5670 0.03879
TMED5 4584874 3024 2.62 -1.7698 0.03078
TMTC4 4496065 1173 2.62 1.5565 0.04164
FLT1 4500095 98 2.61 1.7689 0.02734
SGOL1 4726910 792 2.59 -1.6013 0.00376
DMGDH 4415535 199 2.57 1.8070 0.02996
LCTL 4378199 200 2.56 1.6867 0.01358
ACVR1 4422845 100 2.56 -1.5270 0.01416
SORCS2 4423836 100 2.56 1.5393 0.02582
NLK 4505594 1808 2.55 -1.6462 0.00128
ZFP191 4354070 501 2.55 -1.5352 0.04879
4488454 4240 2.54 -1.8165 0.00005
DDX11 4681249 101 2.53 -1.5091 0.02505
POLR2A 4484954 101 2.53 -1.5278 0.03929
MAD2L1 4363305 1221 2.52 -1.5584 0.00296
CCNG2 4718143 2750 2.51 -1.6380 0.00185
DMD 4641080 102 2.51 1.6966 0.00276
SLC2A3 4479978 102 2.51 1.5092 0.01243
TXNDC8 4367418 204 2.51 1.5540 0.03470
AKT3 4479233 206 2.49 -1.5602 0.01513
4641319 2796 2.47 -1.7974 0.00247
FMO3 4489116 725 2.47 -2.0509 0.01331
4486460 2796 2.47 -2.4199 0.02907
SPATS2L 4310354 207 2.47 1.5334 0.04660
RWDD3 4556722 1249 2.46 -2.1795 0.01520
GAB3 4515765 208 2.46 1.8418 0.03085
EPHX1 4361792 209 2.45 1.6537 0.03559
MSRA 4551929 105 2.44 -1.5724 0.01922
A930024E05RIK 4586822 738 2.43 -1.5868 0.00134
KIF4 4650460 106 2.42 -1.6806 0.00492
KLHL38 4559615 106 2.42 1.6933 0.03897
FOXRED1 4743516 213 2.40 -1.5259 0.02774
RNASEL 4685349 1607 2.39 -1.6046 0.01455
TLR7 4732269 3557 2.38 1.7712 0.01063
CRY1 4621702 108 2.37 1.5289 0.01750
STAG3 4659038 108 2.37 1.6741 0.02355
Appendix XXV
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
ZRSR2 4595108 325 2.36 -1.5142 0.01557
TRANK1 4476297 3050 2.35 1.7118 0.00523
PSMC6 4404885 109 2.35 -1.7306 0.04386
DLC1 4588622 219 2.34 -1.5196 0.02058
KLRA7 4519746 219 2.34 -2.2906 0.03110
LIPA 4351453 110 2.33 1.6418 0.01401
BMPER 4355300 110 2.33 -1.5710 0.01413
CACNB2 4415831 110 2.33 1.6237 0.01448
TCFAP2B 4539678 220 2.33 1.5376 0.01920
SLA 4547683 4066 2.33 -1.8236 0.02292
PHLDA3 4435898 659 2.33 2.1969 0.02718
ADCYAP1 4737637 1548 2.32 1.9273 0.00312
B230354K17RIK 4467887 1107 2.31 -1.6395 0.00303
CREM 4650584 1774 2.31 -1.5764 0.02471
C330027C09RIK 4360097 1335 2.30 -1.6455 0.00133
FAM5C 4518059 223 2.30 1.5546 0.02862
EPHA5 4434153 670 2.29 -1.5359 0.00949
LHX6 4593283 2126 2.29 -1.7716 0.01260
SDC2 4308175 2354 2.28 1.5059 0.01286
KLHL1 4524502 225 2.28 1.6689 0.02347
MCM2 4598865 113 2.27 -1.7781 0.00542
D630003M21RIK 4358288 903 2.27 1.9894 0.01714
D630003M21RIK 4486570 903 2.27 1.5524 0.01882
CALN1 4500272 113 2.27 1.5991 0.02083
THY1 4462459 1241 2.27 1.8176 0.02306
FUNDC1 4737894 339 2.27 -1.7487 0.02882
ASAP3 4715296 226 2.27 -1.6745 0.02993
WWC2 4556420 2702 2.27 -1.6076 0.03983
EPHA5 4733959 1019 2.26 -1.7866 0.01325
RWDD2A 4527541 227 2.26 1.8085 0.03397
ST8SIA6 4330824 6271 2.25 1.9448 0.03751
NFKBID 4443319 229 2.24 1.5006 0.01512
DHFR 4503067 116 2.21 -1.9853 0.00541
FAM20A 4566179 116 2.21 1.5554 0.00662
SLC16A9 4694299 233 2.20 1.5558 0.01308
GRM7 4706559 936 2.19 1.5800 0.02217
RFC4 4651099 353 2.18 -2.1348 0.01560
LRRTM4 4695212 1176 2.18 1.6368 0.03003
LETM1 4694406 2940 2.18 -1.8168 0.03278
SLC5A4B 4448388 1406 2.18 1.5124 0.04781
SLC15A2 4538095 1777 2.16 -1.7086 0.01396
CEP97 4369410 710 2.16 -1.5453 0.01415
PRPF3 4402326 119 2.15 -1.5628 0.03461
ADAMTS1 4380069 2274 2.14 1.6430 0.01942
A730037C10RIK 4311846 1671 2.14 1.5700 0.03940
XXVI Appendix
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
NUAK1 4463507 120 2.13 -1.7956 0.00035
GRID2 4394768 2998 2.13 1.5192 0.00334
SLC24A2 4584831 1081 2.13 1.5315 0.01175
CENPE 4487174 120 2.13 -2.2500 0.03693
ZFP143 4472442 120 2.13 -1.5769 0.03861
4632901 3139 2.12 -1.5679 0.00056
4676952 3139 2.12 -1.7990 0.00857
SOX6 4669046 241 2.12 -1.5687 0.02169
AU021034 4348091 1936 2.12 1.6732 0.03054
ANKRD34B 4596043 3420 2.10 1.6112 0.00553
KCNE3 4590228 732 2.10 1.6163 0.03732
BMP10 4525025 365 2.10 1.6265 0.04137
ENPP5 4738159 864 2.07 1.5101 0.00739
TBC1D1 4683923 871 2.06 1.5337 0.00900
TMIE 4312239 1247 2.05 1.6778 0.00452
AMY1 4373243 126 2.03 1.6669 0.01001
SWAP70 4652190 2273 2.03 1.7312 0.01313
CDC25A 4340311 126 2.03 -1.5322 0.02588
N4BP3 4421228 255 2.01 1.5978 0.00580
PPRC1 4377908 255 2.01 1.9666 0.02180
RFX5 4367286 3568 2.01 -1.6865 0.02182
PMFBP1 4324734 255 2.01 1.7253 0.04228
POU3F2 4603318 6272 2.00 -1.5123 0.01185
CLSPN 4428061 128 2.00 -1.5184 0.03616
PDE1C 4388113 129 1.98 -1.6272 0.01852
CD1D1 4508745 517 1.98 -1.7724 0.02527
SUPT16H 4650061 130 1.97 -1.5031 0.01206
ZFHX3 4509945 6255 1.96 1.5191 0.00720
KIF18B 4595407 526 1.95 -1.6458 0.00976
GDA 4350979 3952 1.94 1.6029 0.02740
MRVI1 4348027 132 1.94 1.5131 0.03021
RET 4499628 264 1.94 1.5090 0.04439
4318939 132 1.94 2.0020 0.04653
LRP1B 4663695 265 1.93 1.7006 0.02002
ADD3 4712355 2402 1.92 1.7947 0.00902
CASP1 4305036 267 1.92 1.5430 0.02294
KIF23 4592278 400 1.92 -1.5841 0.04619
ZBTB8A 4436521 803 1.91 -1.8701 0.02436
OLFR791 4502247 939 1.91 1.5085 0.04465
MCM10 4461183 269 1.90 -1.8054 0.00128
NAA16 4521127 135 1.90 -1.6204 0.01197
DNAHC5 4585508 135 1.90 1.5461 0.03136
PPP2R1B 4378289 135 1.90 -1.6646 0.03331
SP1 4623057 5680 1.89 -2.0571 0.00242
HSD17B3 4338295 406 1.89 -1.5467 0.01858
Appendix XXVII
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
TMEM74 4401375 1353 1.89 -1.6337 0.02176
OLFR1046 4373246 951 1.88 -2.2074 0.01460
GRTP1 4408948 274 1.87 -1.6022 0.00733
PPARGC1B 4391082 1102 1.86 1.5293 0.02159
FOXC1 4514970 3990 1.86 1.5662 0.04646
SYT2 4353516 5675 1.85 1.8027 0.04042
YPEL1 4374592 2221 1.84 -1.6274 0.00694
GADD45G 4348997 418 1.84 -1.6410 0.01916
SULT1A1 4675456 140 1.83 1.6315 0.00056
OPRM1 4379014 420 1.83 -1.5537 0.00223
CP 4623278 140 1.83 1.5105 0.02035
ABCA4 4624016 140 1.83 1.7457 0.02959
SLC11A1 4734800 280 1.83 1.5680 0.04254
HEPACAM 4536924 282 1.82 1.7162 0.02700
HSPA12A 4344248 4248 1.81 1.5990 0.01971
IYD 4419840 848 1.81 1.5495 0.03836
ASPM 4344173 142 1.80 -1.9044 0.01217
PEO1 4632961 142 1.80 -1.5126 0.04437
HBP1 4539199 142 1.80 -1.5597 0.04723
IL1F9 4664033 143 1.79 -1.8881 0.03463
CCL24 4739850 144 1.78 -1.5646 0.00250
MOS 4530521 1449 1.77 1.6046 0.01875
2010300C02RIK 4508931 145 1.77 1.7034 0.03742
GTDC1 4429845 2188 1.76 -1.5118 0.00441
DLL1 4705503 727 1.76 -1.5596 0.01742
SLC6A13 4725872 440 1.75 1.6944 0.00621
COL4A1 4597318 1460 1.75 1.5878 0.02461
FARS2 4354425 292 1.75 -1.5153 0.04131
C330027C09RIK 4553525 148 1.73 -1.7838 0.00516
FANCI 4374601 443 1.73 -1.5347 0.02256
TRAF2 4544512 149 1.72 -1.5788 0.02430
MAP1LC3A 4439349 599 1.71 3.6272 0.00415
DLGAP5 4700686 1945 1.71 -1.6636 0.01610
DCT 4525957 300 1.71 -1.5898 0.03031
DLGAP5 4668991 1945 1.71 -1.9304 0.03748
CNTN6 4552356 151 1.70 1.8251 0.03341
TRANK1 4653312 1517 1.69 1.6748 0.00202
USP3 4499487 3942 1.69 -1.8275 0.01850
CGA 4337438 305 1.68 1.8465 0.01683
RAE1 4380864 457 1.68 -1.8731 0.03900
E330009J07RIK 4521937 154 1.66 -1.5049 0.00230
ITIH2 4569424 309 1.66 1.6252 0.00294
D930015E06RIK 4620859 154 1.66 -1.6091 0.01076
NEUROD2 4741421 2927 1.66 -1.9637 0.01450
SYNJ2 4389452 2007 1.66 1.7214 0.04156
XXVIII Appendix
Gene symbol Probeset ID exon length [bp] AGAA freq. x-fold change p-value
MYRIP 4643639 626 1.64 1.5798 0.00228
KCNC4 4508651 937 1.64 1.6273 0.00580
HNF4A 4631354 156 1.64 1.7118 0.00793
EGR1 4553204 2520 1.63 1.7389 0.00034
EGR1 4472382 2520 1.63 1.5447 0.02558
LIMA1 4546203 2821 1.63 -1.7192 0.02617
ADAMTS10 4744306 157 1.63 -1.9474 0.03812
CENPA 4515076 790 1.62 -1.5357 0.01323
CNTN2 4378107 6213 1.61 -1.5483 0.00218
DNAJC11 4583902 1588 1.61 -1.8878 0.01322
CNTN2 4373088 6213 1.61 -1.6561 0.01422
TBR1 4497886 159 1.61 -1.5634 0.03035
SC4MOL 4654742 1273 1.61 -1.5144 0.03061
PDE4B 4539972 479 1.60 1.5419 0.03749
RACGAP1 4513235 969 1.59 -1.5917 0.00378
PLXDC2 4671369 161 1.59 1.5397 0.00624
FRMD4B 4589852 1768 1.59 -1.7008 0.00797
ZFP784 4503608 1129 1.59 -1.5264 0.01001
BLM 4586409 161 1.59 -1.9113 0.01449
RCOR2 4355418 162 1.58 -1.8296 0.00145
CDC45 4355843 162 1.58 -1.5256 0.01734
PRKD1 4549513 162 1.58 -1.5065 0.02775
PLEKHG2 4531289 162 1.58 -1.7737 0.04283
ALG13 4598957 163 1.57 -1.5787 0.00378
MS4A6D 4410250 163 1.57 1.6310 0.02211
CHAF1B 4625459 163 1.57 -1.9919 0.02430
INPP5B 4455005 163 1.57 1.6600 0.04838
GM5607 4582719 987 1.56 -1.7349 0.00017
CELSR1 4438558 164 1.56 -2.1430 0.00204
FOXM1 4339271 3117 1.56 -1.7902 0.00257
SPAG5 4731535 330 1.55 -1.6863 0.00747
4683721 2659 1.54 1.6527 0.00118
SLC43A1 4414094 832 1.54 -1.5599 0.01719
ITGA2 4698122 166 1.54 1.5499 0.02519
RNF144A 4569727 3993 1.54 -1.5186 0.03155
KIF20A 4527819 166 1.54 -1.5349 0.04300
HSD3B3 4650071 1172 1.53 1.5317 0.00859
2900005J15RIK 4737400 2025 1.52 1.5068 0.01412
IL1R1 4545538 168 1.52 1.5133 0.03741
RCAN2 4372917 2544 1.51 1.6379 0.02219
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